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Allostery refers to the process in which interaction of an effector ligand with one site of the 
protein changes the function of the protein at a distant site. Despite the critical role of allostery 
in regulation of metabolic pathways, little is known about the details of the allosteric networks 
and the remarkable diversity in allosteric mechanisms. This study utilises several examples of 
allosteric proteins to illustrate the interwoven relationships between various allosteric 
mechanisms, ranging from large conformational changes to subtle dynamic communications. 
An important metabolic enzyme, 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase 
(DAH7PS), was selected for this study due to its unique diversity of allosteric regulations and 
its important role as the first committed step in aromatic amino acid biosynthesis. Essential in 
many pathogenic bacteria, however lacking mammalian counterparts, DAH7PS and related 
pathway enzymes provide opportunities in development of novel antimicrobial drugs.  
The first part of this study addresses the determinants of allosteric ligand selectivity and 
potency for DAH7PS enzymes that exhibit large conformational changes, and provides 
structural and functional insights that contribute to the understanding of the role of 
conformational change in allostery. The second part of this study addresses interchangeability 
between two different allosteric mechanisms by demonstrating the ease of gene fusion to link 
two contemporary protein domains and produce functional chimera. The third part of this study 
addresses the allosteric regulation in DAH7PS enzymes from a different subfamily, for which 
no large conformational changes are involved in delivering allosteric communication. The 
crystal structure of a related chorismate mutase enzyme contributes to the understanding of 
protein-protein interactions associated with allosteric regulations employed by this type of 
II 
 
DAH7PS. The final part of this study addresses the current limitations in studying allosteric 
systems and explores the advantages of new techniques, including Förster resonance energy 
transfer and electron paramagnetic resonance, in offering valuable information on the 
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Chapter 1. Introduction and overview 
 
1.1. Introduction 
Control of biosynthesis and degradation of metabolites is an essential part of cellular function 
to ensure normal growth and maintenance of the cell by properly regulating the level of these 
compounds to satisfy various metabolic demands. This fundamental biological process often 
involves regulation of important proteins via intricate networks of interacting molecules.1 
Allosteric regulation is one of the most common mechanisms to achieve direct control of 
protein function, where interaction of an effector ligand molecule with the target protein 
introduces changes in protein conformation and dynamics to modulate the interaction of 
another molecule at a distant functional site. 
 
1.1.1. Evolving concept of allostery 
Allostery as one of the most fundamental and intriguing biological processes in understanding 
cellular chemistry, signalling, metabolism and diseases has drawn increasing attention in the 
central focus of biological research; hence the concept of allostery and its mechanisms continue 
to evolve since it was first articulated more than half century ago.2-3 Some key experiments 
leading to an understanding of allostery were documented in the early 1900s, where Bohr effect 
and Hill equation were described to report the sigmoidal binding affinity of haemoglobin to O2. 
In 1958, the birth of the first X-ray structure of sperm whale myoglobin revolutionised the 
understanding of protein structure.4 Soon after, the discovery of feedback inhibition of enzymes 
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and naming of regulatory sites as ‘allosteric sites’ marked the beginning of allostery.5-6 In 1965 
and 1966, the two classical models, the Monod-Wyman-Changeux (MWC) model and the 
Koshland-Nemethy-Filmer (KNF) model, were introduced to describe ligand binding at one 
site causing conformational change of protein that alters its function at the second site.2-3 The 
MWC model focused on the transition between two pre-existing, distinct conformational states 
(relaxed-R and tensed-T),2 whereas the KNF model emphasised on the sequential change and 
‘induced-fit’ from ligand binding at the first site.3 Both of these rested on the assumption that 
only two defined conformations can exist, and in the presence of ligand, major changes occur 
in the shape of the protein. 
Although the concept of the two models has been proven to be successful at describing basic 
features of the conformational transition,7-9 numerous theoretical realisations and experimental 
observations have demanded the development of more detailed mechanisms (how) and 
energetics (why) in understanding allosteric communication. In 1984, the idea that allostery 
can occur in the absence of conformational change was first proposed based on a theoretical 
proposition.10 Cooper and Dryden demonstrated that changes in amplitude and frequency of 
protein thermal motions can occur upon allosteric interaction, without changing the average 
atomic positions of the protein structure. This important update on the definition of allostery in 
thermodynamic terms laid the foundation for modern concept of allostery and aided in 






1.1.2. Allostery is structured yet dynamic 
The origin of allostery was based on the classic perspective that an allosteric protein is 
structured and the propagation of allosteric signal follows a defined pathway. The current 
understanding of allostery has been significantly advanced with additional structural and 
dynamics data provided by the development of new techniques, such as nuclear magnetic 
resonance (NMR) spectroscopy and Förster resonance energy transfer (FRET), supplemented 
by theoretical analyses and simulations. Copper and Dryden’s prediction of allostery without 
conformational change was validated 20 years later by direct NMR data proving that allostery 
can be mediated purely by transmitted changes in protein dynamics without any conformational 
change.11 This important experiment used relaxation dispersion NMR and NMR-detected 
hydrogen exchange to probe the allosteric details of the dimeric catabolite activator protein 
(CAP) in response to its ligand cyclic AMP (cAMP) (Figure 1.1).  Binding of cAMP to one 
CAP chain was shown to have no conformational effect on the other chain. However, the first 
cAMP partially enhanced the dynamics of the protein, whereas the second cAMP completely 
quenched system dynamics. An entropy penalty for the second cAMP was therefore arose from 
quenching of protein dynamics upon ligand binding leading to the negative cooperative binding 
of cAMP to CAP. Several studies have demonstrated the change in conformational entropy 
upon cAMP binding via backbone and side-chain dynamics.11-13  
The theory of dynamic-driven allostery was verified by another important study where a distal 
element of PDZ domain was shown to significantly affect the side-chain dynamics of the ligand 
binding site without global changes in the backbone as revealed by NMR experiments. This 
effect was almost solely entropic in nature as determined by isothermal titration calorimetry 
(ITC).14 Although it was generally accepted that changes in enthalpy (contributed by large 
conformational change) of some protein systems were essential to transmit allosteric signals, 
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these studies on the CAP and PDZ systems revealed the important role of dynamics (entropy) 
in allosteric mechanism.  
 
Figure 1.1. Structured and dynamic allostery. A. Binding of oxygen to T state of haemoglobin causes 
conformational shift of the subunits and drives the equilibrium towards R state.15-16 B. A remote α helix 
of PDZ domain significantly affects the side-chain dynamics at the ligand binding site. Truncation of 
this helix caused dramatically increased dynamics and reduced ligand affinity.14 C. Binding of ligand 
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cAMP to CAP quenches backbone dynamics and allows appropriate rearrangement of the functional 
domain to activate transcription.11-13 
 
1.2. Aromatic amino acids 
The three aromatic amino acids phenylalanine (Phe), tryptophan (Trp), and tyrosine (Tyr) are 
essential aromatic compounds in metabolism. They are required for protein biosynthesis, 
constituting almost 10% of proteins on average, and play critical roles as precursors for many 
important metabolites involved in cellular growth, regulation and maintenance.17 
 
1.2.1. Biosynthesis of aromatic amino acids  
Phe is a common precursor of many phenolic compounds, such as lignin and flavonoids.18 Phe-
derived compounds constitute almost 30% of organic matter in some plants, hence majority of 
the carbon flux is often directed to Phe.19-20 Trp is a precursor of phytoalexins, alkaloids, and 
some plant hormones. Tyr is important in synthesis of pigment betalains and some quinones.21-
22 All three aromatic amino acids are derived from the shikimate pathway in most 
microorganisms, fungi and plants (Figure 1.2). However, this pathway is never identified in 
animals. Phe and Trp are essential amino acids for humans and livestock, hence must be 
supplied through diet. Tyr can be synthesised in mammals, however a source of Phe is required 
for an enzymatic hydroxylation step.23-24 Trp and Tyr are also precursors of serotonin and some 




Figure 1.2. The shikimate pathway linking metabolism of carbohydrates to biosynthesis of aromatic 
compounds. The pathway produces final product chorismate, a common precursor for Trp, Phe and Tyr, 
as well as other important metabolites. Reactions that involve multiple steps are shown as dashed arrows. 
DAH7PS, 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase. 
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The shikimate pathway links central carbon metabolism and the aromatic amino acid networks 
by converting two carbohydrate precursors phosphoenolpyruvate (PEP) and erythrose 4-
phosphate (E4P) to ultimately produce the end-product of the pathway, chorismate, via seven 
enzyme-catalysed reactions (Figure 1.2). From the universal precursor chorismate, the pathway 
branches towards the formation of prephenate and anthranilate leading to aromatic amino acids 
and other important compounds such as vitamins K1 and B9.
23-24, 26-27 Furthermore, other 
intermediates of the pathway also serve as starting points for biosynthesis of numerous 
secondary products. Clearly, the shikimate pathway is of substantial importance to the 
biosynthesis and regulation of many compounds of commercial and medical interest.  
 
1.2.2. Regulation of the shikimate pathway 
Regulation of key metabolites by enzymatic pathways is vital for maintaining normal 
metabolism of the cell. Regulation of the shikimate pathway is particularly crucial as the 
synthesis of aromatic amino acids is energetically expensive. The three aromatic amino acids 
represent almost the entire output of aromatic biosynthesis in most prokaryotes.26 Activity of 
the shikimate pathway is often monitored by intracellular levels of Phe, Trp, Tyr and other 
pathway intermediates.26  
Metabolic networks are often constituted by branched reaction pathways, for which the 
regulation usually occurs at the committed step of the pathway by interwoven regulatory 
mechanisms controlling gene expression and/or enzyme activity. Specifically, the enzyme 3-
deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS), which catalyses the first 
step of the shikimate pathway, is frequently controlled at both transcriptional level and protein 
level by feedback regulation.23 Feedback regulation is found consistently throughout amino 
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acid metabolism, in which pathway end-products or intermediates inhibit or activate the 
activity of the early enzymes in the pathway to reduce the waste of metabolites, deliver tight 
control of biosynthesis, and ultimately increase the fitness of the cell.28 
Furthermore, regulation of enzymes located at branch points of the aromatic amino acid 
pathway is important for fine-tuning the distribution of metabolites in response to cellular 
requirements. For instance, anthranilate synthase, which converts the branch-point 
intermediate, chorismate, into anthranilate en route to biosynthesis of Trp, is regulated at 
transcriptional level and allosterically regulated by Trp.29 Chorismate mutase (CM), which 
converts chorismate into prephenate, is also feedback regulated by Phe and/or Tyr in some 
organisms.30-31 Besides the primary regulation at the committed step and at branch-points, 
regulation of other enzymes of the pathway is also noted, such as the gene regulation of 5-
enolpyruvylshikimate-3-phosphate (EPSP) synthase at the sixth step of the pathway.23 
 
1.2.3. Applications of the shikimate pathway 
The biosynthetic enzymes comprised in the shikimate pathway are shown to be essential in 
many organisms. Due to the absence of the pathway in mammals, all of the enzymatic steps 
offer important targets for the development of live vaccines, antibiotics, and herbicides.32-34 
For example, mutants of several enzymes in the pathway were reported to attenuate the growth 
of Salmonella enterica and eliminate its infection in mice.35-38 In addition, knockout studies 
identified shikimate enzymes that were essential to the virulence of Shigella flexneri.39-40 
Similar studies on modifications of various shikimate enzymes in a number of pathogenic 
bacteria have shown impaired pathogen growth or nonvirulence in mice.41-45   
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The importance of the shikimate pathway is also demonstrated by the development of enzyme 
inhibitors targeting pathway enzymes. One of the early examples was discovered in the 
herbicide field by Jaworski’s group in 1970s.46 Their lead compound, glyphosate, which targets 
EPSP synthase, is a dominantly used herbicide worldwide. This billion-dollar success is due to 
its highly effective broad-spectrum in weed management, and at the same time it is 
environmentally and toxicologically safe.47 In fact, glyphosate in combination with 
pyrimethamine has also been tested effectively in mice as an anti-parasite agent to limit 
pathogenic infections including toxoplasmosis and malaria.48  
The shikimate pathway has also attracted growing research interest in the field of 
bioengineering and biotechnology, as the intermediates and derivatives of the pathway can be 
utilised for biosynthesis of numerous compounds with a wide range of chemical properties or 
biological activities. For example, extensive research efforts have been made for development 
of highly efficient methods for production of aromatic amino acids in Escherichia coli due to 
their frequent use in dietary supplements as well as industrial products such as artificial 
sweetener aspartame derived from Phe.49-51 The shikimate pathway has also been artificially 
engineered to supply target molecules or precursors for biosynthesis of compounds with 
pharmaceutical activities. Salicylic acid as one of these compounds is the active ingredient of 
aspirin, which is regularly used to treat pain, fever, and inflammation.52 Its production can be 
achieved at gram per litre scale via an engineered shikimate pathway in E. coli, where 
metabolic influx is improved by overexpression of a number of enzymes in the pathway.53-54 
The production of compounds with anticancer activities, including alkaloids,55 flavonoids,56-57 
violacein, and deoxyviolacein,58-59 has also been achieved and improved by rational design of 





The enzyme 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) is the first 
enzyme of the shikimate pathway, catalysing the divalent-metal dependent condensation of 
PEP and E4P to produce DAH7P and inorganic phosphate. DAH7PS is essential for most 
microorganisms due to its key role in the synthesis of chorismate. This enzyme, situated at the 
committed step of the pathway, is precisely feedback regulated in many organisms because of 
the necessity to efficiently control the pathway flux in response to changes in the level of 
pathway outputs.60-64 Due to this critical role, a deep understanding of the regulatory 
mechanisms utilised by DAH7PS is of primary importance for development of pharmaceutical 
and industrial products. 
 
1.3.1. Classifications and structures of DAH7PS 
DAH7PS enzymes are classified into two distinct types: Type I and Type II, on the basis of 
their distinctive amino acid sequence and protein size.65 Type I shares less than 10% sequence 
identity with its Type II counterparts. Type I DAH7PSs are generally smaller than Type II 
enzymes, with molecular weights less than 40 kDa, whereas Type II enzymes are generally 
larger than 50 kDa. Type I enzymes are further divided into two subfamilies based on sequence 
similarity: Iα and Iβ (Figure 1.3). Type Iβ DAH7PSs share low sequence identity of less than 
18% with Type Iα, but are more closely related to 3-deoxy-D-manno-octulosonate-8-phosphate 
synthase (KDO8PS). KDO8PS catalyses a similar aldol-like condensation reaction between 
PEP and arabinose 5-phosphate (A5P) to yield KDO8P, and is involved in biosynthesis of the 
cell wall in Gram-negative bacteria.66-67  
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Since the first crystal structure of DAH7PS was reported in 1999, there have been more than 
60 DAH7PS structures deposited to Protein Data Bank (PDB) to date. Crystal structures of 
DAH7PS have been solved for members of all subtypes, including Type Iα DAH7PSs from E. 
coli,60, 68 Saccharomyces cerevisiae,62 Francisella tularensis,69 and Neisseria meningitidis;70 
Type Iβ enzymes from Pyroccocus furiosus (Pfu),71, 72 Aeropyrum pernix (Ape),73 Bacillus 
subtilis (Bsu),74-75 Thermotoga maritima (Tma),63, 76 Listeria monocytogenes (Lmo),77 and 
Geobacillus sp. (Gsp);78 as well as Type II enzymes from Mycobacterium tuberculosis (Mtu)64 
and Corynebacterium glutamicum.79  
Although sequence similarity is low between Type I and Type II enzymes, the catalytic domain 
of all available structures adopts a (β/α)8 barrel core housing the active site situated towards 
the C-terminus of the barrel. Variations amongst different subtypes of DAH7PS arise from 
structural extensions or additions to the core barrel. Type Iα typically contains a double β-sheet 
insertion and a double α-helix extension at the N-terminus. Type Iβ DAH7PS comprises solely 
the core barrel as observed in PfuDAH7PS and ApeDAH7PS,71, 73 or two domains with the 
catalytic barrel attached to either a chorismate mutase (CM) domain as seen in GspDAH7PS,78 
or an ACT domain as reported in TmaDAH7PS.63 Type II enzymes display extensive 
modifications to the core structure generally with a double-α-helix insertion and a large N-
terminal extension.64 These structural decorations to the DAH7PS catalytic core are believed 




Figure 1.3. Classification of DAH7PS. DAH7PS is classified into Type I and Type II. Type I is further 
divided into Type Iα and Iβ. The simplest DAH7PS, comprised of the catalytic barrel only, is 
unregulated. Monomeric unit and tetrameric assembly are shown for each protein. The α-helices in the 
core barrel are shown in blue, β-sheets are green. N-terminal extensions are red, and insertions are 
orange.   
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1.3.2. Allosteric regulation of DAH7PS 
An array of mechanisms for modulating DAH7PS activity in response to downstream pathway 
product concentrations have been delivered and maintained through the course of evolution. 
Numerous studies have identified the intricate networks of interwoven transcriptional and 
allosteric regulations that interact to control DAH7PS activity.81-83 Although the variability in 
transcriptional control amongst different organisms is intriguing, the remarkable diversity of 
the allosteric mechanisms employed by DAH7PS enzymes is truly exceptional and perhaps the 
most researched for any enzyme.24 Ranging from large conformational changes to delicate 
changes in protein dynamics associated with regulation, DAH7PS is an excellent model system 
for in-depth study of enzyme allostery.  
The simplest form of DAH7PS is best illustrated by the crystal structures of PfuDAH7PS and 
ApeDAH7PS from the Type Iβ subtype, where an uninterrupted DAH7PS catalytic core is 
revealed free of any structural decorations.71-73 The structure comprises a classic (α/β)8 TIM 
barrel fold with the β2-α2 loop capping the entrance of the active site on top of the barrel. The 
lack of additional structural elements or a discrete regulatory domain means that the enzyme is 
unresponsive to any downstream metabolites, and hence has unregulated catalytic activity.71-72  
The rest of the Type Iβ family contains a discrete ACT or CM regulatory domain at either N- 
or C-terminus of the DAH7PS barrel (Chapter 1.4), and appears largely tetrameric in solution 
and in crystalline form.63, 74, 77-78 The addition of these regulatory domains is responsible for 
feedback regulation of DAH7PS by aromatic amino acids, chorismate or prephenate, 
respectively. The enzyme TmaDAH7PS is a well characterised example of Type Iβ DAH7PS 
with an N-terminal ACT domain. Presence of the allosteric ligand Tyr or Phe promotes 
dimerisation of the two ACT domains from opposing chains and effectively blocks the entrance 
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to the active site (Figure 1.5).63 A similar gating mechanism of allostery has been reported in 
GspDAH7PS, which contains a CM regulatory domain at N-terminus of the barrel. Binding of 
the ligand, prephenate, to the dimeric CM domain on each side of the catalytic core results in 
a more compact overall structure with the catalytic component tightly sandwiched by the 
repositioned regulatory domains, hindering substrate access to the active site.78  
The Type Iα enzymes contain structural modifications to the core barrel and are typically 
feedback regulated by aromatic amino acids. The inserted β-sheets and the N-terminal 
extension contribute to the formation of allosteric site. Characterised DAH7PSs from E. coli, 
S. cerevisiae and N. meningitidis share similar quaternary structures comprised of dimers of 
dimer forming the homotetrameric arrangement.60, 70, 84 Different from the aforementioned 
regulated Type Iβ family, members of the Type Iα family do not display major conformational 
changes upon ligand binding, instead subtle changes are involved in communicating the 
allosteric signal following dynamic and entropically-driven mechanisms.85 
The first structurally characterised Type II DAH7PS is from M. tuberculosis.86 It adopts a 
similar homotetrameric quaternary arrangement as Type Iα in the form of dimers of dimer. 
However, the main reason for its low sequence identity with the Type I counterparts is the 
extensive structural modifications to the core barrel. The MtuDAH7PS is equipped with a large 
N-terminal extension (three α-helices and a β-sheet) as well as a double α-helix insertion 
between α2 and β3, which form the allosteric sites for binding of all three aromatic amino acids. 
Combination of Phe and Trp synergistically inhibits the enzyme activity, and this inhibitory 
effect is further enhanced by addition of Tyr.87 Interestingly, this protein forms a non-covalent 
complex with MtuCM and contributes to a complex network of regulation in both proteins.30, 
88-89 The allosteric mechanism employed by MtuDAH7PS is rather reminiscent of the Type Iα 
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family, where no drastic conformational change is observed and allostery is communicated 
through a series of subtle changes in protein dynamics.   
 
1.4. Regulatory modules 
Allosteric regulation of DAH7PS in the Type Iβ family, and some members of the Type II 
family, involves recruitment of regulatory components in the form of a regulatory domain, or 
a regulatory partner to form protein complex. It appears that small protein units, such as the 
ACT domain and CM, are frequently involved in this task. In fact, they have emerged as widely 
distributed regulatory modules in amino acid metabolism. 
 
1.4.1. ACT domain 
Allosteric regulation of enzymes in amino acid and purine metabolism has been found to be 
conferred recurrently by a small (around 60-70 residues) discrete protein unit, known as the 
ACT domain.90 It was first recognised and defined in the 1990s after the crystal structure of E. 
coli 3-phosphoglycerate synthase revealed the βαββαβ fold of the regulatory domain 
responsible for allosteric inhibition by serine.91 This regulatory topology was believed to be 
present in three enzymes in amino acid metabolism including aspartate kinase (AK), 
chorismate mutase, and TyrA (prephenate dehydrogenase).92 A significant number of ACT 
domain containing proteins have been structurally characterised, including ATP 
phosphoribosyl transferase (ATP-PRT) involved in histidine biosynthesis,93 some AKs,94 
mammalian amino acids hydroxylases,95-96 and acetohydroxyacid synthases.97 The widespread 
ACT domains have evolved to play regulatory roles in a large group of proteins by binding to 
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various ligands and often interacting with each other and/or with other functional domains, 
therefore the sequence identity of the ACT domains is in fact very low, despite their similar 
structural folds and regulatory purposes.98  
 
Figure 1.4. The ACT domain from TmaDAH7PS showing the typical βαββαβ topology. 
The only structurally characterised ACT domain containing DAH7PS is TmaDAH7PS. It is a 
homotetrameric unit with each chain composed of an ACT domain fused to the N-terminus of 
the catalytic barrel. This ACT domain adopts the typical βαββαβ fold with four antiparallel β-
sheets and a pair of α-helices. In the Tyr-bound complex, the four β-sheets are positioned face-
to-face to the equivalent β-sheets from the diagonally opposite ACT domain of another chain, 
forming a dimeric arrangement housing two Tyr binding sites on each side of the tetramer 
(Figure 1.5). Allosteric ligand binding at the ACT domain interfaces is believed to be 
associated with changes in protein conformation or quaternary structures in order to transfer 
signals between the remote regulatory sites and the active sites.98 Indeed, the differences are 
clear between the ligand-free and Tyr-bound crystal structures of TmaDAH7PS, in which Tyr 
17 
 
binding appears to stabilise the protein in a closed inactive conformation (Figure 1.5). Similar 
arrangement of the ACT domain has also been identified in the thiamine-binding ACT domains 
of the thiamine/HMP-binding proteins in B. subtilis.99 
 
Figure 1.5. Binding of allosteric ligand to the ACT domain (red) promotes large conformational 
changes in TmaDAH7PS (PDB 1RZM left, 3PG9 right). The ligand, Tyr, is shown as orange spheres. 
 
1.4.2. Chorismate mutase 
Chorismate as the product of the shikimate pathway is situated at a pivotal metabolic branch 
point. The conversion of chorismate to prephenate catalysed by CM directly leads to 
biosynthesis of Phe and Tyr, whereas four other chorismate-utilising enzymes lead the flux 
towards biosynthesis of other metabolites, including Trp (Figure 1.2). The enzyme CM, as the 
best-characterised of the chorismate utilising enzymes, has attracted extensive research interest 
since it was first identified in 1965.100 This is not only due to its highly efficient catalysis of 
the unique pericyclic Claisen rearrangement reaction rarely found in enzyme-catalysed 
reactions (Appendix A), but also because of its wide distribution as a frequently used dual-
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functional (catalytic and regulatory) protein module.27 This type of CMs are mostly 
homodimeric with each chain composed of three α-helices connected by two turns (Figure 1.6), 
as illustrated by the example first observed from E. coli.101  
 
Figure 1.6. The typical three-helical CM architecture represented by EcoCM (PDB 1ECM). This type 
of CM is the most widespread and often adopts a homodimeric quaternary structure (each monomer is 
coloured separately in blue and red). 
Members of the Type Iβ DAH7PS family have developed allosteric regulation in response to 
chorismate and/or prephenate by recruiting a CM domain.74-75, 77-78, 102 CM also appears to be 
involved in allostery of some Type II DAH7PSs (Figure 1.7). MtuDAH7PS forms a protein 
complex with one CM dimer on each side.30 Despite the non-covalent nature of the interaction, 
the structural organisation of the protein complex is somewhat comparable with the Type Iβ 
DAH7PS that contains a CM domain. Both assemblies comprise the DAH7PS tetrameric core 
sandwiched by CM dimers. However, in contrast to delivering regulation to the DAH7PS 
activity in Type Iβ DAH7PS, the recruitment of CM in the MtuDAH7PS-CM complex is 
involved in a more multifaceted regulatory network, where CM activity is also regulated.30 
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This complex formation allows tight control of flux through two important pathway 
checkpoints by responding to the level of multiple pathway products. 
 
 
Figure 1.7. CM (red) is involved in allosteric regulation of DAH7PSs via covalent (Type Iβ, 
GspDAH7PS) or non-covalent interactions (Type II, MtuDAH7PS). 
In addition to its regulatory role in the DAH7PS family, the CM domain has also been identified  
in some other enzymes involved in the aromatic amino acid metabolic pathways, such as in 
prephenate dehydratase (PDT) and prephenate dehydrogenase (PDH).100, 103 The PDT protein, 
also known as the P-protein, consists of a CM domain fused to a PDT domain, which converts 
the product of CM (prephenate) to phenylpyruvate. This bifunctional protein has been 
identified and characterised from a range of Gram-negative bacteria, such as E. coli,100 
Pseudomonas stutzeri,104 Erwinia herbicola,105 and Xanthomonas campestris.106 In EcoPDT, 
the CM domain is essential for the cooperative binding of the allosteric ligand Phe to the 
regulatory domain and prephenate to the PDT domain.107 On the other hand, the PDH protein 
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contains a CM domain linked to the PDH domain and is important in the biosynthetic route of 
Tyr. The PDH domain converts prephenate to 4-hydroxypheylpyruvate, which is subsequently 
transformed to Tyr. Although this protein is believed to be feedback inhibited by Tyr, the 
detailed mechanism of regulation remains controversial and variations in the regulatory 
patterns of the proteins from different organisms are also notable.108-113  
 
Figure 1.8. Structure of AroQ and AroH CMs. A. E. coli CM (PDB 1ECM) of the AroQ class. B. B. 
subtilis CM (PDB 2CHT) of the AroH class. Each chain is coloured separately and the transition state 
analogue at the active site is shown as orange stick model. 
It is worth noting that besides the aforementioned CM, which often acts as regulatory modules, 
another unrelated structural scaffold of CM also catalyses the same reaction with generally 
similar efficiencies.114 In microorganisms, the CM enzymes are divided into two classes, AroQ 
and AroH (named after the gene), based on differences in structure.115 In contrast to the 
previously described homodimeric AroQ CM, the AroH CM is relatively rare in nature and is 
an independent enzyme characterised by a trimeric pseudo α/β barrel structure with active sites 
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located at the monomer interfaces (Figure 1.8). This fold was first exemplified in B. subtilis.116 
The distinct three-dimensional structures but similar function suggest that the two classes likely 
arose from convergent evolution. 
 
1.5. Aims of this thesis 
The primary aim of this thesis is to provide new insights into the diverse mechanisms of 
allosteric regulation using a number of examples from the DAH7PS family. As reviewed above, 
the extraordinary diversity in allostery of DAH7PS has attracted wide research attention for 
the past few decades, contributing to the understanding of the molecular details governing this 
process and to its applications in the field of bioengineering and medicine. However, many 
important questions remain to be answered.  
Chapter 2 describes allosteric mechanism that involves large structural changes and answers 
the questions of whether the conformational change is a general regulatory strategy utilised by 
the Type Iβ family, and what determines the binding of allosteric ligand in DAH7PSs that 
contain ACT domain. Functional and structural characteristics of two ACT domain containing 
DAH7PS enzymes and their variants are described, and molecular determinants for ligand 
selectivity and potency are determined.   
Chapter 3 describes studies on allosteric regulation of DAH7PS enzymes fused with the ACT 
domain or the CM domain, and provides insights into questions around the relationship 
between the two types of regulation meditated by the discrete domains. This work demonstrates 
the interchangeability between different regulatory strategies in the Type Iβ family by 
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engineering of protein chimera with exchanged regulatory domains. The role of the regulatory 
domains in conferring allostery and protein oligomerisation is also discussed.   
Chapter 4 focuses on exploring the allosteric regulation of Type II DAH7PS from human 
pathogen Helicobacter pylori and another important metabolic enzyme HpyCM. This chapter 
reveals a number of systematic differences between Type Iβ and Type II enzymes, and answers 
the question of whether protein complex formation is a common allosteric phenomenon 
observed in the Type II family. Both biochemical and structural features of the two enzymes 
are described in relation to the protein complex identified in M. tuberculosis. 
Given the limitation of current techniques commonly used to understand allostery, Chapter 5 
explores other methods that can access more information on the dynamics of allostery. 
Specifically, the applications of Förster resonance energy transfer (FRET) and electron 
paramagnetic resonance (EPR) based techniques are described to answer questions related to 









The ACT domain is a widely distributed ligand binding module often combined with other 
proteins or domains to confer regulation to its fused partner.98 DAH7PS with fused terminal 
ACT domain represents a major class of Type Iβ DAH7PS enzymes. DAH7PS from T. 
maritima (TmaDAH7PS) is the only ACT-DAH7PS structurally characterised to date. The 
crystal structure of TmaDAH7PS reveals key interactions at the allosteric inhibitor binding site. 
Residue Ser31 forms important contacts with the inhibitor, Tyr, which promotes 
conformational rearrangement to confer allosteric regulation.63 Although there is overall low 
sequence similarity in the ACT domains, multiple sequence alignments of ACT-DAH7PSs 
reveal high level of conservation in the ligand binding region. The motif His-X-Ser, present in 
TmaDAH7PS, is frequently identified in many organisms. Interestingly, another motif His-X-
Ile at the equivalent position appears equally abundant. Two protein candidates were chosen 
that naturally contain the His-X-Ser or the His-X-Ile motif. Characterisation of the two wild-
type proteins and their variants was performed to probe the role of the two motifs in allosteric 







2.1.1. Ligand binding 
In contrast to other DAH7PS enzymes, in which the allosteric ligand binding site is pre-formed 
by structural extensions appended on the (β/α)8 barrel (Chapter 1), allosteric regulation of the 
ACT domain-containing DAH7PSs is mediated by discrete ACT domains which undergo large 
repositioning to establish the allosteric site in the presence of ligand.63, 117-118 Ligand binding 
in the cavity of the ACT domain interface physically obstructs substrate access to the active 
site at the C-terminus of the barrel and encumbers catalysis (Figure 1.5).   
The only structurally characterised ACT-DAH7PS reported to date is TmaDAH7PS. 
Comparison between the apo (PDB 1RZM) and Tyr-bound (PDB 3PG9) structures revealed 
the architecture of the cavity formed between two ACT domains from the diagonally opposing 
chains and uncovered residues that are important for ligand binding (Figure 2.1). The 
antiparallel β-sheets of ACT domains adopt a face-to-face dimeric arrangement with Tyr bound 
at the interface. Important hydrogen bonding interactions between the ACT domains and the 
linker regions include His29 and Ser31, Glu35 and Arg36, as well as Arg36 and Glu75. The 
ACT domain also makes several contacts with the C-terminus of the adjacent catalytic barrel 
through hydrogen bonding. In addition to these direct domain interactions in the Tyr-bound 
structure, the two Tyr molecules contribute key interactions with the ACT domains at each side 
of the tetrameric protein. The carboxylate functionality of Tyr forms hydrogen bonds with the 
main-chain amide of Gln34, Glu35 and Arg36 situated at the β2-β3 loop of one ACT domain, 
and Gly43 of the opposing ACT domain. The amino functionality of Tyr forms hydrogen bonds 
with the main-chain carbonyl oxygens of Ile41, Gly43 and Asp45. Hydrophobic side-chains of 
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Val38, Ile42, and Val65 of the opposing domain are also in close contact (<4 Å) with the phenyl 
ring of Tyr. Residue Ser31 also provides important hydrogen bonding contacts with the 
phenolic hydroxyl group of the Tyr. 
 
 
Figure 2.1. Structure of TmaDAH7PS with Tyr bound in the cavity between the regulatory domains. 
A. Top view of the TmaDAH7PS tetramer with two Tyr molecules (lime spheres) bound on each side. 
B. Details of the Tyr (lime sticks) binding sites sandwiched between the regulatory domains of opposing 
chains. Key residues are labelled and shown as sticks. 
 
2.1.2. Sequence analysis 
Previous study of Type Iα DAH7PS from E. coli suggests that the level of sequence 
conservation at allosteric ligand binding region can aid in accurate prediction of key residues 
involved in ligand sensitivity.62 Sequence analysis of available DAH7PSs suggests the 
significant occurrence of DAH7PS with N-terminal ACT-like domain. A search using 
sequence of the ACT domain and the adjacent linker region (residue 1-80) from TmaDAH7PS 
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identified 197 DAH7PS sequences that share this domain architecture. In general, the important 
contacts identified from the Tyr-bound crystal structure are not well conserved. For instance, 
residues involved in direct contact with Tyr such as Glu35, and Asp45 are only very loosely 
conserved (Figure 2.2 A).  However, substantial conservation is observed in the region of His29 
to Ser31 (TmaDAH7PS numbering), indicating the presence of common motif His-X-Ser, or 
His-X-Ile at equivalent position (where X is Val, Leu, or Ile, Figure 2.2 B). High level of 
conservation of this motif is indicative of its important role in ligand binding and specificity. 
Indeed, a previous study suggests that mutation of some residues around this region impacts 
severely on ligand potency and specificity.119 Additionally, the important hydrogen bonding 
contact formed between the Ser residue and the hydroxyl group of  Tyr in the crystal structure 
suggests that this residue likely plays a critical role in ligand binding, as Phe, which lacks the 
hydroxyl group, was shown to have decreased inhibitory potency compared to Tyr.63 In contrast 
to the direct interaction between Ser31 and Tyr, the conserved His29 is from the opposing chain 
and forms a hydrogen bond with Ser31, which appears to secure the correct positioning of 
Ser31 and/or the ligand. Together, it is reasonable to speculate that substitution of Ser to Ile in 
many organisms, as identified from sequence analysis, may favour binding of Phe as opposed 
to Tyr due to the increased hydrophobicity. This chapter investigates whether the substitution 
of a single amino acid residue is sufficient to determine the different allosteric solution of ACT-




Figure 2.2. Sequence conservation in ACT domain of Type Iβ ACT-DAH7PS. A. Region of interest is 
highlighted with black rectangle. Positions corresponding to the key residues involved in direct 
hydrogen bonding with Tyr in TmaDAH7PS are highlighted in red rectangles. WebLogo3 was used to 
generate this figure.120 B. Partial sequence alignment of ACT-DAH7PS showing observed sequence 





2.2. Choice of mutants 
To investigate the role of Ser and Ile in ligand specificity of ACT-DAH7PS, two candidates 
were carefully selected, including one with the His-X-Ser motif and the other with the His-X-
Ile motif. As TmaDAH7PS is the only structurally characterised ACT-DAH7PS reported to 
date and has been well studied, it was chosen to examine the role of His-X-Ser. To minimise 
irrelevant variables, the most similar sequence that comprises the His-X-Ile motif was selected 
by Blast of TmaDAH7PS against all other ACT-DAH7PS sequences. The ACT-DAH7PS from 
Thermodesulfovibrio yellowstonii (Tye) was selected, which shares 52% sequence identity with 
TmaDAH7PS (Appendix B, Figure S2).  
TmaDAH7PS is naturally inhibited by Tyr and to a reduced level by Phe.63 Mutations were 
designed on the basis of the sequence conservation, side-chain interactions with Tyr, and the 
by analogy with a previous study of Type Iα DAH7PS, in which a single amino acid appears 
to determine ligand binding.62 Substitution of Ser31 to an Ile in TmaDAH7PS was designed to 
diminish hydrogen bonding capabilities of the ligand binding site with the hydroxyl group of 
Tyr. Another mutation of Ser31 to a Val was created, as Val was the third most conserved 
residue at this position after Ser and Ile. Additionally, the degree of hydrophobicity required 
for potential Phe binding could also be examined with this mutant. Features of the wild-type 
TyeDAH7PS were characterised for the first time and the corresponding Ile to Ser mutation 







2.3. TmaDAH7PS mutants 
2.3.1. Preparation of TmaDAH7PS S31V and S31I 
Single-point mutants of TmaDAH7PS S31V and S31I were created using QuikChange® 
site-directed mutagenesis technique with wild-type TmaDAH7PS plasmid as template 
(Chapter 7). The PCR product was treated with DpnI to eliminate contamination from the 
wild-type plasmid. Once DNA sequence was verified to incorporate the correct mutation, 
the plasmid was transformed, expressed and purified following the methods for wild-type 
TmaDAH7PS as described fully in Chapter 7.63 Purified products were confirmed to have 
the correct molecular weights by mass spectrometry (Appendix B, TableS1). 
 
2.3.2. Kinetic properties 
Kinetic parameters for wild-type TmaDAH7PS and the two mutants were determined 
following published procedures by measuring consumption of PEP (Chapter 7). Both 
TmaDAH7PS mutants were catalytically active and the activities were enhanced as the 
temperature increased, displaying altered kinetic parameters to those of the wild-type protein 
(Table 2.1, Figure 2.3, Appendix B, Figure S3). They displayed higher KM values for both 
substrates compared to the wild-type and lower turnover numbers (kcat). The overall catalytic 




Table 2.1. Kinetic parameters of TmaDAH7PS variants at 60 °C.*  




TmaDAH7PSWT 8.4 ± 0.7 15 ± 1 14 ± 0.3 1.67 0.93 
TmaDAH7PSS31I 34 ± 3 53 ± 4 5.4  0.3 0.16 0.1 
TmaDAH7PSS31V 20 ± 1 51 ± 3 6.1 ± 0.1 0.3 0.12 
* Concentration of PEP was fixed at 215 µM when KM for E4P was determined. Concentration of E4P was fixed 
at 310 µM when KM for PEP was determined.   
 
 
Figure 2.3. Effect of temperature on specific activities of wild-type TmaDAH7PS and mutants. Each 
reaction contained 283 µM PEP, 308 µM E4P, and 100 µM Mn2+ in 50 mM BTP with pH fixed at 7.5 
at all temperatures tested. Enzyme activities are specified in U (1 U = consumption of 1 μmol 







The effect of Tyr or Phe on the activity of the mutants was measured by kinetic assays and 
compared to the wild-type TmaDAH7PS (Figure 2.4). Notably, substitution of Ser31 to an Ile 
or a Val resulted in reduced sensitivity of the protein towards Tyr (Figure 2.4 A). This effect 
was especially profound for the mutant TmaDAH7PSS31I, for which the presence of Tyr did not 
have a significant impact on its activity under the experimented conditions. Although the 
activity of the other mutant TmaDAH7PSS31V was still affected by the presence of Tyr at high 
concentrations, the IC50 value was increased significantly (greater than 600 µM) compared to 
that of the wild-type protein (20 ± 2 µM).  
 
Figure 2.4. Effect of Tyr (A) or Phe (B) on the activity of TmaDAH7PS variants at 60 °C. Each 
reaction contained 283 µM PEP, 308 µM E4P, 100 µM Mn2+, 0 to 1 mM Tyr or 0 to 0.5 mM Phe in 
50 mM BTP (pH 7.5). Enzyme was incubated with ligand for at least 5 minutes before reaction was 
initiated. 
In the presence of Phe, the two mutants displayed increased sensitivity and more profound 
inhibitory response compared to the wild-type TmaDAH7PS (Figure 2.4 B). The wild-type 
protein had approximately 50% activity remaining at high Phe concentrations, whereas the 




TmaDAH7PSS31I and TmaDAH7PSS31V towards Phe were 41 ± 4, 14 ± 2.4, and 15 ± 3 µM 
respectively, reflecting the enhanced sensitivity of the mutants towards Phe.  
It is worth noting that albeit having a similar trend in ligand sensitivity, the two mutants 
displayed interesting differences. Mutant TmaDAH7PSS31I exhibited clear switched ligand 
selectivity when compared to the wild-type protein, whereas TmaDAH7PSS31V displayed 
similar degree of inhibition towards Tyr and Phe at high ligand concentrations, although it was 
still more sensitive towards Phe than Tyr as demonstrated by the IC50 values. This difference 
may relate to the increased hydrophobicity at the ligand-binding site in TmaDAH7PSS31I 
compared to TmaDAH7PSS31V. Further study was focused on the TmaDAH7PSS31I mutant.  
Conformational change  
In the presence of the allosteric ligand, Tyr, a large conformational change of wild-type 
TmaDAH7PS, compared to the apo enzyme, was observed by using small angle X-ray 
scattering (SAXS) experiments (Figure 2.5 A). This technique was also used to examine the 
solution behavior of the mutant and investigate whether conformational changes could be 
detected in response to the presence of ligand. SAXS data were collected for the 
TmaDAH7PSS31I mutant in the absence or presence of 1 mM Phe or Tyr. 
Initially, TmaDAH7PSS31I was injected on the SEC column at high protein concentration (at 
least 10 mg·mL-1) prior to exposure to X-ray beam. The high concentration was routinely 
applied due to concerns over signal to noise. However, no obvious change in scattering profile 
could be observed in the absence and presence of Phe (Figure 2.5 B). This was somewhat 
surprising as strong inhibition effect of Phe on this mutant was observed by activity assays. 
Further analysis of the experimental data in comparison with the theoretical scattering 
calculated from the crystal structures suggested that the protein appeared to be in a ‘closed-
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like’ conformation under the experimental conditions, regardless of the absence or presence of 
Phe (Figure 2.5 B).  
 
Figure 2.5. SAXS profiles of wild-type TmaDAH7PS and TmaDAH7PSS31I (10 mg·mL-1). A. The wild-
type enzyme displays changes in the presence of Tyr (red dots) or Phe (blue dots), compared to the apo 
scattering (black dots). B. Scattering profiles and calculated scatterings of TmaDAH7PSS31I in the 
absence or presence Phe. Experimental scatterings are shown as dots and theoretical scatterings are 
shown as lines. Theoretical scatterings are calculated from crystal structures of wild-type TmaDAH7PS 
(PDB 1RZM and 3PG9). Scattering for TmaDAH7PSS31I in the presence of Tyr is not included here, as 
all scatterings are the same at high protein concentration.  
Close inspection of open- and closed-form crystal structures of wild-type TmaDAH7PS 
revealed substantial intermolecular interactions mediated by the ACT domain with the core 
barrel from adjacent symmetry mates (Figure 2.6). Additional barrel-barrel interactions 
between different molecules were also present in the crystal structures. At high protein 
concentrations used for SAXS experiments, intermolecular interactions such as those identified 
in the crystals were likely enhanced in contrast to a diluted solution. These interactions might 
affect the average conformation observed from SAXS scatterings, which could contribute to 





Figure 2.6. Symmetry mates of TmaDAH7PS show intermolecular interactions between ACT domain 
with adjacent barrel, and between barrels. A. Open form. B. Closed form. Bottom panel shows the key 
residues (sticks) involved in these interactions. Molecule from adjacent tetramer is shown in different 
colours. 
Based on the analyses above, SAXS experiments for TmaDAH7PSS31I were repeated at low 
protein concentrations (1 and 2 mg·mL-1). The SAXS intensity scattering profile can be 
interpreted by the Fourier-transformation, which transforms I(s) into the P(r)-distribution 
(Figure 2.7), illustrating the relationship between reciprocal space (Å−1) and real space (Å).121 
The scattering profiles showed clear changes in the presence of Phe at the low concentrations 
tested (Figure 2.7 A), in contrast to the previous data collected at high concentrations. This data 
35 
 
supports the analysis on intermolecular interactions, and such interactions are reduced for a 
diluted protein solution. The P(r)-distribution profile is an indication of the data quality and it 
represents the domain structure and symmetry within the protein molecule so that the initial 
estimation about the shape of the molecule can be quickly assessed. TmaDAH7PSS31I appeared 
to have an overall globular shape in solution as suggested by the pair distribution plots (Figure 
2.7 E), and the presence of Phe shifted the r towards smaller distance, indicative of a more 
compact average state. Indeed, this compaction was reflected in the Kratky plots (Figure 2.7 
B). The Kratky plot [s2I(s) as a function of s] is calculated directly from the scattering curve 
and provides an excellent way for evaluation of protein folding and flexibility.122 In the 
presence of Phe, this mutant appeared less flexible. Although the presence of Tyr seemed to 
impact on the shape and flexibility of the protein (Figure 2.7 C, D), the degree of observed 
change was less profound than that caused by Phe.    
In addition to the semi-quantitative examination of comparative protein folding, flexibility and 
conformations from SAXS profiles, the data also allow direct quantitative assessments of the 
derived structural parameters including radius-of-gyration (Rg), maximum dimension of the 
particle (Dmax) and Porod volume (Vp). Rg is defined as the mass distribution of the molecule 
around its gravity centre, and often used to describe the overall compaction of the molecule. 
Dmax measures the longest dimension of the molecule. Vp provides the hydrated volume of the 
molecule, as determined by application of Porod’s law.121-122 In the presence of Phe, 
TmaDAH7PSS31I appeared to adopt a smaller and more compact state in contrast to the apo 
state, as suggested by Rg, Dmax and Vp values (Table 2.2). The presence of Tyr did not cause 




Figure 2.7. A, C. SAXS profiles of TmaDAH7PSS31I in the absence (black dots) or presence of Phe 
(blue dots) or Tyr (red dots). B, D. Kratky plots showing differences in protein flexibility. E. Pair 





Table 2.2. SAXS parameters of TmaDAH7PSS31I in the absence or presence of Phe or Tyr. 





I(0) (cm-1) [from P(r)] 0.278 ± 0.006 0.261 ± 0.01 0.274 ± 0.006 
Rg (Å) [from P(r)] 36.83 ± 0.17 35.89 ± 0.16 36.78 ± 0.15 
I(0) (cm-1) (from Guinier) 0.278 ± 0.001 0.261 ± 0.001 0.274 ± 0.001 
Dmax (Å) 146.93  125.09  140.46 
Rg (Å) (from Guinier) 36.84 ± 0.2 35.95 ± 0.2 36.78 ± 0.2 
Porod volume estimate (Å3) 290,171  289,364 289,854 
 
SAXS data obtained from wild-type TmaDAH7PS in the absence of Tyr suggests that the 
average states of the protein exist in an equilibrium between the open and closed conformations 
as observed in the crystal structures (Figure 1.5), and the presence of Tyr shifts the equilibrium 
towards the closed conformation.63 The mutant TmaDAH7PSS31I has increased hydrophobicity 
at the ligand binding site, which is located right at the interface of the antiparallel β-sheets of 
two ACT domains. A number of residues with hydrophobic side-chains are found in this region 
(Figure 2.1 B).  It is possible that substitution of Ser to Ile shifts the position of the equilibrium 
to favour ‘closed-like’ conformations in the absence of ligand, as shown by the SAXS data.  
SAXS experiments were therefore repeated at elevated temperatures with the consideration of 
changing the position of the equilibrium by increasing the entropic contribution (ΔS) to ΔG 
(where ΔG = ΔH – TΔS) and to aid the protein in overcoming any local energy barriers. The 
aim was to investigate whether the equilibrium between different states can be shifted, as well 
as to examine if the thermophilic nature of the host organism impacts the protein behaviour. 
Initial tests with a typical SEC-SAXS setup were not ideal due to technical limitations of 
precise temperature control on the SEC column, and the lag period post SEC and prior to X-
ray beam exposure. Therefore, static SAXS experiments were performed for both the wild-type 
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protein and the mutant on a temperature controlled plate at 25 °C and 50 °C (Figure 2.8). 
Generally, no significant change was observed as temperature changed. However, it was 
difficult to conclude the effect of temperature change on the conformations of these proteins 
from this experiment alone, partially because of the mobile feature of the ACT domain. 
Additionally, the nature of the static SAXS experiment did not allow separation of populations 
so that all species in the solution contributed to an averaged scattering profile, which made it 
difficult to distinguish the population of interest.  
 
 
Figure 2.8. Effect of temperature change on SAXS profiles of wild-type TmaDAH7PS (A) and 
TmaDAH7PSS31I (B). No significant difference is observed at 25 °C (black/grey dots) and 50 °C 
(red/pink dots). 
Ligand co-crystallisation  
Extensive efforts were made in attempt to crystallise the TmaDAH7PSS31I mutant in the 
presence of Phe. Initial sitting-drop crystallisation trials included screens JCSG+, PACT, Clear 
Strategy I and II screens (Chapter 7). Crystals with various shapes were identified from 
condition C7 and G5 of the PACT screen, and B8 of the JCSG+ screen. Protein concentration 
ranging from 9 to 12 mg·mL-1 was ideal for crystal growth under these conditions. All three 
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conditions were optimised and crystals from G5 of PACT and B8 of JCSG+ were examined 
using the MX2 beamline at the Australian Synchrotron for diffraction and data collection.  
Initial diffractions pattern showed heavily smeared spots and were up to 3 Å in resolution 
(Figure 2.9). Data were processed using XDS,123-124 cut and scaled using AIMLESS and 
TRUNCATE (CCP4 program suite),125 which suggested the absence of strong data at high 
resolutions with maximum resolution of 4.1 Å, and high mosaicity (1.09). Significant degree 
of twining was also flagged with 50% twin fraction estimated by L-test and 24% estimated by 
Britton. Although molecular replacement using MOLREP failed to generate a solution with the 
wild-type TmaDAH7PS crystal structure (PDB 3PG9) as search model,126 one solution was 
identified by PHASER, however, it was incorrect as suggested by very poor statistics 
(Rfree >45%) from initial refinement. Continuous efforts are being made to obtain better 
crystallography data.  
 
Figure 2.9. Crystal and diffraction images of TmaDAH7PSS31I co-crystallised with Phe. Most images 





2.4. Characterisation of TyeDAH7PS 
2.4.1. Cloning, expression and purification 
The gene encoding for TyeDAH7PS was codon-optimised for expression in E. coli and 
purchased from GeneArt. The construct was designed to incorporate a uncleavable C-terminal 
polyhistidine affinity tag (His6) preserved from pET28-b(+) vector using NcoI and XhoI 
restriction site (Chapter 7). This construct was then transformed into E. coli BL21*(DE3) cells, 
for which the expression level was tested to be sufficient. Transformation and expression 
followed standard procedures described in Chapter 7.  
 
Figure 2.10. Purification of TyeDAH7PS. A. 1, crude lysate. 2, soluble fraction. 3, insoluble fraction. 
4, unbound fraction from His-Trap column. 5, washed fraction. 6-7, eluted fraction containing protein 
of interest. B. 1-6 eluted fraction from SEC column. M, protein size marker. 
A simple two-step protocol was established for purification of TyeDAH7PS (Figure 2.10). The 
protocol isolated the His6-tagged protein from crude soluble fraction by using immobilised 
metal affinity chromatography (IMAC). Desalted protein was then further purified using size-
exclusion chromatography (SEC). The yield of the protein was around 45 mg per litre of cell 
growth. It is worth noting that purification at room temperature was sufficient, as the protein 
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was heat stable at temperatures up to 60 °C (Figure 2.11), consistent with the observed optimal 
growth temperature of the organism at 65 °C.127 An optional heat treatment step at 60 °C could 
be included before the SEC step, depending on the level of purity.  
 
Figure 2.11. Heat stability test of TyeDAH7PS. 1-3, soluble fraction at 60 °C, 70 °C, and 80 °C 
respectively. 4-6, insoluble fraction at 60 °C, 70 °C and 80 °C respectively. M, protein size marker. 
 
2.4.2. Kinetic properties 
Metal and temperature dependence 
The DAH7PS-catalysed reaction is dependent on the presence of a divalent metal ion as 
introduced in Chapter 1. The presence of the metal ion in the active site allows activation of 
E4P as an electrophile, enabling the nucleophilic attack of PEP. A range of divalent metal ions 
were tested to determine the most activating metal for future experiments (Figure 2.12 A). In 
the presence of Cd2+, TyeDAH7PS was significantly more active than other metal ions tested. 
The general trend of metal preference largely followed that of TmaDAH7PS (Figure 3.3). 
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The catalytic activity of TyeDAH7PS was enhanced as temperature increased (Figure 2.12 B), 
and diminished at temperatures beyond 70 °C. Compared to the temperature profile of 
TmaDAH7PS (Figure 3.3), this enzyme generally adopted a lower temperature range than that 
of TmaDAH7PS, which was in agreement with the different growth temperatures of the two 
organisms. 
 
Figure 2.12. Catalytic activity of TyeDAH7PS in response to changes in metal ions and temperature. 
A. DAH7PS activity in the presence of 100 µM metal ion, or EDTA. The mean of triplicate 
measurements from Cd2+ were set as 100% activity. B. The effect of temperature on the DAH7PS 
activity. 
Kinetic parameters 
Kinetic parameters for TyeDAH7PS catalytic activities were determined following published 
procedures for TmaDAH7PS by measuring consumption of PEP at 232 nm (Chapter 7). Cd2+ 
was used for all assays. The apparent KM values for PEP and E4P were 55 ± 2.2 µM and 39 ± 
2.7 µM respectively, and the kcat value was calculated as 23.8  0.7 s
-1 (Figure 2.13). These 
values are generally in line with other Type Iβ DAH7PSs reported in this thesis (Chapter 2.3 




Figure 2.13. Michaelis-Menten kinetics for catalysis of TyeDAH7PS with varying PEP (A) or E4P (B) 
concentrations. Concentration of PEP was fixed at 300 µM when KM for E4P was determined. 
Concentration of E4P was fixed at 210 µM when KM for PEP was determined. Error bar shows SD of 
triplicate measurements.  
 
2.4.3. Regulation 
To test whether TyeDAH7PS is naturally sensitive to the presence of Phe and/or Tyr, kinetic 
assays were performed at 60 °C following the same procedures as that of TmaDAH7PS. The 
catalytic activity of the protein was sensitive to the presence of both Phe and Tyr, and the level 
of sensitivity was significantly different between the two inhibitors (Figure 2.14). The 
inhibitory effect introduced by Phe (~12% remaining activity) was substantially more than that 
of Tyr (~46% remaining activity). The IC50 value of TyeDAH7PS towards Phe was 25 ± 4 µM, 
and IC50 for Tyr was 121 ± 13 µM. In comparison with the apo-protein (Figure 2.13), substrate 
affinity was reduced for both substrates in the presence of 500 µM Phe with a KM value of 176 





Figure 2.14. Activity of TyeDAH7PS in the presence of increasing concentrations of Phe or Tyr. Assays 
contained 255 µM PEP, 181 µM E4P, 100 µM CdCl2, and 0.05 µM enzyme in 50 mM BTP buffer (pH 
7.5 at 60 °C). Error bar represents SD of triplicate measurements.  
 
2.4.4. Structural characteristics 
Gel filtration 
Structural features of the TyeDAH7PS were investigated for the first time. Analytical gel 
filtration is a standard method used to predict the quaternary structure of a protein in solution 
based on the molecular size and shape. Compared to advanced biophysical techniques such as 
AUC, gel filtration is a cheap and simple method widely accessible in many laboratories. 
Calibration of the analytical SEC column with protein standards of known molecular weight 
allows the molecular weight of the unknown protein to be determined based on elution volume. 
The size of TyeDAH7PS was determined by extrapolation from a standard curve of the log of 
molecular weight against elution volume/void volume (Ve/Vo) of protein standards. Different 
from other Type Iβ DAH7PS enzymes characterised so far, the TyeDAH7PS appeared to exist 
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as tetrameric and dimeric species in solution (Figure 2.15). The calculated molecular weight of 
each peak of TyeDAH7PS was approximately 160 kDa at 1 mg·mL-1 injection, in agreement 
with the size of the tetramer; and 68 kDa, which was smaller than but close to the size of the 
dimer. Although the C-terminal His6 uncleavable tag was unlikely to affect oligomeric state of 
the protein as it was located away from the tetramer interface, another construct without 
purification tag was created as a control (Table 7.1). This construct also displayed tetrameric 
and dimeric states and similar kinetic properties compared to the His6-tagged construct.  
The two peaks were collected separately and immediately applied on the analytic SEC column 
again to assess whether the tetrameric and dimeric species were in equilibrium (Figure 2.15). 
The protein collected from the tetramer peak (Peak 1) eluted off the column in two peaks, 
which corresponded to the size of the tetramer and dimer respectively. Protein fractions 
collected from the dimer peak (Peak 2) was also separated into two peaks with the dimeric 
species being dominant. This result indicates that TyeDAH7PS likely exists in solution in an 
equilibrium between dimer and tetramer. Interestingly, it seemed that a shift in equilibrium 
occurred when Phe was added into the two protein samples. Both samples showed a significant 
increase in tetramer population, indicating the presence of Phe might affect the position of the 





Figure 2.15. Gel filtration of TyeDAH7PS in the absence or presence of Phe. A. A typical purification 
trace of TyeDAH7PS contains two major peaks. Peak 1 corresponds to tetramer. Peak 2 corresponds to 
dimer. B. Elution trace of Peak 1 in the absence or presence of 1 mM Phe at 1 mg·mL-1 injection. C. 




AUC experiments were also performed to further examine the interesting observation 
introduced by the presence of Phe and study the nature of the unique dimer-tetramer 
equilibrium. In an ultracentrifuge, macromolecular behaviour is observed under the influence 
of extreme levels of gravity. Under these forces, even small molecules begin to sediment. The 
sedimentation velocity experiment utilises high velocity and measures the shift of the 
sedimentation boundary along the radius over time.128 This movement of molecules through 
the buffer and the diffusion at the boundary provide information about the state of the 
molecules as a function of concentration distribution. Operation of the instrument was 
performed by Dr Sarah Kessans. The AUC sedimentation velocity data was collected for 
TyeDAH7PS in the absence (Figure 2.16 A) or presence (Figure 2.16 B) of Phe at 0.1, 0.4 and 
1.6 mg·mL-1, and processed using SEDNTERP and SEDFIT software (Chapter 7).129  
 
Figure 2.16. AUC sedimentation experiments for TyeDAH7PS in the absence (A) or presence (B) of 2 
mM Phe. Buffer contained 10 mM BTP (pH 7.5) and 100 mM KCl. 
Both data showed the presence of two major oligomers at all concentrations with the small 
species at approximately 3.4 S and the large species at around 7 to 8 S. The small species 
corresponded to a molecular weight in between that of a monomer and dimer, the large species 
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resembled the size of a tetramer. It was difficult to determine whether the smaller species was 
a monomer or a dimer from this experiment alone as the sedimentation coefficient was affected 
by not only the molecular weight, but also the shape and density of the molecule.128 Similarly, 
the calculated molecular weight from gel filtration experiments in the previous section was also 
smaller than the theoretical size of a dimer, suggesting the shape of dimer might affect the 
calculations from gel filtration and AUC velocity experiments. Intriguingly, the presence of 
Phe appeared to shift the sedimentation coefficient of the tetramer towards smaller values 
(Figure 2.16 B), and this change was especially notable at higher concentrations. For example, 
the sedimentation coefficient decreased from 7.9 S (apo) to 7.5 S (Phe) at 1.6 mg·mL-1. The 
tetramer fraction also increased from approximately 65% to 70%. This observation implied 
that the state of the protein was sensitive to the presence of Phe, which appeared to alter the 
position of oligomeric equilibrium and make the structure of the protein more compact.   
Complementary to the sedimentation velocity experiments, sedimentation equilibrium is a 
thermodynamic method under smaller centrifugal force, where an equilibrium distribution of 
species is achieved when the flux by sedimentation and flux by diffusion is balanced.128 
Different from the sedimentation velocity method, sedimentation equilibrium is entirely 
independent on the shape of the molecule allowing accurate determination of oligomeric state 
with typically 1-2% precision.128 The equilibrium constant (Kd) for association of different 
oligomers may also be derived from the sedimentation equilibrium experiment. This method 
was used to further investigate the quaternary structure of TyeDAH7PS and answer important 
questions of whether the protein is in a true oligomeric equilibrium, and what the association 
constant is between different oligomeric states. 
The AUC data was collected over a concentration gradient at 7000, 10000, 12000, and 18000 




solvent density ((s = 1.0032 g·mL-1) and viscosity ( = 1.00267e-02 cP) were calculated from 
protein sequence and buffer composition using SEDNTERP.130 All data obtained from multiple 
cells and concentrations were modelled globally using SEDPHAT with the standard monomer-
dimer association model applied. The TyeDAH7PS dimer was defined as the ‘monomer’ and 
TyeDAH7PS tetramer was defined as the ‘dimer’. The monomer-dimer association model 
produced the best global fitting at all conditions, compared to other models tested including 
the monomer-n-mer association model and the monomer-dimer-tetramer model. This supports 
the dimer-tetramer equilibrium of TyeDAH7PS and verifies that the small species observed 
previously from analytical gel filtration and sedimentation velocity experiments is dimeric, 
rather than monomeric. Key parameters were derived from data collected at 0.2 mg·mL-1 for 
maximum accuracy (χ2 = 1.357, rmsd error of fit = 0.0028). The oligomeric equilibrium was 
also reflected by the fitted molecular weights of approximately 79 kDa and 158 kDa, in precise 
agreement with the theoretical values for the dimer and tetramer respectively. The dissociation 
constant, Kd, for the dimer-tetramer equilibrium was calculated to be 5.13 µM. The dimer (D)-
tetramer (T) association is described as below: 
 





Where [D] and [T] present the molar concentrations of dimer and tetramer respectively. The 
total concentration of protein dimers can be expressed as: 




Figure 2.17. Analysis of AUC sedimentation equilibrium data for TyeDAH7PS. Experimental radical 
distribution profiles (shown as circles) of the protein at all concentrations [0.1 (A), and 0.2 (B) mg·mL-
1] are best fitted to the monomer-dimer model (shown as solid lines) with the ‘monomer’ defined as 
TyeDAH7PS dimer and ‘dimer’ defined as TyeDAH7PS tetramer. Experiments were performed at 7000 
(black), 10000 (red), 12000 (green), and 18000 (blue) rpm, in buffer containing 10 mM BTP (pH 7.5) 
and 100 mM KCl. Fitting from the 0.2 mg·mL-1 data (B) produces the best global reduced χ2 value and 
is used for derivation of other key parameters (C).  
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The dissociation constant (Kd) of 5.13 µM suggests that the protein is likely to be primarily 
dimeric under kinetic assay conditions in the absence of Phe. Therefore, the strong inhibition 
in catalysis observed in the presence of Phe may support the role of Phe in altering the position 
of the dimer-tetramer equilibrium as the tetramer form is expected to be responsible for 
inhibition. Similar AUC sedimentation equilibrium experiments should be performed in the 
future to assess in detail the shift in sedimentation coefficient observed from velocity 
experiments introduced by the presence of Phe, which will aid in defining more clear the effect 
of Phe on the oligomeric equilibrium. 
SAXS 
Initially SEC-SAXS was performed in attempt to separate and observe the dimer and tetramer 
peaks of TyeDAH7PS by SEC prior to X-ray exposure. As relatively low protein concentration 
was required to detect both UV280 peaks, it was difficult to achieve sufficient scattering 
intensity to produce satisfactory level of signal to noise. Static SAXS experiments were then 
designed with a concentration gradient applied based on the Kd value (5.13 µM) of the apo-
protein obtained from AUC, as well as limits on signal to noise. A range of theoretical 
concentration ratios between dimer (D) and tetramer (T) were calculated and used based on the 
relevant equations described previously. These [D]:[T] ratios included 2:1, 1.5:1, 1:1, and 1:1.5, 





Figure 2.18. SAXS scattering of TyeDAH7PS in the absence (A) or presence (B) of 1 mM Phe. 
Concentration series of 0.5, 1, 2, and 4 mg·mL-1 were applied. 
Concentration dependent changes in scattering profiles were evident both in the absence and 
the presence of Phe (Figure 2.18). While in the absence of Phe, a clear trend was observed that 
the averaged molecule became larger as total protein concentration increased (Table 2.3), the 
trend in the presence of Phe was not straight forward. As the Kd value used to calculate the 
theoretical concentrations of dimer and tetramer was derived from AUC of the protein in the 
absence of Phe, and the effect of Phe on Kd was not yet known, the calculated ratio of dimer 
and tetramer may not represent the real experimental ratios in the presence of Phe. This 
unknown equilibrium constant in the presence of Phe posed complications in analysing the 
SAXS data. As described in Chapter 2.3, the addition of Tyr in TmaDAH7PS caused the protein 
structure to change from an open conformation to a closed and more compact conformation, 
leading to decrease in SAXS structural parameters such as Rg, Vp and Dmax for an overall smaller 
structure. For the homologous TyeDAH7PS, similar inhibitory effect occurred in the presence 
of Phe. Assuming Phe impacted on the TyeDAH7PS structure in a similar manner as Tyr did 
on TmaDAH7PS, smaller values of the SAXS parameters were expected in the presence Phe 
for the tetrameric TyeDAH7PS molecules. From Table 2.3, this was the case when the tetramer 
concentration was high. For instance, values of Rg, Vp and Dmax were all clearly reduced when 
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Phe was added to the 1D:1.5T sample. However, as the dimeric species became dominant (i.e. 
as total protein concentration decreased), there was no clear trend on the changes of SAXS 
structural parameters. As observed preciously from gel filtration and AUC experiments, the 
presence of Phe appeared to alter the position of the dimer-tetramer equilibrium and promote 
the formation of tetramer from dimers. Therefore, in the samples that contained supposedly 
more dimers, the addition of Phe might cause more tetramers being formed resulting in an 
increased average molecule size. These tetramers were then subject to inhibition by Phe and 
became more compact resulting in a smaller average molecule size. This mixed contradictory 
effect on the overall molecule size may explain the variations in the structural parameters in 
the presence of Phe at low protein concentrations.  
Table 2.3. SAXS structural parameters of TyeDAH7PS in the absence or presence of 1 mM Phe. 
Theoretical ratios represent molar ratios of dimer (D) to tetramer (T) based on the dissociation constant 
Kd of 5.13 µM. Estimation of sample composition was achieved by using OLIGOMER with 
TmaDAH7PS coordinates as templates.  
Theoretical 
ratio_Apo Rg (Å) Vp (Å





2D:1T 37.31 ± 0.6 245,477 149.75 47.9 ± 21.7 39.3 ± 20 12.8 ± 1.2 
1.5D:1T 38.85 ± 0.5 292,095 150.52 32.6 ± 22.2 57.4 ± 18.6 9.4 ± 4.8 
1D:1T 40.26 ± 0.08 342,564 164.52 21.6 ± 10.9 64.4 ± 10.8 13.9 ± 0.8 
1D:1.5T 42.12 ± 0.12 392,092 174.04 10.5 ± 8 73.1 ± 5.5 16.3 ± 0.6 
Theoretical 
ratio_Phe 





2D:1T 38.45 ± 0.7 271,421 136.63 21.5 ± 22.2 27.8 ± 9.2 50.6 ± 20.3 
1.5D:1T 38.30 ± 0.7 258,440 140.38 19.6 ± 9.1 29.6 ± 6.6 50.7 ± 10.8 
1D:1T 40.29 ± 0.6 303,745 157.16 16.8 ± 5 20.9 ± 2.1 62.2 ± 5.5 




OLIGOMER was also used to analyse the composition of each sample (Table 2.3). Coordinates 
from crystal structures of TmaDAH7PS 1RZM, 3PG9 and a dimeric form derived from 1RZM 
were applied as templates to fit experimental data of TyeDAH7PS. A general trend was derived, 
even though the error appeared large, which was possibly due to the mixed effect caused by 
the heterogenous samples having both oligomeric and allosteric changes. In the absence of Phe, 
most tetrameric species were in an ‘open-like’ form. In contrast, the presence of Phe seemed 
to reduce the dimer component and the majority of the tetramer species appeared closed, 
supporting the shift of Kd caused by the presence of Phe. The variations between theoretical 
ratios calculated based on Kd and experimental ratio estimated using OLIGOMER were also 
noted. OLIGOMER predicted higher ratio of the tetrameric form compared to the theoretical 
value. This was partially because the default setting of the program counted aggregations as 
the largest input molecule. It should be noted that OLIGOMER prediction applied here only 
represents a general estimation and the real Kd value may also be affected by experimental 
conditions such as temperature and pH. Future SEC-SAXS experiments at high protein 
concentrations may be designed to observe the conformational change of tetrameric 
TyeDAH7PS introduced by Phe without interference from the dimeric species. However, the 
effect of Phe on the dimeric species is difficult to be captured by SEC-SAXS experiments due 
to limitations of signal to noise as very low protein concentrations are required.  
Crystallisation 
Continuous efforts were made to crystallise the TyeDAH7PS. Several 96-well conditions from 
Molecular Dimensions were screened using sitting-drop vapour diffusion method, including 
JCSG+, PACT, Clear Strategy I and II, and Proplex. The protein precipitated easily and its 
concentration must be limited to lower than 6 mg·mL-1 to achieve effective screening. 
Additives including PEP, E4P, Cd2+, and Phe were also included in the screening individually 
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or in combinations. Unfortunately, these approaches were unsuccessful in producing lead 
protein crystals. Purified TyeDAH7PS samples in the absence or presence of Phe were then 
sent to the Collaborative Crystallisation Centre (C3) facility in Melbourne for further screening 
of crystallisation conditions. Almost 400 conditions were screened and monitored for two and 
half months, however no lead condition has been identified. The oligomeric equilibrium of 
TyeDAH7PS may contribute to the difficulty in crystallisation.  
 
2.5. TyeDAH7PS mutant 
2.5.1. Preparation of TyeDAH7PS I31S 
Site-directed mutagenesis was performed to create the single-point mutant, 
TyeDAH7PSI31S, by using QuikChange® technique with wild-type TyeDAH7PS-pET28-
b(+) plasmid as template (Chapter 7). The sequence of the PCR product was verified to 
incorporate the correct mutation. The plasmid was transformed in E. coli BL21* (DE3) 
cells. The protein was expressed and purified following the same method developed for 
the wild-type TyeDAH7PS. Purified mutant was confirmed to have the correct molecular 
weight by mass spectrometry (Appendix B, Table S1). 
2.5.2. Kinetic properties 
Kinetic parameters for TyeDAH7PSI31S were determined following the same procedures as for 
the wild-type protein by measuring consumption of PEP. The mutant was catalytically active 
and displayed mildly altered kinetic parameters compared to those of the wild-type protein 
(Table 2.4, Appendix B, Figure S3), with similar KM for PEP and slightly increased KM for E4P. 
The turnover number was increased, which largely contributed to the slightly enhanced 
catalytic efficiencies for both substrates.  
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Table 2.4. Kinetic parameters of TyeDAH7PSWT and TyeDAH7PSI31S.* 




TyeDAH7PSWT 55 ± 2 39 ± 3 24  1 0.44 0.62 
TyeDAH7PSI31S 56 ± 5 46 ± 4 32  1 0.57 0.69 
*Concentration of PEP was fixed at 300 µM when KM for E4P was determined. Concentration of E4P was fixed 
at 210 µM when KM for PEP was determined. 
 
2.5.3. Inhibition 
Mutation of Ile to Ser in the regulatory domain was hypothesised to switch ligand selectivity 
of TyeDAH7PS from Phe to Tyr, complementing the ligand switch by S31I mutation in 
TmaDAH7PS. This hypothesis was tested by adding Tyr or Phe in the enzyme kinetic assays 
for TyeDAH7PSI31S (Figure 2.19). The presence of Tyr inhibited the enzyme activity by 
approximately 80%, while the presence of Phe inhibited catalysis by around 30%, opposite to 
the inhibitory effect observed for the wild-type TyeDAH7PS (Figure 2.14). The IC50 values for 
Tyr and Phe were 73 ± 12 and 161 ± 29 µM respectively. The IC50 value of Tyr was reduced 
by almost two-fold compared to the wild-type protein, suggesting higher sensitivity of the 
mutant towards Tyr. The IC50 value of Phe was increased by almost six-fold, indicating that 
Phe binding to TyeDAH7PSI31S was much more unfavorable.  
Similar to the wild-type TyeDAH7PS, mutant TyeDAH7PSI31S was also in a dimer-tetramer 
equilibrium (Figure 2.20 A). As a result, similar complications are involved in SAXS analysis. 
Nevertheless, scattering profile of TyeDAH7PSI31S was indicative of some sort of 
conformational change when Tyr was present (Figure 2.20 B). The overall shape of the 
averaged molecule appeared to display more globular features in the presence of Tyr compared 
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to the apo protein. As discussed for the wild-type protein, this conformational change in SAXS 
profile observed for TyeDAH7PSI31S was likely contributed by the combination of a few factors. 
First, structural changes of the tetramer population from ‘open-like’ to ‘closed-like’ 
conformation may occur upon addition of Tyr. Second, the formation of tetramers from dimers 
may be facilitated with the presence of Tyr. Additionally, substitution of Ile to Ser at the ACT 
domain interface may also change the population distribution. Further AUC sedimentation 
velocity and equilibrium experiments are necessary for determining the dissociation constant 
of this mutant in the absence or presence of Tyr, so that accurate SAXS experiments may be 
designed that provide more detailed solution behaviour of the dimeric and tetrameric species.  
 
Figure 2.19. Activity of TyeDAH7PSI31S in the presence of Tyr or Phe. Assays contained 255 µM PEP, 
220 µM E4P, 100 µM CdCl2, various concentrations of Tyr or Phe (0-1 mM) and 0.05 µM enzyme in 




Figure 2.20. A. Gel filtration of TyeDAH7PSI31S. Similar to the wild-type TyeDAH7PS, this mutant is 
in a dimer-tetramer equilibrium. B. SAXS scattering of TyeDAH7PSI31S in the absence or presence of 
1 mM Tyr. Protein concentration applied was around 2 mg·mL-1. 
 
2.6. Summary and discussion 
The TmaDAH7PS-like Type Iβ DAH7PS enzymes represent a major class of Type Iβ DAH7PS, 
in which the undecorated (β/α)8 catalytic barrel is attached to an ACT-like domain responsible 
for allosteric ligand binding. Residue Ser31 in the ACT domain of TmaDAH7PS is important 
for Tyr binding, which promotes dimerisation of two ACT domains from diagonally opposing 
DAH7PS chains and hinders substrate entrance to the active site. In this Chapter, the detailed 
characterisation of another Type Iβ DAH7PS from T. yellowstonii shows that the ACT domain-
mediated regulation is likely a general allosteric mechanism utilised by this class of DAH7PS 
enzymes. The studies performed on Ser and Ile mutations of TmaDAH7PS or TyeDAH7PS 





2.6.1. Inhibition of TyeDAH7PS 
The TyeDAH7PS is functionally similar to TmaDAH7PS in many aspects, such as catalytic 
efficiencies, metal dependencies, and temperature-dependent activity profiles. Instead of being 
inhibited by Tyr, TyeDAH7PS displays strong inhibition in the presence of Phe as predicted 
based on the substitution of Ser to Ile in the ligand binding site of the ACT domain. Despite 
the lack of a crystal structure, the inhibition profile and results from AUC and SAXS 
experiments indicate that the mechanism of inhibition employed by TyeDAH7PS likely 
resembles that of TmaDAH7PS, in which a physical gating mechanism occurs in the presence 
of inhibitor.  
Homology models of the open- and closed- forms of TyeDAH7PS have been kindly provided 
by Dr Wanting Jiao using the crystal structures of TmaDAH7PS as templates (PDB IRZM and 
3PG9). The model allows the prediction of the binding conformation for Phe. Phe binds to the 
hydrophobic pocket formed at the dimer interface constructed by the antiparallel β-sheets of 
two ACT domains. In contrast, Tyr binding appears to be relatively unfavourable due to the 
high hydrophobicity around the location of its hydroxyl functionality. The benzene side-chain 
of Phe are primarily stabilised by multiple nearby hydrophobic residues located on β2, β3 and 
beginning of β1 of the ACT domain, including Val2, Ile31, Val38, and Val42 (Figure 2.21). In 
this model, the carboxylate functionality of Phe can form hydrogen bonds with nearby charged 
residues such as Arg46 on the α2-β3 loop, and polar residues on the β2-β3 loop from the other 
chain such as Thr34 and 35. The amino group of Phe can be stabilised by some charged residues 
from the α2-β3 loop, such as Glu45. In this predicted ligand binding pocket, His29 is the only 
charged residue positioned near the hydrophobic side-chain of Phe. This residue is likely 
important in stabilisation of the phenolic hydroxyl group of Tyr, supporting the weak inhibition 
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and high IC50 in the presence of Tyr. Mutation to remove His29 may knock out the Tyr binding 
ability of the protein. 
 
Figure 2.21. A. Phe binding pocket of TyeDAH7PS as predicted based on homology model. Residues 
that contribute to stabilisation of Phe are shown as sticks. Phe is shown as green sticks. Four monomers 
of TyeDAH7PS are coloured separately in red, blue, orange and lime. B. Closed-form model of 
TyeDAH7PS with side-chains of hydrophobic residues highlighted in orange and Phe highlighted in 




2.6.2. Ligand specificity 
The allosteric regulation of TmaDAH7PS and TyeDAH7PS are both conferred by discrete ACT 
domains. As introduced in Chapter 1.4, the ACT domain is a common ligand binding module 
believed to occur early in evolution, and is generally combined with other protein folds.98, 131 
Unlike other DAH7PSs in which allosteric binding sites are preformed, oligomerisation of 
ACT domains contributes to the construction of ligand binding sites at the domain interfaces.98 
Despite the similar structural fold of ACT domains, their low sequence identity is thought to 
be associated with the ability to bind a broad range of ligands.98 This diverse ligand binding 
ability of ACT domains is of substantial interest in understanding the molecular determinants 
of ligand specificity in ACT domain containing proteins. 
 
Figure 2.22. Partial sequence alignment of two Type Iβ TyeDAH7PSs. The key ligand binding motif 
in ACT domain is highlighted in black rectangle. 
The wild-type TmaDAH7PS displays strong inhibition by Tyr and a reduced level of inhibition 
by Phe. Only one protein homologous to a DAH7PS can be identified in the T. maritima 
genome, indicating that the level of Tyr is sufficient in reporting cellular requirements for the 
DAH7PS activity and feedback regulates entry to the shikimate pathway. In contrast, there are 
two proteins homologous to a DAH7PS in the T. yellowstonii genome, encoded by aroF1 
(examined in this study) and aroF2. Both proteins appear to be Type Iβ DAH7PSs, sharing 
55.4 % sequence identity and 73% similarity (Appendix B, Figure S4). Interestingly, instead 
of having the ‘His-X-Ile’ motif at the ligand binding site, the aroF2 DAH7PS has ‘His-X-Ser’ 
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at the equivalent site (Figure 2.22). This suggests that the two Type Iβ isozymes in the organism 
are each responsible for reporting the cellular level of Phe (aroF1) or Tyr (aroF2). 
The Ser or Ile mutation of TmaDAH7PS and TyeDAH7PS demonstrates the important role of 
the residue at position 31 of the ACT domain. The location of this residue is in the middle of 
the interface formed between the β-sheets of the two ACT domains, where the side-chain of 
ligand Phe or Tyr binds to the pocket (Figure 2.23). Sensibly, the electrostatic character of this 
position determines the ligand selectivity. If Ser is present, its hydroxyl side-chain forms key 
hydrogen bonding interaction with Tyr, allowing Tyr binding and subsequent inhibition to 
occur. Although His29 ensures correct positioning of Ser31, by itself it is not sufficient to 
stabilise Tyr. If Ile is present at equivalent position, Tyr binding cannot be stabilised and the 
additional hydrophobicity allows binding of Phe. Single amino acid substitution between Ser 
and Ile at residue 31 is sufficient to interchange ligand binding specificity between Tyr and 
Phe.  
 
Figure 2.23. Ligand binding at ACT domains of TmaDAH7PS (A) and TyeDAH7PS (B). A. Tyr 
binding to TmaDAH7PS (PDB 3PG9). B. Phe binding to TyeDAH7PS (homology model). Tyr and Phe 
are shown as green sticks.  
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2.6.3. Oligomeric state 
Despite the highly similar sequences, structures and functions of TyeDAH7PS and 
TmaDAH7PS, one of the most significant differences between the two Iβ DAH7PSs is their 
oligomeric state. TmaDAH7PS is solely tetrameric, whereas TyeDAH7PS is in a dimer-
tetramer equilibrium. This experimentally identified variation is supported by analysis of the 
tetramer interfaces of the two proteins. The interfaces in TyeDAH7PS model was compared 
with those in the crystal structure of TmaDAH7PS (PDB 1RZM) using program PISA.132 
Slightly smaller interface area was predicted in the tetramer interface of TyeDAH7PS (average 
1377 Å2) compare to TmaDAH7PS (1417 Å2). TyeDAH7PS also lacked multiple hydrogen 
bonding and salt bridge interactions, such as at Arg192 (TmaDAH7PS residue numbering) at 
the tetramer interface, which supports its dimer-tetramer equilibrium (Figure 2.24).  
Inhibitor binding may promote tetramer formation by dimerisation of the ACT domains, as no 
repulsive interactions are identified at the tetramer interface. In fact, ACT domain dimerisation 
is likely a key contributing factor for tetramer formation. Purely tetrameric TyeDAH7PS was 
observed in an N-terminal His6-tagged version of the protein, evident from SEC-purification 
and gel filtration experiments where a single peak corresponding to the size of tetrameric 
species was eluted (Appendix B, Figure S5). This protein was created in reference to a His6-
tagged TmaDAH7PS crystal structure (PDB 1VR6), in which His residues from the elongated 
N-terminus interact with the opposing ACT domains and inadvertently lock the protein in the 
‘closed-like’ inactive conformation without Tyr present (Figure 2.25). The N-terminal His6-
tagged TyeDAH7PS may resemble this crystal structure of TmaDAH7PS and exists as ‘closed 
tetramers’, as no dimeric species was observed from gel filtration experiments. Although 
further studies are required to validate the predicted ‘closed-like’ conformation, this construct 
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may be useful in future crystallisation trials as the complications arisen from the oligomeric 
equilibrium are eliminated.  
 
Figure 2. 24. Comparison between tetramer interfaces of TmaDAH7PS and TyeDAH7PS. A. Side-view 
of TmaDAH7PS with the tight dimer positioned at the front as shown by red and orange, the other pair 
of tight dimer is shown as blue and green. B. Top-view of TmaDAH7PS showing tetramer interface and 
tight dimer interface. C. Hydrogen bonding (blue) and salt bridge (red) interactions identified at the 
tetramer interface of TmaDAH7PS. D. Hydrogen bonding interactions (blue) and salt bridges (red) 




Figure 2.25. N-terminal His tag locks TmaDAH7PS in a closed inactive conformation in the absence 
of allosteric inhibitor (PDB 1VR6). ACT domain is shown in red. DAH7PS barrel is in blue or light 
blue. His tag is shown as green sticks. 
The assembly of oligomeric proteins plays an important role in protein function. For instance, 
active sites or regulatory sites of some protein are constructed at oligomer interfaces; and 
oligomerisation also contributes to protein dynamics and stability.133-138 In general, it appears 
that, although most characterised Type Iβ DAH7PSs are tetrameric, the tetramer interfaces are 
weak in many cases. For instance, removal of the ACT domain from TmaDAH7PS and deletion 
of the CM domain from GspDAH7PS both result in the presence of dimeric species, while the 
wild-type proteins are solely tetrameric.63, 78 Additionally, the unregulated PfuDAH7PS 
becomes dimeric by a single amino acid substitution at the tetramer interface.134 Therefore, 
perhaps unsurprisingly, the newly characterised member of Type Iβ DAH7PS from T. 
yellowstonii is naturally in a dimer-tetramer equilibrium. Future experiments testing the impact 
of factors such as salt concentrations, temperature, or pH on the equilibrium may help further 
the understanding of this equilibrium. Truncation of the ACT domain from TyeDAH7PS may 
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also aid in defining more clear the role of the ACT domain in delivering the oligomeric state 
of the protein.  
The tetrameric form of TyeDAH7PS appears to be responsible for allosteric regulation as the 
addition of Phe promotes formation of tetramer from dimer, perhaps largely due to dimerisation 
of the ACT domains. Consistent with the native TIM barrels being functional as a dimer,135 it 
is possible that the TyeDAH7PS dimer is primarily responsible for providing DAH7PS activity 
in the organism, and the tetramer is responsible for providing allosteric regulation as the protein 
can only be inhibited when tetramer is formed, although the role of oligomerisation in protein 
stability is not yet studied for TyeDAH7PS. The existence of functional dimer appears to be a 
recurring theme and has been reported in Type Iβ, Type Iα and Type II DAH7PSs, for which 
further oligomerisation delivers protein stability and/or allostery.134, 139-140 However, it is 
important to note that whether the dimeric species of TyeDAH7PS occur in vivo is not yet 
known, and the biological function of the dimer (if any) is yet to be determined. The cellular 








Chapter 3. Interchangeability of modular allostery  
 
Preface 
Most proteins comprise two or more domains from a limited suite of protein families. These 
domains are often rearranged in various combinations through gene fusion events to evolve 
new protein functions, including the acquisition of protein allostery through the incorporation 
of regulatory domains. The enzyme DAH7PS is the first enzyme of aromatic amino acid 
biosynthesis and displays a diverse range of allosteric mechanisms as described in previous 
chapters. DAH7PSs adopt a common architecture with a shared (β/α)8 catalytic domain which 
can be attached to an ACT-like or a chorismate mutase regulatory domain that operate via 
distinct mechanisms. These domains confer allosteric regulation by controlling DAH7PS 
function in response to ligand Tyr or prephenate, respectively. Starting with contemporary 
DAH7PS proteins, two protein chimera were created, with interchanged regulatory domains. 
Both engineered proteins are catalytically active, and deliver new functional allostery with 
switched ligand specificity and mechanisms provided by their regulatory domains. This 
interchangeability of protein domains represents an efficient method to not only engineer 
allostery in multidomain proteins but to create a new bifunctional enzyme. Part of the work 






As briefly described in Chapter 1, protein allostery is central to the regulation of many 
biological processes, ranging from ligand transport to metabolic function and control. Allostery 
occurs when ligand binding at one site communicates with a remote functional site, resulting 
in a change in protein function. Allosteric regulation of protein functions often involves a 
complex network of interactions to deliver signal between distal sites. Signal communication 
is achieved via diverse mechanisms ranging from large conformational changes to subtle 
changes in protein dynamics. 1, 141-142 The understanding of these remote communications is of 
great interest, particularly in the fields of drug design and protein engineering.143-144 
Most proteins contain two or more domains.145 These domains and their interactions govern 
the function of a protein and are considered evolutionary units for modular assembly of new 
protein architectures.146-148 Biological data suggest that only a limited number of protein folds 
exists in nature, and protein functions evolve from mutation, duplication and recombination of 
ancestral genes under selective pressure.149 Domain recombination via gene fusion events 
represents one of the major pathways for the evolution of allostery.150-153 This principle has 
been recognised in many natural systems.151 
The enzyme DAH7PS, situated at a crucial biosynthetic node in the shikimate pathway, is often 
precisely feedback-regulated to control pathway flux in response to metabolic demand via a 
variety of allosteric strategies in different organisms (Chapter 1.3). Most characterised 
DAH7PS enzymes are tetrameric in solution, with each chain comprising a (β/α)8 catalytic 
barrel. This barrel is frequently decorated with additional structural elements, which are 
responsible for conferring allostery.80 One major class of DAH7PS enzymes (Type Iβ) share a 
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catalytic domain of a structurally uninterrupted classic TIM barrel (β/α)8 fold, and are either 
unregulated or allosterically regulated (Figure 3.1 A). The simplest form is composed solely of 
the barrel without any additional domain, such as PfuDAH7PS, and hence is unregulated.72-73, 
134 The regulated DAH7PSs in this group display discrete domains appended to the catalytic 
barrel at N- or C- terminus. These domains are either an ACT-like domain98 or a CM (AroQ) 
domain, which possesses CM enzymatic activity. The attached ACT-like and CM domains 
deliver allostery on a tetrameric DAH7PS scaffold via physical gating of the active site 
associated with the binding of an allosteric ligand (Figure 3.1 B, C).63, 77-78 This is best 
exemplified in the well-characterised DAH7PS from Thermotoga maritima, which undergoes 
a remarkable conformational change in response to the presence of Tyr, in which the ACT-like 
domains from opposing chains dimerise to form binding sites for the allosteric ligand and block 
substrate access (Chapter 2).63 This enzyme is also partially inhibited by Phe, although to a 
reduced extent. Similarly, prephenate binding to the CM domain in DAH7PS from Geobacillus 
sp is associated with the more intimate association between the CM and DAH7PS domains to 
form a compact structure and limit catalysis (Figure 3.1 C).78 
It has been demonstrated that the allosteric domain of the T. maritima DAH7PS can be 
transferred onto the unadorned, unregulated DAH7PS of P. furiosus to confer an allosteric 
response in the latter DAH7PS.117 We propose that the recruitment of a regulatory domain is a 
general strategy that by itself is sufficient for providing allosteric control of enzymes. To 
validate this hypothesis and to demonstrate that the key information associated with delivery 
of allostery resides in the regulatory domain, this chapter explores the interchangeability of the 
two distinct regulatory strategies employed by different allosterically controlled DAH7PS 
enzymes, through construction of protein variants that mix and match catalytic and regulatory 
domains of DAH7PSs from T. maritima and G. sp. These studies illustrate the remarkable ease 
with which functional allostery can be acquired by gene fusion events, and provide insights 
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into the evolution of modular allostery, in which existing ligand-binding domains or enzymes 
can be repurposed to provide allostery. 
 
Figure 3.1. Structure and allostery of Type Iβ DAH7PS. A. Monomeric unit of DAH7PS from P. 
furiosus, T. maritima, and G. sp share an uninterrupted catalytic barrel. ACT domain in TmaDAH7PS 
is shown in red; and CM domain in GspDAH7PS is shown in orange. B. Both TmaDAH7PS and 
GspDAH7PS display significant conformational changes in the presence of ligand, compared to the apo 
forms (Tyr is shown as green spheres, and prephenate is shown as navy spheres).  
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3.2. Design and preparation of protein variants 
Crystal structures of the TmaDAH7PS and GspDAH7PS suggest similar architecture and 
arrangement of the homotetramers with the catalytic barrels connected to their respective N-
terminal regulatory domains via a β-hairpin and a flexible linker region. The linker region is 
crucial for the interaction between regulatory and catalytic domains in both enzymes and 
allowing appropriate conformational change between active and inhibited states.63 The amino-
acid regions that incorporate regulatory domains, linker regions and catalytic domains of 
TmaDAH7PS and GspDAH7PS were identified individually from sequence and structure 
alignments (Figure 3.2). Two protein variants with exchanged regulatory and catalytic domains 
were designed: TmaACT-GspDAH7PS with the regulatory domain and linker region from 
TmaDAH7PS (residue 1-93) and the catalytic domain from GspDAH7PS (residues 118-362), 
and the complementary chimera GspCM-TmaDAH7PS with the regulatory domain and the linker 
region from GspDAH7PS (residues 1-117) and catalytic domain from TmaDAH7PS (residue 
94-338). Both constructs were created by amplifying each segment from the corresponding 
parent wild-type gene with overlap and fusing the amplified products (Table 7.1). The fused 
gene fragments encoding each chimeric protein were cloned using Gateway© technique.  
TmaACT-GspDAH7PS was transformed in pDEST14 and expressed in BL21(DE3)* cells, and 
its expression and purification were performed following previously published procedures for 
TmaDAH7PS (Appendix C, Figure S6).63 Briefly, expression was induced with 0.5 mM IPTG 
followed by overnight growth at 23 °C. Two-step purification involved hydrophobic interaction 
chromatography (SourcePhe) and size-exclusion chromatography (Superdex 200 26/60). The 
GspCM-TmaDAH7PS was transformed in pDEST15 and expressed in BL21(DE3)pLysS cells 
using the same expression conditions, and purified using GSTrap HP column following 
published procedures for the truncated GspDAH7PS.78 Size-exclusion chromatography was 
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also used for final step of purification in buffer containing 10 mM BTP (pH 7.5), 100 mM KCl, 
and 200 µM PEP.  
 
Figure 3.2. Scheme of chimera design. Red represents ACT domain from TmaDAH7PS, orange 
represents CM domain from GspDAH7PS, blue represents catalytic domain of TmaDAH7PS domain, 
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and green represents catalytic domain of GspDAH7PS. Alignment includes sequences of the wild-type 
parent proteins and two protein chimera. Black arrow identifies the fusion site. 
 
3.3. Results 
3.3.1. Function of the chimeric proteins  
The wild-type parent proteins TmaDAH7PS and GspDAH7PS share similar homotetrameric 
quaternary structures and tertiary structures with each chain composed of an N-terminal 
regulatory domain (respectively, ACT or CM) attached to a catalytic (βα)8-barrel housing the 
active site. The TmaDAH7PS and GspDAH7PS catalytic barrels share moderate sequence 
identity of 56% (Figure 3.2). Two protein variants were created with exchanged regulatory and 
catalytic domains based on the analysis of wild-type sequences and architectures. Kinetic 
parameters for DAH7PS and/or CM activities of the chimeric proteins were determined 
following previously described procedures by measuring consumption of chorismate at 274 nm 
or PEP at 232 nm, with each reaction containing 0.05 µM enzyme.78 Kinetic parameters KM 
and kcat were determined by fitting data into the Michaelis–Menten equation by using GraphPad 
Prism 7 software. 
Both domain swapped variants delivered DAH7PS catalysis, albeit with some alterations in 
their catalytic efficiencies (Table 3.1). Compared to the wild-type TmaDAH7PS, GspCM-
TmaDAH7PS, which shares the same catalytic core, exhibited impaired activity with 
significantly decreased kcat/KM values for both PEP and E4P substrates, implying there may be 
some restriction of access for substrates to the catalytic centre introduced by the fused CM 
domains. The origin of this may lie in the fact that the CM domain is dimeric both in the absence 
and presence of the allosteric ligand, whereas the ACT-like domain only dimerises upon ligand 
74 
 
binding.63, 78 Hence, perhaps unsurprisingly, the adoption of the more restricted GspCM 
domain to the TmaDAH7PS catalytic core was accompanied by attenuation of catalysis, 
whereas TmaACT-GspDAH7PS displayed an approximately two-fold boost in catalytic 
efficiency compared to the wild-type GspDAH7PS. That physical constraints restrict catalysis 
by the DAH7PS core barrel is supported by the higher activity displayed by truncated forms of 
TmaDAH7PS and GspDAH7PS in which, respectively, the ACT and CM domains have been 
removed.63, 78 
Table 3.1. Kinetic parameters for the two protein variants and their wild-type counterparts.* 






















GspCM-TmaDAH7PS 34 ± 2.7 19 ± 1.8 4.8 ± 0.1 0.14 0.25 190 ± 16 4.1 ± 0.1 0.02 
TmaACT-GspDAH7PS 57 ± 1.6 54 ± 1.4 60 ±2 1.05 1.11 NA NA NA 
GspDAH7PSWT 45 ± 4 61 ± 8 28 ± 0.9 0.62 0.46 98 ± 7 3.4 ± 0.1 0.03 
TmaDAH7PSWT 8.4 ± 0.7 15 ± 1 14 ± 0.3 1.67 0.93 NA NA NA 
*Concentration of E4P was varied between 5 µM and 400 µM while PEP was held at 295 µM. Concentration of 
PEP was varied between 6 µM and 350 µM while E4P was fixed at 310 µM. Reactions contained enzyme, PEP, 
and 100 µM Mn2+ (for proteins containing catalytic barrel from T. maritima) or Cd2+ (for proteins containing 
catalytic barrel from G. sp.), and were equilibrated in 50 mM BTP buffer at 60 °C (pH 7.5) before E4P was added 
to initiate the reaction.  
Unlike the ACT domain, which has only a ligand-binding role, the regulatory domain of full-
length GspDAH7PS has both catalytic and regulatory functions.78 The CM catalytic activity 
was comparably maintained when the domain was transferred to the alternative catalytic barrel 
in GspCM-TmaDAH7PS (Table 3.1), although this chimera displayed an approximately two-fold 
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increase in KM for chorismate compared to wild-type GspDAH7PS. As expected, with no CM 
domain, the variant TmaACT-GspDAH7PS displayed only DAH7PS activity. 
As with all wild-type DAH7PS enzymes characterised to date, the catalytic activity of the 
protein chimera depends on presence of a divalent metal ion (Figure 3.3 A). Mn2+ is most 
activating metal ion for the wild-type TmaDAH7PS, whereas Cd2+ delivers maximal activity 
for GspDAH7PS.63, 78 A range of metal ions were tested with the protein chimera. Largely as 
expected, each of the DAH7PS catalytic cores reflected their inherent metal preference, with 
TmaACT-GspDAH7PS highly favoring Cd2+, whereas GspCM-TmaDAH7PS showed more than 90% 
activity in the presence of Mn2+ or Cd2+.  
 
Figure 3.3. Catalytic activity of the chimera and parent proteins. A. DAH7PS activities of 
TmaDAH7PSWT (blue), GspDAH7PSWT(green), TmaACT-GspDAH7PS (red) and GspCM-TmaDAH7PS 
(orange), in the presence (or absence) of a range of metals. B. The effect of temperature on specific 
activity of the four enzymes in the same colour coding as Figure 3.3 A. Triplicate measurements were 
performed and SD values were used as errors.   
Activity profiles of the two chimeric proteins and parent proteins with elevated temperatures 
(30 °C-80 °C) were also assessed using the standard methods for kinetic measurements of 
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DAH7PS activity (Chapter 7). Consistent with the thermophilic properties of the wild-type 
enzymes, both enzymes became more active at elevated temperatures, reaching their optimal 
activity at temperatures above 60 °C (Figure 3.3 B). Intriguingly, activity of TmaACT-
GspDAH7PS was enhanced significantly at elevated temperatures compared to the wild-type 
GspDAH7PS. On the other hand, GspCM-TmaDAH7PS appeared to be least active across all 
temperatures. Proteins with the GspCM domain, chimeric and wild-type, generally displayed 
lower activities than proteins with the TmaACT domain at the temperatures tested. This change 
in activity profile may relate to the structural difference in the regulatory domains and the 
different optimal temperatures of the parent proteins.  
 
3.3.2. Allosteric regulation 
To test the effect of potential allosteric ligands, inhibition assays were performed for both 
DAH7PS chimera and compared with the response of the wild-type proteins (Figure 3.4, 
Appendix C, Figure S7). Consistent with the presence of a regulatory domain in both chimera, 
inhibition of both enzymes was observed. Presenting the ACT domain, the DAH7PS activity 
of TmaACT-GspDAH7PS was reduced by 70% at high Tyr concentrations, and approximately 
30% at high Phe concentrations. This difference in ligand sensitivity for Tyr and Phe was 
comparable with that of the wild-type TmaDAH7PS, for which Tyr exhibited more significant 
inhibitory effect than Phe, although the IC50 value of Tyr for the chimera (210 µM) was almost 
10-fold higher than that of the wild-type enzyme (22.5 µM). Presence of the CM domain in 
GspCM-TmaDAH7PS delivered sensitivity towards prephenate, although the inhibition was less 
profound than that for the wild-type GspDAH7PS. The presence of 77 µM prephenate reduced 
DAH7PS activity to 50% of its uninhibited value, compared to 20 µM required for the same 
attenuation of wild-type protein catalytic activity. The maximum level of inhibition was also 
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altered; the chimeric protein retained 31% activity at higher prephenate concentrations in 
comparison to the 4% residual activity observed for the wild-type enzyme.   
 
Figure 3. 4. Inhibition of DAH7PS activity in parent proteins and chimera. A. Wild-type TmaDAH7PS 
and TmaACT-GspDAH7PS showed sensitivity towards Tyr. B. Wild-type GspDAH7PS and GspCM-
TmaDAH7PS displayed impaired catalysis with increasing prephenate concentrations.  
Binding of allosteric ligands stabilised the parent proteins and the chimera as demonstrated by 
differential scanning fluorimetry (DSF) results (Figure 3.5, Appendix C, Figure S8). 
Experimental details of the thermostability measurements are included in Chapter 7. In the 
presence of inhibitors, the melting temperatures of both chimera increased by around 3 °C, in 
close agreement with the degree of stabilisation for the wild-type proteins. Interestingly, the 
thermostability of TmaACT-GspDAH7PS improved almost 20 °C compared to the wild-type 
GspDAH7PS. On the other hand, the stability of the GspCM-TmaDAH7PS appeared to be largely 
determined by the TmaDAH7PS core with the denaturing event occurring at above 96 °C. The 
thermostability profiles exhibited by the chimera largely reflect the difference in inherent 
thermostability of the wild-type proteins, remarkably, even when the transferred domain is only 





Figure 3.5. Thermostability of the parent and chimeric proteins in the presence or absence of ligand.  
 
3.3.3. Conformational change 
The allosteric mechanisms of both parental proteins involve conformational rearrangements as 
observed in solution by SAXS experiments.63, 78 To investigate the allosteric strategies 
employed by the chimera, SAXS experiments were performed. In the presence of Tyr, TmaACT-
GspDAH7PS became more compact with a reduced Rg value (derived from Guinier plot) of 
32.8 ± 0.2 Å, compared to the Rg of the apo form 34.0 ± 0.2 Å (Figure 3.6 A, Table 3.2). The 
Kratky plot displayed a more defined curve in the presence of Tyr than without Tyr, consistent 
with the decreased flexibility of the protein (Figure 3.6 B). The GspCM-TmaDAH7PS also 
showed a conformational change with addition of prephenate, with Rg decreasing from 36.9 ± 
0.2 Å to 34.8 ± 0.2 Å, consistent also with the more defined Kratky plot (Figure 3.6 C and D, 





Figure 3.6. SAXS profiles of the chimera. A. TmaACT-GspDAH7PS SAXS scattering profiles fitting with 
the appropriate theoretical scatterings calculated from TmaDAH7PS crystal structures. B. Kratky plot 
of TmaACT-GspDAH7PS SAXS profiles in the absence or presence of Tyr. C. GspCM-TmaDAH7PS SAXS 
scattering profiles fitting with the appropriate theoretical scatterings calculated from GspDAH7PS 
crystal structure (closed form) or model (open form). D. Kratky plot of GspCM-TmaDAH7PS SAXS 
profiles in the absence or presence of prephenate. 
To compare these conformational changes observed in the protein chimera, with those observed 
for the wild-type proteins, the SAXS profiles were fitted with the calculated theoretical 
scattering from crystal structures or homology model of each parent protein (Figure 3.6, Table 
3.2). Scattering profiles for TmaACT-GspDAH7PS showed a good fit with the open-form of the 
TmaDAH7PS crystal structure, but not the closed form, in the absence of Tyr. Conversely, in 
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the presence of Tyr the scattering profile of TmaACT-GspDAH7PS gave a better fit with the 
closed, Tyr bound TmaDAH7PS than with the open apo form. In the absence of prephenate, 
the scattering profile of GspCM-TmaDAH7PS fitted closely with the open-form model of the 
wild-type GspDAH7PS and poorly with the closed, prephenate-bound form of GspDAH7PS. 
In the presence of prephenate, GspCM-TmaDAH7PS was better fitted by the closed prephenate-
bound form of GspDAH7PS than by the open apo form.  












I(0) (cm-1) [from P(r)] 0.12 ± 0.003 0.116 ± 0.002 0.408 ± 0.002 0.397 ± 0.003 
Rg (Å) [from P(r)] 33.96 ± 0.08 32.71 ± 0.08 36.89 ± 0.2 34.76 ± 0.2 
I(0) (cm-1) (from Guinier) 0.12 ± 0.001 0.116 ± 0.001 0.408 ± 0.001 0.397 ± 0.001 
Dmax (Å) 104.16  101.35  120.71  118.43  
Rg (Å) (from Guinier) 34.04 ± 0.2 32.75 ± 0.2 36.91 ± 0.2 34.77 ± 0.2 
Porod volume estimate 
(Å3) 
226,364  222,091  274,596  258,918  
Fit with crystal/model 
structure (χ2) (from 
CRYSOL) 
1.08 0.7 0.78 1.33 
 
 
3.4. Summary and discussion 
Design of proteins with new properties and functions is an important goal of biotechnology. 
The modular feature of many natural proteins suggests that common building domains and 
modules are likely to have the evolutionary advantages of being autonomous and portable, 
offering simplicity in recombination to generate new functions by allowing transfer of 
information through their interactions.154 Statistical coupling analysis of several naturally fused 
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protein systems revealed networks of coevolving amino acids involved in allosteric 
communication, and these networks displayed strong connectivity, proposing the feasibility of 
engineering artificial allosteric systems by transfer of allosteric networks between proteins.144, 
155 Although this transferability has not been extensively explored, a few studies indicate its 
plausibility. For example, a modulating maltose binding protein was fused to an unrelated 
enzyme β-lactamase, introducing maltose regulation to the unregulated β-lactamase.156-158 In 
another example, ultrasensitive molecular switches were built by modular recombination of 
multiple SH3-peptide autoinhibitory interactions on the WASP protein to introduce strong 
cooperativity with respect to the ligand SH3.159-160 Also, an E. coli dihydrofolate reductase 
(DHFR) enzyme was coupled with a light-sensing protein from plants to generate a light-
sensitive DHFR.144 These studies demonstrate that methods of ‘mix and match’ between 
modular components can be effective ways to create substantial functional changes associated 
with allostery and expand the repertoire of artificial proteins.  
Studies described in this chapter demonstrate for the first time the interchangeability of 
regulatory domains in a homo-oligomeric protein. By simple gene recombination of 
contemporary sequences, the Tyr-binding ACT domain on one DAH7PS can be interchanged 
with a prephenate-binding CM domain from another DAH7PS. This interchange functionally 
swaps allosteric regulation in both DAH7PS enzymes elicited by formation of or changes to a 
dimeric structure upon binding of the appropriate allosteric effector. What is somewhat 
surprising is that gene fusion to functionally link these contemporary domains requires no 
modifications to the core catalytic barrels. Fusion of regulatory domain nevertheless inflicts 
some catalytic penalty on the barrel, and the degree of compensated activity may be associated 
with the nature of the extended domains. Allostery mediated by the ACT domain and CM 
domain represent feedback regulatory strategies on different levels, in which the end-products 
of the shikimate pathway are regulatory reporters for ACT-DAH7PS functions, whereas the 
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intermediate product reports cellular demand to control CM-DAH7PS function. The 
interchangeability of the two feedback regulation strategies may reflect the ease in which 
appropriate regulation can be obtained by the organism based on its demand.  
Despite the ease of functional allostery interchange, there are enabling features of the 
contemporary DAH7PS scaffold that are important in accommodating the recombination and 
for maintaining allosteric networks. Core barrel oligomerisation is a prerequisite for allostery 
that involves dimerisation of the regulatory module.62-63, 72, 78 The DAH7PS barrel 
homotetramer adopts an overall conformation that supports the allosteric function, with 
diagonally opposite chains delivering the regulatory domain on either side of the tetramer plane 
(Figure 3.1). This tetrameric assembly appears to be a common feature of most Type I 
DAH7PSs, which is shared by both regulated and unregulated DAH7PS,63, 78, 118, 134 and a 
related enzyme 3-deoxy-D-manno-2-octulosonate 8-phosphate synthase (KDO8PS).161 
Intriguingly, quaternary structure is delicately balanced in this DAH7PS enzyme class. 
Removal of the ACT-like domain from TmaDAH7PS results in dimerisation and the 
(unregulated) PfuDAH7PS is rendered dimeric by a single amino acid substitution.63, 134 
Association of dimers into tetramers was probably followed by acquisition of terminal 
regulatory domains.72 Thus, it appears that the functional gene fusion to deliver allostery was 




Figure 3.7. Analysis of key interactions associated with allostery. Key residues involved in interactions 
between regulatory and catalytic domains are identified in TmaDAH7PS (top view, A) and 
GspDAH7PS (B). C. Partial alignment of Type Iβ DAH7PS sequences, showing segments of the 
catalytic barrel. Black rectangles highlight the location of key barrel residues identified in Figure 3.7 A 




The barrels are not highly conserved overall, but there do appear to be some sequence elements 
that are associated with delivering allostery in both systems that are shared between 
GspDAH7PS and TmaDAH7PS. The key hydrogen bond contacts between either ACT domain 
or the CM domain with the catalytic DAH7PS domain reside mostly at the C-terminus of the 
diagonally adjacent barrel (Figure 3.7 A, B). In the ligand-bound form of TmaDAH7PS, major 
hydrogen bonds are formed between an ACT domain and the barrel from the adjacent chain, 
including Asp51 and Asp309, Ser55 and Arg277, Asp57 and Glu304. Due to the asymmetrical 
nature of the domain arrangement across the vertical plane in the crystal structure GspDAH7PS, 
each CM polypeptide chain communicates with its adjacent barrel through different hydrogen 
bonding interactions. Key interactions are found between the α1-α2 loop of the CM domain 
with the C-terminal end of the barrel, including Arg52 and Asp326, as well as Tyr46 and Glu29 
on one end of the barrel, plus Gly42 and Arg157 on the other end. Sequence alignment between 
TmaDAH7PS and GspDAH7PS suggests that these key regions on the catalytic barrel involved 
in the communication of the allosteric information are highly similar. Indeed, these regions are 
generally well conserved across the Type Iβ family (Figure 3.7 C), which is consistent with the 
involvement of these contact regions in DAH7PS catalysis. All contact regions are located on 
the top side of the barrel, close to the active site. Key residues of the β2-α2 and β8-α8 loops 
form direct hydrogen bonding interactions with the substrates, PEP and E4P, and segments of 
loop β1-α1 and β7-α7 appear to secure the correct positioning of those residues that interact 
with substrates. Together, the DAH7PS barrel appears to be a versatile platform for additional 
functions, which tend to be developed conveniently by hijacking the conserved features of the 
active site, so that allostery can be created with ease when interdomain interactions are re-
established in the presence of ligand. Additionally, some conservation of residue character for 
the N-terminal regulatory domains (charged, polar, and non-polar) may also contribute to the 
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establishment of an allosteric network between DAH7PS and regulatory domain, despite very 
different secondary and tertiary structures of the ACT and CM domains. The linkers between 
the DAH7PS and its regulatory domain share a surprisingly high degree of conservation, 
possibly because of the conformational restrictions for the hinging motions occurring on 
binding the allosteric effectors.  
In addition to the transfer of allostery, enzymatic activity of the chorismate mutase domain was 
also transferred into the GspCM-TmaDAH7PS chimera. Remarkably, thermostability was 
determined by the more thermophilic component of the chimera, even when that component, 
as in the case of the ACT domain of the DAH7PS from the hyperthermophilic T. maritima was 
transferred onto the much larger DAH7PS domain from the less thermophilic G. sp – the 
proverbial tail wagging the dog. The generality of this phenomenon, as a mechanism for 
inducing thermostability into more mesophilic enzymes remains to be elucidated.    
From one enzyme and two distinct regulatory domains, we have four allosterically regulated 
enzymes, two occurring in Nature and two created in the laboratory, one of which is 
additionally a new bifunctional enzyme. The engineering of allosteric control, enzymatic 
activities and thermostability by domain swapping illustrates that homologous (β/α)8 structures 
can tolerate new modular domain combinations. Future investigations into the details of the 
corresponding allosteric networks experimentally and computationally are important for the 





Chapter 4. Allostery of Type II DAH7PS 
 
Preface 
The non-covalent protein complex between DAH7PS and CM from M. tuberculosis was 
previously identified by Sasso et al. Complex formation was shown to significantly boost the 
catalytic activity of CM and allow a fine-tuned allosteric network between the two proteins.30 
Whether or not the allosteric regulation displayed by MtuCM-DAH7PS represents a general 
allosteric strategy employed by microorganisms with a Type II DAH7PS is unknown. In the 
absence of MtuCM, MtuDAH7PS by itself presents unusual synergistic regulation by aromatic 
amino acids without large conformational change,64 in contrast to the regulation via a discrete 
ligand-binding domain in Type Iβ DAH7PS. This chapter describes characterisation of Type II 
DAH7PS and CM from bacterial pathogen H. pylori individually, followed by investigations 
of the potential interactions between the two proteins. Published in Protein Data Bank in 2017, 
the crystal structure of HpyCM (PDB 6AL9) reveals unusual features in the active site 
architecture and provides structural clues for interactions with HpyDAH7PS. The implications 
of this work for providing a rational target for design of novel antibiotics against H. pylori are 






4.1. Introduction  
4.1.1. Allostery and drug design  
Given the extensive occurrence of allosteric regulation built on intrinsic flexibility of proteins 
in biological systems as described in Chapter 1, it is therefore not surprising that the field of 
allosteric drug discovery is being actively explored.162-163 Compared to the classical approach 
targeting the functional site of a protein to execute an inhibitory effect, allosteric drugs are 
developed to activate or inhibit a function from a site remote to the active site. Examples of 
several allosteric activators are reported in an excellent review.164  
Similar to the classical orthosteric drugs, allosteric drugs form noncovalent or covalent 
interactions with the target molecule.163 Their effectiveness often relies on the conformational 
switch between the on- and off- states of the protein. Binding of the allosteric drug to the protein 
is designed to shift the free-energy landscape towards the desired energy state. The level of 
allosteric drugs modulates the reversible functional switch between active and inactive states, 
rather than eliminating a function of the target completely. Examples of allosteric drugs include 
valium and benzodiazepines, which target the major neurotransmitter gamma-aminobutyric 
acid (GABA) receptor and enhance the effect of GABA.165-166  
Features of allosteric drugs provide them with numerous advantages over orthosteric drugs that 
target the active site. As allosteric sites tend to be less conserved in protein families than active 
sites, allosteric drugs can be highly specific with lower risk of toxicity and side effects.163 
Moreover, allosteric drugs can allow direct allosteric modulation by binding to the target 
protein, or indirect modulation by propagation of signals among a series of proteins through 
88 
 
protein-protein interactions.144, 167 This indirect allosteric modulation can potentially expand 
the repertoire of allosteric drugs and allow fine-tuned allosteric control. 
The discovery of allosteric drugs is challenging due to many factors. Unlike orthosteric drugs 
targeting known functional sites, it is difficult to predict or identify binding sites for allosteric 
effectors.163 Slight alteration of allosteric interaction may cause diverse downstream effects, 
especially for drugs designed based on indirect allosteric modulations.168 As with all drugs, the 
development of allosteric drugs also faces common problems, such as drug resistance as well 
as metabolic and genetic variations among patients.163  
 
4.1.2. Human pathogen Helicobacter pylori 
Helicobacter pylori (Hpy) is a Gram-negative bacterium that inhabits the epithelial lining of 
the human stomach. The bacteria rely on the contact-dependent molecular communications 
with the host to modulate or hijack the signal transduction pathways in the host cell.169 It is one 
of the most successful human pathogens colonising around half of the population worldwide. 
Chronic gastritis is developed often unnoticed in all carriers, but severe gastric diseases, such 
as gastric cancer and peptic ulcer, occur in almost 15% of the infected population.170-171 H. 
pylori causes a high mortality rate following these severe gastric diseases. 700,000 deaths occur 
every year from gastric adenocarcinoma, representing the third leading cause of cancer-related 
deaths worldwide.171 
Over a decade ago, the treatment for H. pylori infection seemed to provide high level of success. 
The commonly recommended ‘legacy triple therapy’ includes a proton pump inhibitor (PPI), 
amoxicillin and clarithromycin.172 The effectiveness of the current treatments has now declined 
significantly to unacceptable levels in most populations, largely due to the increase in 
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antimicrobial resistance to clarithromycin.172-173 The world’s leading H. pylori scientists have 
pointed out the long overdue necessity to develop alternative treatments.172  
The long co-evolution history of H. pylori with humans in the past 100,000 years makes it 
challenging to identify alternative therapies against this bacterial infection.169 Aforementioned 
knockout studies and development of enzyme inhibitors of the shikimate pathway (Chapter 1.2) 
emphasise the necessity of the pathway in many pathogens, providing a rational avenue for 
design of novel antimicrobials against H. pylori.  
 
4.1.3. Interactions between DAH7PS and CM  
Protein-protein interactions play important role in enzyme functions. For example, formation 
of protein complexes may facilitate the regulation of enzymatic activities, and substrate 
channelling of pathway metabolites between active sites may decrease fusion time and 
therefore enhance the capacity of a metabolic route.174 
Chapter 3 detailed the interactions between Type Iβ DAH7PS barrel and its covalently tethered 
CM regulatory domain to support allosteric regulation of DAH7PS activity by chorismate or 
prephenate. In addition to this inter-domain interaction, the crystal structure of a non-covalent 
protein complex between Type II DAH7PS and CM from M. tuberculosis revealed a second 
type of interaction between the two proteins as briefly introduced in Chapter 1.4 (Figure 1.7).30 
Interestingly, MtuCM alone was reported poorly active and unregulated. Upon complex 
formation, CM activity was dramatically enhanced and became regulated by Phe and Tyr 
synergistically, whereas the MtuDAH7PS activity was unaffected.30 The more than 100-fold 
increase of the CM activity suggests that this complex formation may be physiologically 
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essential for CM function. Recently, another Type II DAH7PS from Corynebacterium 
glutamicum was also found to form a similar non-covalent protein complex with CM.79, 175 
 
4.2. Helicobacter pylori DAH7PS 
4.2.1. Cloning, expression and purification of HpyDAH7PS 
The gene encoding for HpyDAH7PS, from H. pylori strain J99 genomic DNA, was ligated into 
pET-32a(+) and transformed into E. coli BL21(DE3)-pGroESL cells by former researcher Dr 
Celia Webby from Parker group.176 Attempts to replicate the previously published method for 
the expression and purification of HpyDAH7PS were initially conducted.177 However, the 
protein showed low solubility and stability under the reported experimental conditions, only 
10% of enzyme activity was retained after two-days storage at 4 °C attesting to the instability 
of the protein (Figure 4.1 A).176  In addition, the purification protocol involved frequent 
changes in the net charge of the protein by both cation exchange chromatography and anion 
exchange chromatography. As a result, very low yield of purified protein was obtained (1 mg 
per litre of cell growth). A number of methods were tested to improve the protein solubility 
and purification efficiency. These methods included varying growth temperatures from 37 C 
to 30 C or 23 C, decreasing IPTG concentration from 1 mM to 0.5 mM or 0.2 mM, and 
varying lysis conditions and buffers with addition of additives such as DTT, various 
concentrations of salt, divalent metals and substrate PEP. None of these appeared to effectively 
improve the solubility and overall yield of the protein.  
Cloning of the gene encoded for HpyDAH7PS into a pDEST17 vector was performed in 
attempt to optimise the purification procedure by avoiding the use of ion exchange 
chromatography and introducing a polyhistidine affinity tag (His6) on the protein for the ease 
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of detection and purification. Vector pDEST17 allows the incorporation of a TEV protease-
cleavable His6 tag on the N-terminus of HpyDAH7PS via Gateway® cloning technique. The 
sequence-verified HpyDAH7PS-pDEST17 plasmid was then transformed into E. coli 
Chaperone 3 cells for expression following standard procedures described in Chapter 7.  
 
Figure 4.1. Expression and purification of HpyDAH7PS. A. Soluble fraction of the unoptimised 
HpyDAH7PS-BL21(DE3)-pGroESL construct. M, marker. 1, soluble fraction. B. Purification of the 
optimised His6-HpyDAH7PS-BL21(DE3)-pDEST17 construct. M, marker. 1, crude lysate of the new 
construct grown at 37 °C. 2, soluble fraction. 3, insoluble fraction. Lane 4-6 are repeats of 1-3, however 
at 23 °C growth temperature. 7, purified HpyDAH7PS. 
Expression trials of HpyDAH7PS-pDEST17 in E. coli BL21*(DE3) were performed at 23 °C 
and 37 °C after induction with IPTG. Cell growth at 23 °C appeared to yield a high expression 
level of the protein with appropriate molecular weight in the soluble fraction (Figure 4.1 B). 
Cell lysis procedures and detailed purification methods are stated in Chapter 7. Briefly, a fast 
and simple purification protocol exploiting the His6 tag on HpyDAH7PS was developed. 
Immobilised metal affinity chromatography (IMAC) was first used to isolate His6-
HpyDAH7PS from crude supernatant with mild elution conditions. Desalted protein was then 
treated with TEV protease to cleave the His6 tag, which was removed by a subsequent IMAC 
step to produce pure HpyDAH7PS. A SEC step was added when ultrapure protein was required, 
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such as for screening of protein crystals. A yield of 6.5 mg pure HpyDAH7PS was produced 
per litre of cell growth, which was a significant improvement compared to the original construct. 
Purified protein was tested to be enzymatically active, and verified by mass spectrometry to be 
51087.5 Da (theoretical value 51088.6 Da). This mass includes the complete HpyDAH7PS 
open reading frame and three N-terminal linker residues (SGA) left over from the TEV 
recognition site.  
 
4.2.2. Functional analysis 
Kinetic parameters 
Kinetic parameters for HpyDAH7PS catalytic activities were determined following published 
procedures by measuring consumption of PEP at 232 nm.177 Detailed descriptions are included 
in Chapter 7. The apparent KM values for PEP and E4P were 5 ± 0.5 µM and 11 ± 1 µM 
respectively, and the kcat value was calculated as 5.4  0.1 s
-1 (Figure 4.2). 
The kinetic parameters are in line with the reported values for HpyDAH7PS and MtuDAH7PS 
(Table 4.1). Although the KM values of HpyDAH7PS for both substrates appeared to be larger 
than the reported values, the catalytic efficiencies remained highly consistent (1 µM-1s-1 for 
PEP and 0.5 µM-1s-1 for E4P). The differences between this experiment and the reported 
experiment include different protein constructs as stated in Chapter 4.2.1 and different 
experimental conditions. For example, the reported kinetic assays were performed in the 
presence of Mn2+, however, Co2+ was used in this study as it is the most activating metal for 





Figure 4.2. Michaelis-Menten plots for catalysis of HpyDAH7PS with varying PEP (A) or E4P (B) 
concentrations. Concentration of PEP was fixed at 98 µM when KM for E4P was determined. 
Concentration of E4P was fixed at 211 µM when KM for PEP was determined. Error bar shows SD of 
triplicate measurements.    





 kcat  
(s-1) 
Activation by 
divalent metal*  
Reference 
H. pylori 5 ± 0.5 11 ± 1 5.4  0.1 Co2+, Mn2+, Ni2+ This study 
H. pylori 3 ± 1 6 ± 1 3.0  0.3 Co2+, Mn2+, Ca2+ Webby177 
M. tuberculosis 25 ± 1 37 ± 3 3.1 ± 0.1 Co2+, Mn2+, Cd2+ Webby178 
*Only the top three most activating metal ions in decreasing order of effect are shown.   
Metal dependency 
Several divalent metal ions were examined to identify the most activating metal for the activity 
of HpyDAH7PS. In the presence of Co2+, HpyDAH7PS exhibited the highest catalytic activity, 
followed by Mn2+ and Ni2+ (Figure 4.3), Both Co2+ and Mn2+ provided more than 90% of 
HpyDAH7PS activity. This is consistent with the published results for this enzyme.177 In fact, 
Co2+ was reported to be the most activating metal ion for the activity of Type II DAH7PS in 
other organisms including M. tuberculosis, X. campestris and S. caespitosus.178-180 However, 
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this does not imply that the metal dependency is type-specific. The structure of the DAH7PS 
catalytic core may play an important role in determining the selection of metals, as shown by 
two members of the Type Iβ family in Chapter 3. Large structural variations among DAH7PS 
members within each family should also be considered.   
 
Figure 4.3. Activity of HpyDAH7PS in the presence of 100 µM metal ion, or EDTA. Error bar shows 
SD from triplicate measurements. The mean of triplicate measurements from Co2+ were set as 100% 
activity.  
pH dependency 
The activities of HpyDAH7PS were examined in assay buffers at a range of pH values, 
determined based on the theoretical pI of the protein (pI = 7.23). These values included 6.5, 7, 
7.5, 8 and 8.5. The optimal pH of this protein was determined to be around 8 at experimental 
conditions (Figure 4.4). This pH was applied for all experiments used to characterise 




Figure 4.4. The catalytic activity of DAH7PS in response to changes in pH. Error bar shows SD from 
triplicate measurements. 
Regulation 
Kinetics - All Type II DAH7PS enzymes characterised to date are feedback regulated by 
aromatic amino acid(s), chorismate or prephenate.179-184 The functionally and structurally 
characterised Type II DAH7PS from M. tuberculosis is synergistically inhibited by all three 
aromatic amino acids.64 To test the sensitivity of HpyDAH7PS towards aromatic amino acids, 
chorismate and prephenate, enzyme assays were conducted following procedures described in 
Chapter 7. No significant change in the HpyDAH7PS activity was observed in the presence of 
various ligands and combinations of ligands. Different assay conditions, including different 
buffers (BTP, phosphate, Tris, and MES), salt concentrations (0-500 mM NaCl), and various 




Table 4.2. The activity of HpyDAH7PS in the presence of ligand(s). Concentration of each ligand was 
250 µM. PEP concentration was 100 µM, while E4P concentration was varied (180, 50, or 15 µM). The 
mean activity of apo-HpyDAH7PS was set to be 100%. Error represents SD of triplicate measurements. 
Condition A. Activity (%) 
[E4P]=180 µM 
B. Activity (%) 
[E4P]=50 µM 
C. Activity (%) 
[E4P]=15 µM 
Apo 100 ± 0.2 100 ± 0.5 100 ± 0.5 
Phe 102 ± 1 100 ± 1 86 ± 2 
Tyr 110 ± 6 90 ± 6 69 ± 4 
Trp 94 ± 5 92 ± 4 80 ± 1.5 
Prephenate 109 ± 5 98 ± 3 95 ± 5 
Phe + Tyr 101 ± 1 101 ± 1 74 ± 3 
Phe + Trp 91 ± 4 86 ± 2 78 ± 0.5 
Tyr + Trp 99 ± 0.5 96 ± 4 73 ± 4 
Phe + Tyr + Trp 94 ± 5 97 ± 2 62 ± 1 
 
This non-inhibitory result was unexpected, as HpyDAH7PS is the only protein with homology 
to a DAH7PS in the H. pylori genome and located at a crucial node controlling the carbon flow 
from primary metabolism. It is also equipped with (β/α)8 barrel decorations believed to be 
important in ligand binding as suggested from amino acid sequence. In addition, other 
DAH7PS enzymes with Type II features are feedback-regulated by a single or combinations of 
aromatic amino acid.64, 179-180 In MtuDAH7PS, the presence of allosteric regulators alters the 
substrate affinity of the enzyme towards E4P.64 Therefore, the effect of substrate concentration 
on regulation of HpyDAH7PS was investigated. Substrate concentration was reduced from 
saturating level to 50 µM or 15 µM, as it is possible that the presence of ligand only alters KM 
values of HpyDAH7PS towards substrates while keeping Vmax unchanged. Some inhibitory 
effect occurred only when E4P concentration was low (Table 4.2). The enzyme showed 
substantial level of inhibition when Tyr alone, or in combinations, was present in the assay 
with approximately 60 to 70% activity remaining. The presence of Phe and/or Trp also 
appeared to reduce the enzyme activity by around 10 to 20%. In contrast to MtuDAH7PS, in 
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which combination of all three aromatic amino acid completely inhibits the DAH7PS activity,87 
the presence of Tyr, Trp and Phe only eliminated around 40% of HpyDAH7PS activity.  
 
Figure 4.5. Michaelis-Menten kinetics of HpyDAH7PS in the presence of individual aromatic amino 
acid. Concentration of PEP was fixed at 110 µM. Inhibitor concentration was 250 µM in each reaction. 
Error bar shows SD of triplicate measurements. 
Kinetic parameters for HpyDAH7PS were then determined in the presence of aromatic amino 
acids and compared with that of the apo-protein (Figure 4.5). The KM value for PEP did not 
change remarkably with addition of individual aromatic amino acid (data not shown). However, 
the KM for E4P increased around three fold in the presence of Tyr (38 ± 2 compared to 11 ± 1 
µM) and around two fold in the presence of Trp (25 ± 3 µM). In the presence of Phe, the KM 
only increased slightly (13 ± 2 µM), while Vmax values were largely maintained. This result 
supports the non-detectable inhibition observed previously at saturating substrate 
concentrations. Additionally, it was reported that the presence of multiple aromatic amino acids 
(two or three) was able to alter the steady-state kinetic profile of MtuDAH7PS towards E4P 
from the standard hyperbolic response to sigmoidal response demonstrating homotropic 
cooperativity.64 The effect of combinations of inhibitors on kinetic parameters of HpyDAH7PS 
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may be important for future investigations into the difference in allosteric regulation utilised 
by the two Type II DAH7PS enzymes.  
 
Figure 4.6. DSF analysis of HpyDAH7PS. A. Thermostability of HpyDAH7PS in the presence of 
various ligand(s). Error bar represents SD of triplicate measurements. B. Comparison between melting 
events of HpyDAH7PS in the absence (blue) and presence (red) of three aromatic amino acids. Dashed 
lines show the melting curves and solid lines show the inflection points of the melting curves, which 
represent observed Tm values.  
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DSF - Given the effect of aromatic amino acids on HpyDAH7PS activity, DSF was used as an 
initial probe to assess whether aromatic amino acids, chorismate or prephenate could bind to 
the protein and impact on the protein thermostability. The results showed an increase 
(approximately 4-6 °C) in thermostability of the protein in the presence of two, or three 
aromatic amino acids, compared to conditions with no ligand or single ligand (Figure 4.6). 
Chorismate and prephenate appeared to have no obvious effect on the thermostability of the 
protein. This data suggests that the protein is stabilised in the presence of aromatic amino acids, 
however, it does not necessarily mean that the interactions between these ligands and the 
protein are biologically relevant. Techniques such as isothermal titration calorimetry (ITC) 
could be used to verify the observations from kinetic assays and DSF, and quantify the binding 
affinity of the ligands towards HpyDAH7PS.  
 
4.2.3. Structural characteristics  
Quaternary structure 
Analytical gel filtration was used to assess the quaternary structure of HpyDAH7PS (Chapter 
7). The size of HpyDAH7PS was determined by extrapolation from a standard curve of the log 
of molecular weight against elution volume/void volume (Ve/Vo) of protein standards (Figure 
4.7). The calculated molecular weight of HpyDAH7PS was approximately 210 kDa at 1 




Figure 4.7. Analytical gel filtration profile of HpyDAH7PS at 1 (solid line) and 0.2 (dashed line) 
mg·mL-1. 
This result is indicative of the strong presence of tetrameric species in solution under the 
experimental conditions. This quaternary structure is consistent with that of the Type II 
DAH7PS from M. tuberculosis,64 however the shape of the major elution peak is not 
symmetrical, indicating that a mixture of species might be present with the tetrameric species 
being predominant. In addition, the slight right shift of the main peak at low concentration, 
compared to higher concentration, indicates the possible presence of smaller species. A 
previous publication stated that the protein was purely dimeric in solution by gel filtration,177 
however the concentration of the injected protein was not reported. This discrepancy can arise 
from different experimental conditions, such as concentrations, choice of protein standards, 
and the resolution of the analytical SEC column. To test whether HpyDAH7PS exists in a true 
tetramer-dimer equilibrium, accurate and advanced methods including AUC and SAXS were 




Figure 4.8. Sedimentation velocity analysis of HpyDAH7PS performed at 0.9 (black line), 0.3 (blue 
line) and 0.1 mg·mL-1 (red line) at 20 °C. Data were collected at 50,000 rpm. A. The best fit (lines) of 
the experimental data (dots). B. Normalised distribution of the species. 
Operation of the AUC instrument was performed by Dr Ali Nazmi. The absorbance versus 
radial position data from AUC sedimentation velocity experiments displayed multiple 
sedimentation boundaries (Figure 4.8 A), which suggested that two or more oligomeric 
populations of HpyDAH7PS were present. The difference between the two major populations 
was confirmed by fitting the data to a continuous size-distribution model, which presented 
standardised sedimentation coefficients of 6 S and 8 S. The molecular mass for each population 
was determined to be approximately 100 kDa, and 200 kDa respectively, based on 
sedimentation coefficients. This was consistent with the molecular weights of the dimeric (102 
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kDa) and tetrameric (204 kDa) species of HpyDAH7PS (Figure 4.8 B). As the protein 
concentration increased, the proportion of tetramer also increased relative to dimer. The shift 
of sedimentation coefficient towards higher values at high concentrations also supported the 
concentration-dependent equilibrium. Further sedimentation velocity experiments at even 
lower concentrations, or sedimentation equilibrium experiments, should be performed to 
determine if the equilibrium can be shifted towards dimer-dominant positions.  
SAXS 
The SAXS scattering profiles of HpyDAH7PS were collected and analysed following 
procedures described in Chapter 7. Both reciprocal [I (s)] and real space (pair distribution 
function) profiles suggested an overall oblate spheroid shape of the protein. The volume and 
size of the protein were estimated using the structural parameters derived from SAXS (Table 
4.3). The radius of gyration (Rg) determined by Guinier analysis (41.62 ± 0.03 Å) was similar 
to that determined by the pair distribution function (41.64 ± 0.07 Å). Dmax was 129.77 and 
porod volume was estimated to be 280,256 Å3, consistent with the theoretical volume 
calculated from sequence (247,256 Å3). The molecular mass of the protein in solution was 
estimated to be four-times of the calculated monomeric molecular mass, confirming tetramer 
formation in solution.185 OLIGOMER analysis estimated 97% of tetramer and 3% dimer in the 
mixture.186 The oligomeric state of HpyDAH7PS in solution determined by SAXS experiments 
was consistent with results from analytical gel filtration and AUC experiments. Although a 
concentration-dependent equilibrium between tetramer and dimer may exist, the dominant 
species was tetrameric at the concentrations examined.  
Experimental data was then compared to the theoretical scattering data calculated from the 
HpyDAH7PS homology model (generated by Dr Wanting Jiao using MtuDAH7PS crystal 
structure) by CRYSOL (Figure 4.9).187 Under the SAXS experiment conditions, the scattering 
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profile showed relatively poor correlation to the theoretical scattering profile calculated from 
the homology model (χ2 value of 3.5). This may be an indication of a bias in the HpyDAH7PS 
homology model towards the crystal structure of the MtuDAH7PS. In addition, despite the 
almost 60% sequence similarity (43% sequence identity) between the two Type II DAH7PS 
proteins, they display important differences (Appendix D, Figure S9). The potential variations 
between crystal packing and solution structure may also contribute to the discrepancy between 
the homology model and the SAXS profile.  
 
Figure 4.9. SAXS scattering profiles and P(r)-distribution of HpyDAH7PS at 2 mg·mL-1 (blue). The 
SAXS data was fitted with the theoretical scattering calculated from HpyDAH7PS homology model 





Table 4.3. Structural parameters of HpyDAH7PS obtained by SAXS. 
Structural parameters HpyDAH7PS 
I(0) (cm-1) [from P(r)] 0.29 ± 0.0005 
Rg (Å) [from P(r)] 41.64 ± 0.07 
I(0) (cm-1) (from Guinier) 0.29 ± 0.0003 
Dmax (Å) 126.77  
Rg (Å) (from Guinier) 41.62 ± 0.03 
Porod volume estimate (Å3) 280,256  
Dry tetrameric volume calculated 
from sequence (Å3) 
247,256  
Calculated monomeric molecular 
mass from sequence (Da) 
51,088.6 
Molecular mass from Porod volume 




Due to the poor correlation between the homology model of HpyDAH7PS with the SAXS 
profile, a new model was generated with the assistance from SAXS beamline scientist Dr 
Nathan Cowieson at the Australian Synchrotron. Rigid-body modelling was conducted using 
the coordinates from individual chain of the homology model to determine relative position 
and orientation by maximising the agreement between experimental and theoretical SAXS 
scatterings. For this type of modelling, each chain is considered static objects and only their 
relative locations are modified. Rigid-body modelling with atomic models is an efficient 
method to reduce fitting problem and represents a powerful and economical way to utilise 
information from SAXS data.122  
The new model that correlated best with the SAXS profile (χ2=0.73) was selected for future 
studies. Compared to the homology model, a significant twist at the tetramer plane was 
identified (Figure 4.10). The two halves of the dimer were rotated by 25° compared with the 
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homology model, and to accommodate this twist the two halves were also moved apart by 
approximately 10 Å. A previous study compared the solution scattering of MtuDAH7PS with 
its crystal structure and suggested close correlation between the two (χ2 = 1.24).188 This 
indicates that the twist in HpyDAH7PS observed from its solution state likely represents a 
genuine structural difference between HpyDAH7PS and MtuDAH7PS, although the crystal 
structure of HpyDAH7PS is not yet determined.  
 
Figure 4.10. Comparison of homology model (A) and SAXS model (B) of HpyDAH7PS. A twist in 
tetramer plane is observed in the SAXS model, indicating this protein may adopt a different shape in 
solution compared to the protein crystal from which it was modelled from. 
Crystallisation 
Extensive crystal screening of several thousand conditions was performed using highly purified 
HpyDAH7PS in attempt to identify lead conditions for producing protein crystals. Multiple 96-
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well screens from Molecular Dimensions were tested using sitting-drop vapour diffusion 
method, including JCSG+, PACT, Clear Strategy I and II, Proplex, MIDAS, and Morpheus 
(Chapter 7). Various protein conditions were also tested, including different protein 
concentrations (2, 4, 6, 8, and 10 mg·mL-1, severe protein precipitation occurred at 
concentrations higher than 10 mg·mL-1), addition of ligand and ligand combinations (PEP, E4P, 
Co2+, Mn2+, aromatic amino acids), and different incubation temperatures (5 C° and 20 C°). 
These attempts were unsuccessful in producing crystals with diffractions that were 
characteristic of protein. The equilibrium between tetramer and dimer, as well as the twisted 
shape of the protein in solution may contribute to the difficulty in crystallisation of this protein.  
 
Figure 4.11. Crystals of HpyDAH7PS from lead conditions. 
Purified apo-HpyDAH7PS (5 and 10 mg·mL-1) samples were then sent to the Collaborative 
Crystallisation Centre (C3) facility in Melbourne for screening of crystallisation conditions. 
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Two shapes of crystals were found in two conditions out of almost four hundred conditions 
screened (Figure 4.11). Optimisation of both conditions was performed by varying salt 
concentrations (0.15-0.3 M trisodium citrate or sodium sulphate) and PEG 3350 concentrations 
(16-26%). Only crystals with the long needle shape (Figure 4.11 B) were reproducible at low 
PEG concentrations (<18%). Protein samples with 5 mg·mL-1 concentration appeared to yield 
better crystals than 10 mg·mL-1, however, the needles were very fragile as observed when 
looping. These crystals were sent to both MX1 and MX2 at the Australian Synchrotron and 
shown to have diffractions that were characteristic of protein, although very poor. Some 
optimisations in crystallisation and cryoprotection conditions were performed, however, none 
of which improved diffraction to a workable level. Further investigation is necessary to 
optimise and identify conditions required to produce HpyDAH7PS crystals with acceptable 
diffractions, as the structural information is essential in understanding the unusual structural 
and regulatory characteristics of this protein in molecular details.   
 
4.3. Characterisation of HpyCM 
4.3.1. Expression and purification  
A synthetic gene encoding for HpyCM (strain 26695) was purchased from GeneArt and was 
codon-optimised for expression in E. coli. The HpyCM-pDEST15-BL21*(DE3) construct was 
available in the Parker laboratory prior to the commencement of this project. Test expression 
of HpyCM produced protein with the expected molecular weight by using standard protein 
expression techniques described in Chapter 7. The N-terminus of the HpyCM construct is fused 
to a 26 kDa glutathione S-transferase (GST) solubility tag. A four-step purification protocol 
was established to isolate HpyCM from impurities and the GST-tag. This purification was 
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achieved by firstly using a GSTrap column containing immobilised glutathione to bind to the 
GST-tag and isolate GST-HpyCM from the crude supernatant. The resulting GST-HpyCM was 
treated with TEV protease prior to a second GSTrap affinity chromatography step and a final 
SEC step (Chapter 7). The resulting HpyCM was sufficiently pure (Figure 4.12).  It is worth 
noting that the cleaved GST-tag could co-elute with HpyCM at times. This residual GST-tag 
was removed by repeated application of the protein on the GSTrap column multiple times until 
the desired purity was achieved. The overall purification of HpyCM yielded approximately 18 
mg of protein per litre of cell culture. The size of the purified protein was determined to be 
11646.2 Da by mass spectrometry, in close agreement with theoretical value of 11641.4 Da. 
 
Figure 4.12. Purification of HpyCM. M, marker. 1, crude lysate. 2, soluble fraction. 3, insoluble fraction. 
4-5, cleaved GST tag. 6-9, purified HpyCM. 
 
4.3.2. Functional analysis 
Kinetic parameters 
Kinetic assays for HpyCM were performed and analysed following the published procedures 
by measuring the consumption of chorismic acid at 274 nm at 30 °C (Chapter 7).30 The apparent 
KM value was calculated to be 94 ± 6 µM, and the kcat value was 3 ± 0.1 s
-1 (Figure 4.13). The 
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KM value is in the micro-molar range, broadly in line with that of other CMs except for the 
MtuCM, which has a KM more than one order of magnitude higher than others (Table 4.4). The 
catalytic efficiencies tend to vary among different CMs, and MtuCM appears to have the lowest 
efficiency. 
 
Figure 4.13. Michaelis-Menten plot for determination of the KM value of chorismic acid for HpyCM. 
Initial velocity values were determined as a function of chorismate concentration in BTP buffer (50 
mM, pH 7.5) at 30 °C. The reaction was initiated by the addition of chorismate.   
Table 4.4. Kinetic parameters of AroQ CMs from different organisms.  
Organism KM (µM)  kcat (s-1) kcat/KM (µM-1 s-1)  Reference 
H. pylori 94 ± 6 3  0.1 3.2 x 10-2 This study 
M. tuberculosis 1140 ± 20 2 ± 0.1 1.7 x 10-3 Sasso30 
E. coli* 30 ± 1 41 ± 0.4 1.4 Zhang189 
P. aeruginosa† 98  6  6.5 x 10-2 Calhoun190 
S. typhimurium† 142  9  6.3 x 10-2 Calhoun190 
P. furiosus 25 ± 2 7 ± 0.7 2.8 x 10-1 This study‡ 
*This CM is part of the E. coli P-protein. †Periplasmic CMs. ‡PfuCM was characterised as part of 




Thermal denaturation of HpyCM was followed by using differential scanning fluorimetry (DSF) 
in 0.2 °C increments from 20 to 98 °C (Figure 4.14). The denaturation profile of the protein 
displays a sharp transition at approximately 51 °C followed by a subsequent denaturation event 
at 66 °C from the native to the complete denatured state. This biphasic melting pattern may be 
attributed to a two-step unfolding event, with each unfolding element occurring at a separate 
temperature.  
 
Figure 4.14. Denaturation profile of HpyCM indicates a biphasic melting process. Solid line shows the 
melting curves and dashed line shows the inflection points of the melting curves, which represent 
observed Tm values.  
Regulation 
The AroQ CMs from different organisms appear to show either no regulation or diverse 
allosteric regulation by aromatic amino acids.30-31, 115, 191-195 Inclusion of individual or 
combinations of Phe, Tyr, or Trp in the kinetic assays did not alter the CM activity significantly 
(Table 4.5). However, the presence of aromatic amino acids, especially Phe and Tyr, seemed 
to stabilise the protein by 2-5 °C individually, and by 7-9 °C with combinations of Phe/Tyr or 
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Phe/Tyr/Trp for each denaturation event measured by DSF (Figure 4.15). Trp alone did not 
have obvious effect on the protein denaturation. Combinations that contained Phe and Tyr 
exhibited similar degree of stabilisation as that for prephenate. This significant stabilisation of 
the protein by Phe and Tyr is intriguing, as chorismate, the end-product of the shikimate 
pathway, is either directed towards biosynthesis of Trp by anthranilate synthase or towards the 
formation of Phe and Tyr by CM. These results imply that although the aromatic amino acids 
do not have direct effect on the catalytic activity of HpyCM, they may still interact with the 
protein and exhibit other roles under cellular conditions, such as, in the presence of cofactor or 
a protein partner. 
Table 4.5. The activity of HpyCM in the presence of ligand(s). Total concentration of ligand(s) in each 
condition was 500 µM. The mean activity of apo-HpyCM was set to be 100%. Error represents SD of 
triplicate measurements. 
Condition Activity (%) 
Apo 100 ± 1 
Phe 98 ± 1 
Tyr 110 ± 8 
Trp 105 ± 7 
Phe + Tyr 103 ± 8 
Phe + Trp 100 ± 1 
Tyr + Trp 107 ± 4 






Figure 4.15. Thermostability of HpyCM in the presence of aromatic amino acid(s). Tm values were 
recorded from the first denature event of the protein. Error bar represents SD of triplicate DSF 
measurements. 
 
4.3.3. Structural characteristics 
The commonly distributed AroQ-type CM typically comprises a dimer of three α-helices and 
is represented by the crystal structure of MtuCM in complex with MtuDAH7PS.30 Thorough 
biochemical and structural characterisation of the HpyCM were performed to aid in the 
investigation of the potential protein complex from H. pylori and the comparison with that of 
the M. tuberculosis. The solution structure of HpyCM was examined mostly using techniques 
including analytical gel filtration, AUC and SAXS. Atomic structure was obtained and 




Figure 4.16. Secondary structure of HpyCM. A. Secondary structure prediction from amino acid 
sequence using PSIPRED server. B. CD spectrum recorded from 0.1 µM protein in SEC storage buffer. 
Secondary structure  
The amino acid sequence of HpyCM was analysed by using the PSIPRED server,196 which 
predicted the secondary structure of the protein to comprise three α-helices connected by two 
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loop regions consistent with the typical fold of an AroQ CM (Figure 4.16 A). This structure 
was verified by circular dichroism (CD) spectroscopy with the observed troughs at 
approximately 208 nm and 222 nm, typical of α-helical proteins (Figure 4.16 B).197 The 81% 
α-helix content predicted from amino acid sequence was in agreement with the 79% estimated 
from the CM spectrum.198  
Solution structure  
The quaternary structure of HpyCM was investigated by analytical gel filtration and AUC 
(Figure 4.17). The molecular weight of HpyCM calculated from the standard curve generated 
by gel filtration experiments was 24 kDa, approximately twice of the theoretical molecular 
mass 11.5 kDa. This result suggests that the protein is dimeric in solution under experimental 
conditions. This quaternary assembly was confirmed by AUC experiments. Operation of the 
AUC instrument was performed by Dr Ali Nazmi. Data from sedimentation velocity 
experiments was fitted to a continuous size-distribution model, which presented standardised 
sedimentation coefficients of approximately 2.2 S. The molecular mass was determined to be 
approximately 25 kDa based on sedimentation coefficients, in close agreement with the 





Figure 4.17. Quaternary structure of HpyCM in solution is dimeric as determined by gel filtration (A) 
and AUC (B). A. Injected protein concentration was 1 mg·mL-1. B. Normalised distribution of the 
species from sedimentation velocity experiments performed at 0.6 (red line), 0.4 (blue line) and 0.2 
mg·mL-1 (black line) at 20 °C. 
SAXS was used to examine the characteristics of HpyCM in the absence and presence of 
chorismate or prephenate. The scattering data were collected with the co-flow technique at the 
Australian Synchrotron, and analysed following procedures described in Chapter 7. The 
reciprocal and real space profiles suggested an overall long rod shape of the protein (Figure 
4.18 AB). Upon addition of chorismate or prephenate, the rod shape appeared to be more 
stretched and extended. The protein also became less flexible in the presence of ligand as 
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suggested by the Kratky plots (Figure 4.18 C), and smaller and more compact as suggested by 
the decreased Rg, Dmax, and porod volume values of the protein (Table 4.6). The SAXS MoW 
data also confirmed the dimeric assembly of HpyCM in solution as determined by gel filtration 
and AUC.  
 
Figure 4.18. SAXS profiles of HpyCM in the absence or presence of 500 µM chorismate or prephenate. 
A. Reciprocal scattering profiles. B. Pair distribution function. C. Kratky plots. Data from apo-HpyCM 
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are shown in black dots or line. Conditions contained chorismate are in red. Conditions with prephenate 
are in blue.  
Table 4.6. Structural parameters of HpyCM obtained by SAXS in the absence or presence of chorismate 
or prephenate. 





I(0) (cm-1) [from P(r)] 0.28 ± 0.001 0.276 ± 0.001 0.275 ± 0.001 
Rg (Å) [from P(r)] 22.83 ± 0.17 22.03 ± 0.18 21.89 ± 0.17 
I(0) (cm-1) (from Guinier) 0.28 ± 0.001 0.276 ± 0.001 0.275 ± 0.001 
Dmax (Å) 80.25  78.88  79.43  
Rg (Å) (from Guinier) 22.81 ± 0.2 21.9 ± 0.2 21.84 ± 0.2 
Porod volume estimate (Å3) 46,282  41,737  41,180  
Dry tetrameric volume 
calculated from sequence 
(Å3) 
13,969 13,969 13,969 
Calculated monomeric 
molecular mass from 
sequence (Da) 
11,546 11,546 11,546 
Molecular mass from Porod 
volume (Da) (from MoW) 
26,712 24,015 21,613 
Number of subunits (from 
MoW) 
2 2 2 
Fit with crystal structure (χ2) 
(from CRYSOL) 
2.284 1.619 1.699 
 
Crystallisation 
Initial crystallisation trials for apo-HpyCM at multiple concentrations were conducted using 
JCSG+, PACT, Clear Strategy I (CSI) and II (CSII) screens (Chapter 7). Some small and 
shattered crystallites were observed in several conditions, including CSI A3, C1 and G10, CSII 
H8, and JCSG+D6, unfortunately none of the conditions produced crystals appropriate for 
diffraction. Chorismate was then added to the protein at a final concentration of 500 µM, and 
the mixture was incubated at 4 °C for three hours prior to crystallisation screening. In addition 
to the aforementioned screens, Morpheus and MIDAS were also used to screen protein samples 
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at multiple concentrations from 5 to 22 mg·mL-1. Heavy precipitation occurred at 
concentrations higher than 22 mg·mL-1. Two shapes of crystals were found in MIDAS 
conditions D8 (0.1 M Tris, pH 8.0, 20% v/v glycerol ethoxylate) and G7 (0.2 M Ammonium 
acetate, 0.1 M MES, pH 6.5, 30% v/v glycerol ethoxylate), sharing the same precipitant 
glycerol ethoxylate (Figure 4.19 AB). However, these crystals diffracted poorly (9 Å) at the 
MX1 beamline largely due to their small size. 
Optimisations of both MIDAS conditions were performed by varying pH, and the 
concentrations of protein, salt, and precipitant. Very slow crystal growth with condition G7 
was observed after at least two weeks of incubation at 20 °C. No crystal was observed in 
condition D8. Therefore, G7 condition was treated as the key target for further optimisation. 
The pH value at around 6 to 6.5 was optimal. Ideal protein concentrations to produce the best 
crystals ranged from 8 to 11 mg·mL-1. Minimal and optimal ammonium acetate concentration 
was 0.2 M, as low salt content could prevent crystal growth completely. Minimal precipitant 
concentration was found to be 30%, with optimal concentrations ranging from 35% to 38%. 
Under optimal conditions, crystals formed after at least three days of incubation at 20 °C 
(Figure 4.19 C). Cryoprotectant was also optimised for best diffraction. Conditions including 
20% PEG 400, 20% sucrose, 25% glycerol, and no cryoprotectant were tested. Both sucrose 





Figure 4.19. HpyCM crystals. A. MIDAS condition D8. B. MIDAS condition G7. C. Optimised G7. 
Table 4.7. Data collection and refinement statistics for HpyCM. 
 HpyCM-chorismate 
Data collection  
Space group C2221 
Cell dimensions  
    a, b, c (Å) 38.87, 63.53, 166.92 
 ()  90, 90, 90 
Resolution (Å) 41.73-2.21 (2.28-2.21)*  
Rmerge 0.121 (0.372)* 
I / I 11.6 (4.1)* 
CC1/2 0.996 (0.911)* 






Resolution (Å) 19.43-2.30 
No. reflections 9097 
Rwork / Rfree 0.2061/0.2369 
Chain length  
    Protein 90 (Chain A) 91 (Chain B) 
    Ligand/ion 3 
    Water 13 
Mean B-factors (Å)2  
    Protein 31.30 
    Ligand/ion 38.58 (PHB) 49.03 (PYR) 34.32 (PRE) 
    Water 33.15 
R.m.s. deviations  
    Bond lengths (Å) 0.010 
    Bond angles () 1.301 
Ramachandran  
    Preferred (%) 97 
    Allowed (%) 3 
    Outliers (%) 0 
PDB entry 6AL9 
*Values in parentheses are for highest-resolution shell. 




Structure determination and refinement 
Three X-ray diffraction data sets were collected from different positions of the crystal at the 
Australian synchrotron using the MX2 beamline at 100 K following single wavelength protocol 
at 0.9537 Å.199 The collected data sets were integrated and processed using XDS and 
AIMLESS (CCP4 program suite).123-125 Data from two of the three data sets (collected from 
the ends of the crystal) showed significant twinning problem (50% by L-test, 15% by Britton). 
The remaining data set (collected form the centre of the crystal) appeared to be less twinned 
(6% by L-test, 10% by Britton) and was used for further processing and model determination. 
The appropriate cut-off resolution was determined via CC1/2 ≥ 0.5 while ensuring the data set 
was complete in the highest resolution shell.200 The data collection statistics are summarised in 
Table 4.7, along with key structure refinement details.  
Protein HpyCM was crystallised in the orthorhombic space group C2221 and diffracted to 2.21 
Å. Molecular replacement was performed with kind assistance from Professor Geoffrey 
Jameson. The monomeric structure of three search models (PDB 1YBZ, 2D8D, 3RMI with 
sequence identity 17.8%, 30%, 35%, respectively to HpyCM) were modified by moving the 
loop connecting the first helix (α1) with the second and third helices (α2α3) and trimming side 
chains by CHAINSAW with the atoms in common with HpyCM preserved.201 The modified 
models were used as multicopy search models with MOLREP.126 DM (CCP4 program suite) 
was used for density modifications in solvent flattening and histogram matching mode.202 
Solutions were produced with α1 and α2α3 identified consecutively by molecular replacement. 
TLS and restrained refinements (TLS group 1: residue 6-95/Chain A, TLS group2: residue 5-
95/Chain B) were conducted with Refmac5.203 The quality of the model was optimised by 
consecutive model building in Coot and refinement with Refmac5.203-204 Water molecules were 
added via interpretation of the 2|Fo|-|Fc| and |Fo|-|Fc| maps, with the requirement that putative 
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water molecules formed at least one hydrogen bond with the protein. Electron density for 
residues 1-5 and 96 in Chain A, and 1-4 and 96 in Chain B was absent, which may be attributed 
to these residues being part of the flexible loop at both termini. The validation tools of Coot 
were used to assess structure quality during refinement cycles and before deposition.204 
Following refinement of the protein and water molecules, electron density of respective ligands 
was observed in the active sites. Ligands PRE, PHB and PYR were added and manually 
positioned into the electron density using Coot and then refined with Refmac5. Model 
elaboration and refinement continued until no further improvement of Rwork/Rfree could be 
achieved.  
Crystal structure 
Overall structure - The asymmetric unit contains two HpyCM monomers, each composed of 
three α-helices connected by loops forming an intertwined tight dimer packed into the unit cell 
(Figure 4.20 A). Several residues in the α1α2 loop regions and the C-termini are disordered. 
This disordering appears to be more severe in Chain B, resulting in poorly defined α1α2 loop 
compared to that of Chain A. Superposition of Chain A and Chain B shows high similarity 
between the two chains as expected, with a root square mean deviation (RMSD) value of 0.19 
Å. The only differences are situated in the active-site loop regions and the termini (Figure 4.20 




Figure 4.20. Crystal structure of HpyCM. A. The protein is composed of two monomers in blue and 
red. B. Structural superposition of the two monomer shows differences in α1α2 loop and terminal 
regions. 
Although the sequence identity between HpyCM and EcoCM is only 25%, their overall 
structural features are comparable (Appendix D, Figure S10). The overall RMSD for the 
superposition of HpyCM with EcoCM (PDB 1ECM) is 3.61 Å. The major differences between 
the two structures arise from the orientation of the C-terminal pair of helices (α2 and 3) 
compared to the N-terminal helix, the disordered active-site loop and difference in length of 
the C-terminal helix (Figure 4.21 A). These helices appear to be more arched in HpyCM. 
Furthermore, superposition of available CM structures with similar fold from PDB shows 
substantial variations with these regions, and the differences in the shortest α-helix (α2) is 
especially profound as evident in Figure 4.21 B. In contrast, the positioning of α1 and 3 appear 




Figure 4.21. Structural comparison of HpyCM with other available structures. A. Superposition of 
HpyCM (blue) and EcoCM (green). B. Superposition of all CM structures with similar fold to HpyCM, 
including PDB 1ECM, 5HUB, 2VKL, 2D8E, 2D8D and 1YBZ. C. Superposition of HpyCM (blue) and 
PaeIPL (orange). Ligands at the active sites are shown in sticks. 
Active site - Ligand electron density for prephenate (PRE) is identified in the active site and 
well-fitted in Chain A (Figure 4.22). In contrast, the density in the equivalent position of Chain 
B is unequivocally inconsistent with PRE, and is well-fitted by para-hydroxybenzoate (PHB) 
and pyruvate (PYR). This difference in ligand density at active site between each chain is also 
observed in other data sets collected under the same conditions. The difference in the active-
site loops between each chain may be associated with the difference in ligand density between 
each active site. The active-site loop in Chain A lightly caps the active site, forming a tunnel 
with PRE bound in the middle and both ends opening to solvent (Figure 4.23 A). Whereas in 
Chain B, the active-site loop latches the entrance to the active-site pocket tightly leaving 
smaller solvent accessible areas and forms a relatively more ‘capped’ active site compared to 
Chain A and to the corresponding chain in EcoCM (Figure 4.23 B). Upon closer inspection, 
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the main contact associated with the tight latching of the active site is formed between the 
main-chain amide group of Pro45 and Ile46 in the loop region of Chain B with the carboxylate 
group of Glu88 from α3 helix (Figure 4.23 C). The different loop positioning in Chain A 
distances the sidechain of Glu88 from the loop, therefore no interaction is observed to cap the 
active site of Chain A exposing the active site to a larger solvent accessible area.  
 
Figure 4.22. Electron density maps for the PRE, PHB and PYR bound structure of HpyCM. Ligands 
bound at the active sites are shown as yellow sticks with their density shown by weighted |Fo|-|Fc| omit 
maps (grey) contoured at 3σ, generated using program FFT (CCP4 program suite) before addition of 
the ligand to the model. 
The substrate chorismate included in the crystallisation condition is converted to product 
prephenate in Chain A, and to PHB and PYR in Chain B, which suggests that HpyCM may 
moonlight as a lyase (Figure 4.24). Interestingly, the isochorismate-pyruvate lyase from 
Pseudomonas aeruginosa (PaeIPL), which is a structural homologue of CM, has both lyase 
(converts isochorismate to pyruvate and salicylate) and chorismate mutase activity (Figure 4.21 
125 
 
C).205-206 This enzyme shares striking structural similarity with HpyCM yielding RMSD of 2.15 
Å (PDB 2H9D), albeit low sequence identity (18%). In fact, this RMSD value is lower than 
that with any other available CM structure (ranging from 3.19 to 9.66 Å). 
Further inspection of the details of the active site shows that the PRE binding mode in Chain 
A of HpyCM is highly similar to that of a transition state analogue (TSA), an oxabicyclic acid, 
in EcoCM (Figure 4.25 A and C).101 In the active site of the EcoCM, Arg11’ (from the opposing 
chain), Arg28, and Ser84 interact strongly with the carboxylate group at C11 of the TSA with 
a water molecule bridging the two carboxylates and Arg 51. Asp48 and Glu52 interact with the 
hydroxyl group at C4, and Lys39 interacts with the carboxylate at C11 and the ether oxygen, 
which also forms a hydrogen bond to Gln88. In HpyCM, seven out of the eight residues 
important for TSA binding in EcoCM are highly conserved, including Arg13’, Arg30, Lys41, 
Arg51, Glu52, Ser83 and Gln87. Six of these residues Arg13’, Arg30, Arg51, Glu52, Ser83 
and Gln87 form highly similar contacts with PRE in the active site of Chain A, compared to 
the active site of EcoCM. Lys41, located in the disordered active-site loop does not form direct 
contact with PHB in the observed crystal structure. However, it could interact with the 
carboxylate on C6 in alternative rotamer conformations. Also located at the active site, Tyr47 
and Cys48 are not conserved. Cys48 appears to secure the correct positioning of Arg51 and 
Glu52. The hydroxyl group C13 of PRE also interacts with main-chain amide of Tyr47 and 
Cys48. Sidechain of Tyr47 is pointed away from the active site and is not involved in binding 




Figure 4.23. Comparison of the active-site loops in each chain of HpyCM. Differences in loop 
arrangements cause different active-site architectures. A. Surface representation of HpyCM (blue) with 
active-site loop highlighted in green. Cross section of solvent accessible surface showing the ‘tunnel’ 
with product PRE in the active site of Chain A. B. Active-site pocket in Chain B is less solvent 
accessible due to the tight latching of the active-site loop. C. Interactions between the active site loop 
(Pro45 and Ile46, green sticks) and α3 helix (Glu88, blue sticks) in Chain B contribute to the enclosed 




Figure 4.24. Proposed reaction scheme in each chain of the HpyCM crystal. In Chain A, a typical CM 
catalysed reaction occurs converting chorismate to prephenate via a transition state (reaction mechanism 
shown in Appendix A). In Chain B, the meta pyruvyl group of chorismate appears to be removed and 
results in formation of 4-hydroxybenzonate and pyruvate. 
The binding mode of PHB and PYR at the active site of Chain B in HpyCM is highly similar 
to that of PRE binding to Chain A, with same residues involved (Figure 4.25 A and B). With 
the concomitant aromatisation of the ring, the contacts between the carboxylate group and 
Arg30 change slightly due to its altered orientation. The PYR binding mode is consistent with 
that observed in PaeIPL (Figure 4.25 D). PYR forms direct interactions with Arg13’ and Gln87, 
and indirect interactions with Arg51 and PHB via the water molecule (HpyCM numbering). 
The carboxylate functionalities of PHB in HpyCM and of salicylate (SAL) in PaeIPL form 
similar contacts with the water molecule and Arg30 (Arg31 in PaeIPL). Additional hydrogen 
bonding is provided by Ser83 in HpyCM. The hydroxyl functionality of PHB forms a hydrogen 
bond with the main-chain amide of Tyr47 and Cys48, whereas the hydroxyl group of SAL 
hydrogen bonds to the conserved Gln90 in PaeIPL. Overall, the key residues in the active sites 




Figure 4.25. Active site constructions of HpyCM, EcoCM and PaeIPL. A. Active site in Chain A of 
HpyCM with PRE bound. B. Active site in Chain B of HpyCM with PHB and PYR bound. C. Active 
site of EcoCM with TSA bound. D. Active site of PaeIPL with SAL and PYR bound. Key residues that 
form the active site are shown as sticks, active site ligand is shown as black sticks. Water molecules 
(WAT) are shown as red spheres.  
The reduced charged interactions in the active site of HpyCM compared to EcoCM, combined 
with the unusual positioning of the disordered loop may explain the active site promiscuity that 
probably allows the lyase activity to occur under the crystallisation conditions. This may be 
supported by the fact that the promiscuous active site of PaeIPL also has reduced charged/polar 
contacts compared to that of EcoCM. Furthermore, the conserved Lys residue in the active-site 
loop forms a gateway for substrate entry and product release.205 The Lys is hypothesised to be 
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vital in electrostatic stabilisation of the transition state of the CM reaction, a single amino acid 
substitution of the Lys to a His in PaeIPL maintained the active site architecture but completely 
perished the CM activity, signifying the importance of electrostatic strength in the active site 
for CM catalysis.206 In HpyCM, this conserved Lys residue unexpectedly does not form obvious 
contact with ligand due to its unusual rotameter positioning observed in the crystal, which may 
alter the electrostatic field of the active site and affect CM catalysis.  
Comparison with solution structure – The crystal structure of HpyCM in complex with PRE, 
PHB and PYR was compared with the SAXS scattering profile of the protein in the absence or 
presence of chorismate or prephenate (Figure 4.26 A). Scattering profile calculated from the 
crystallographic data was best fitted with the experimental scattering of the protein in the 
presence of prephenate with χ2 of 1.619 (Table 4.6). Fitting of data from the sample with 
chorismate was similar to that of prephenate, with a slightly higher χ2. In contrast, scattering 
data from apo-protein was not well fitted with the theoretical scattering. Although the crystal 
structure appeared to resemble the ligand-bound SAXS data closely, some differences may 
reflect the effect of crystal packing on the protein structure. As evident in Figure 4.26 B, the 
protein from crystallographic data appeared more rigid than any sample in solution. A slightly 
more defined curvature in the theoretical scattering of the crystal data was also apparent (Figure 
4.26 A), suggesting that crystallographic constraints may affect the observed HpyCM structure, 
and the actual biological structure of this protein is possibly more relaxed than the crystal 




Figure 4.26. Comparison between crystal structure and solution structure of HpyCM. A. SAXS 
scatterings of HpyCM in the absence (black dots) or presence of chorismate (red dots) or prephenate 
(blue dots), fitted with the theoretical scattering calculated from crystallographic data (green line). B. 
Kratky plots show that flexibility of the protein in the crystal form closely resembles the solution 




4.4. Interaction of HpyDAH7PS and HpyCM  
4.4.1. Protein complex detection 
Several techniques were tested in attempt to capture the complex between HpyDAH7PS and 
HpyCM in solution and in crystalline form. Due to the small size of HpyCM in relation to the 
putative protein complex and the limited resolution of some techniques, it was difficult to 
differentiate the complex from the HpyDAH7PS tetramer. Preliminary gel filtration 
experiments showed a slight left shift of peak position towards larger species in HpyDAH7PS 
sample preincubated with HpyCM, compared to HpyDAH7PS alone (Figure 4.27). The 
calculated mass for the putative complex was approximately 220 kDa, although larger than the 
uncomplexed HpyDAH7PS (~204 kDa), it was still much smaller than the theoretical mass of 
the complex (~251 kDa). Therefore, a definite conclusion could not be drawn from this 
experiment, although the peak corresponding to the largest species might contain a mixture of 
complexed and uncomplexed HpyDAH7PS.  
 
Figure 4.27. Analytical gel filtration results of HpyDAH7PS with HpyCM. Blue line shows sample that 
contained HpyDAH7PS alone, red line shows a mixture of HpyDAH7PS and HpyCM at 1:8 molar ratio.  
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An IMAC pull down assay exploiting the His6 tag on MtuDAH7PS was successful in detecting 
the formation of complex between MtuDAH7PS and MtuCM.207 Similar experiments were 
designed to assess potential complex formation between HpyDAH7PS and HpyCM. The 
experimental setup was intended to allow the binding of His6-HpyDAH7PS to the IMAC 
column and subsequently applying HpyCM on the column, if complex formation occurred, 
HpyCM would be bound to and co-eluted with HpyDAH7PS. The His6-HpyDAH7PS was 
purified following same procedure as for HpyDAH7PS, with the exception that the His6 tag 
was retained. The protein was applied to an IMAC column and unbound protein was washed 
off before HpyCM was added in the column. After half-hour incubation, unbound protein was 
washed off and bound protein was eluted with elution buffer.  
 
Figure 4.28. SDS-PAGE for IMAC pull down assay. M, marker. 1, His6-HpyDAH7PS loaded on the 
column. 2, purified His6-HpyDAH7PS. 3-5, washed fractions from IMAC. 6-8, eluted fractions from 
IMAC. 
The SDS-PAGE (Figure 4.28) containing the unbound fractions showed a single band at 
approximately 10 kDa, consistent with the monomeric mass of HpyCM. The eluted fractions 
contained a single species between 50 and 60 kDa, consistent with the monomeric mass of 
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His6-HpyDAH7PS. This result indicated that all HpyCM was washed off and not complexed 
with HpyDAH7PS. Only HpyDAH7PS was bound to the column, thus no evidence of complex 
formation was identified from this experiment.  
Table 4.8. SAXS parameters for HpyDAH7PS-HpyCM experiments. The sample column shows the 
molar ratio of each protein used (HpyDAH7PS is shown as ‘D’, HpyCM is shown as ‘C’). 






0D:10C 1.33 5715 29.49 0 ± 0 0.185 ± 0.003 0.815 ± 0.012 
1D:9C  1.23 11162 32.42 0.09 ± 0.033 0.372 ± 0.04 0.538 ± 0.013 
2D:8C 1.22 14543 33.08 0.119 ± 0.027 0.518 ± 0.031 0.363 ± 0.01 
3D:7C 1.2 16575 33.32 0.115 ± 0.022 0.631 ± 0.026 0.254 ± 0.008 
4D:6C 1.05 17391 33.46 0.195 ± 0.018 0.583 ± 0.021 0.222 ± 0.007 
5D:5C 1.23 18750 33.57 0.181 ± 0.017 0.671 ± 0.02 0.148 ± 0.006 
6D:4C 1.06 19072 33.64 0.239 ± 0.014 0.622 ± 0.017 0.139 ± 0.005 
7D:3C 1 19569 33.68 0.257 ± 0.013 0.627 ± 0.015 0.115 ± 0.005 
8D:2C 1.12 20334 33.72 0.239 ± 0.012 0.689 ± 0.014 0.072 ± 0.004 
9D:1C 1.17 20799 33.76 0.244 ± 0.011 0.708 ± 0.013 0.048 ± 0.004 
10D:0C 1.15 20975 33.79 0.274 ± 0.01 0.684 ± 0.012 0.043 ± 0.004 
 
Static SAXS experiments were also designed with various molar ratios between HpyDAH7PS 
and HpyCM to determine whether complex formation could be detected. Ratios of 0:10, 1:9, 
2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1 and 10:0 of HpyDAH7PS and HpyCM with total 
concentration of 20 µM were applied for serial sample preparation in attempt to observe a peak 
of complex at close to equimolar HpyDAH7PS and HpyCM.  
Singular value decomposition (SVD) analysis was first used to analyse the whole concentration 
series and determine the number of independent components in the system. Three distinct 
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species were theoretically expected including HpyDAH7PS, HpyCM, and the complex. Four 
species were experimentally identified to be above the significance threshold (0.002) for the 
calculated files. Two were highly significant (1.69 and 0.02) and the other two were barely 
above the level for significance (0.0029 and 0.0024).  
ATSAS program OLIGOMER was then used with coordinates from crystallographic data of 
HpyCM, rigid body model of HpyDAH7PS generated from previous SAXS experiments 
(Chapter 4.2), and homology model of the complex.186 It is worth noting that due to signs of 
aggregation observed in the HpyCM data, the program automatically incorporated around 18.5% 
HpyDAH7PS to account for the aggregates (Table 4.8). Nevertheless, the decreasing trend of 
HpyCM was still observed across the series as well as an invert trend on HpyDAH7PS, 
consistent with the concentration series applied. A steady increase in both HpyDAH7PS and 
the complex was observed, possibly suggesting the similarity between the two species was so 
high that it was difficult to differentiate them. No peak of complex was observed; hence no 
evidence of complex formation was identified.     
The lack of evidence for complex formation is also evident by analysis of the P(r) functions 
from the SAXS data (Figure 4.29). Theoretical profiles of HpyDAH7PS alone and the protein 
complex were calculated and compared with that from experimental data. The experimental 
profile most different from the HpyDAH7PS alone was chosen for comparison. There was a 
subtle shift of the experimental curve to the right of the calculated curve from HpyDAH7PS 
alone, however this change was not significant compared to the shift of the theoretical curve 
of the complex from that of the HpyDAH7PS alone (~5 Å). Therefore, it is sensible to conclude 
from this experiment that the majority of the sample did not contain protein complex formed 
between HpyDAH7PS and HpyCM, and approximately 5-10% material might be in the 
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complex form. Such insignificant signal was not sufficient to differentiate the protein complex 
from HpyDAH7PS alone. 
 
Figure 4.29. Calculated and experimental P(r) distribution of HpyDAH7PS and the complex. 
Theoretical profile of HpyDAH7PS is shown as a solid line, the complex is shown as dot-dashed line. 
Dashed line represents the 5D:5C experimental data.   
 
4.4.2. Effect on HpyCM 
Structural investigations described above did not provide sufficient support for the formation 
of the protein complex between HpyDAH7PS and HpyCM, functional studies were performed 
to examine the effect of the protein mixture on each individual protein. In the MtuDAH7PS-
MtuCM complex system, the activity of MtuCM was significantly enhanced (>100-fold) in the 
presence of MtuDAH7PS. This was believed to be a result of active site reorganisation upon 
complex formation in order to facilitate catalysis, while the DAH7PS activity was relatively 
unaffected by complex formation.30 Similar experiments were designed to assess the effect of 
HpyDAH7PS on HpyCM and vice versa. The specific activity of one enzyme was determined 
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under a series of concentrations of the other enzyme. The presence of excess HpyCM did not 
have significant effect on the specific activity of HpyDAH7PS as determined by kinetic assays 
(data not shown), whereas the presence of HpyDAH7PS appeared to influence the CM activity 
as shown in Figure 4.30.  
 
Figure 4.30. Specific activity of HpyCM in the presence of HpyDAH7PS, MtuDAH7PS, PfuDAH7PS 
and BSA. HpyCM concentration was held constant (0.1 µM) in each reaction. Enzyme activities are 
specified in U (1 U = consumption of 1 μmol substrate·min-1). Specific activities are given as U·mg 
−1. Error bar represents the SD of three independent measurements. Background activity from 
DAH7PSs and BSA alone was subtracted from the initial rate. 
In the presence of excess HpyDAH7PS, the specific activity of HpyCM increased by 
approximately 2-fold. Proteins including MtuDAH7PS, PfuDAH7PS (Type Iβ) and bovine 
serum albumin (BSA) were also tested as controls. Weak activation was observed when 
MtuDAH7PS was present. The presence of PfuDAH7PS or BSA did not cause significant 
change in the CM activity. Closer inspection indicated that this activity enhancement was 
primarily contributed by the decrease in KM value from 94 ± 6 to 52 ± 3 µM, and slightly 
contributed by the increased kcat from 3 ± 0.1 to 3.5 ± 0.2 s
-1. However, these changes were 
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insignificant compared to that of the MtuCM, for which the KM value dramatically decreased 
from 1140 ± 20 to 34 ± 3 µM, and kcat increased from 2 ± 0.1 to 9 ± 1.9 s
-1 conveying the 
MtuCM activity to a normal range in the presence of MtuDAH7PS.  
Although the activation of CM activity may be linked to interaction with HpyDAH7PS, it may 
not be physiologically relevant for two possible reasons. Firstly, compared to the weakly active 
MtuCM, HpyCM exhibits normal-range catalytic activity by itself (Table 4.4) suggesting it is 
functionally sufficient. Secondly, weak activation is observed in the presence of MtuDAH7PS, 
suggesting that the Type II DAH7PS scaffolds may somehow interact with HpyCM non-
specifically, but not necessarily in the form of a protein complex. This intermolecular 
interaction may facilitate the affinity of HpyCM for the substrate chorismate and influence the 
CM catalysis. In fact, Sasso et al. proposed that some homologous AroQ-type CMs would 
engage in activation by a Type II DAH7PS due to their consensus active-site and structural 
features, supported by the observation that C. glutamicum CM (with naturally low activity) was 
activated by MtuDAH7PS by more than an order of magnitude.30 Therefore, perhaps 
unsurprisingly, the relatively weak activation of HpyCM activity was observed in the presence 
of HpyDAH7PS or MtuDAH7PS.  
In addition to activation of CM activity, it has been reported that complex formation between 
MtuCM and MtuDAH7PS deliverd significant regulation to the previously unregulated MtuCM 
by the presence of Phe and Tyr by 70% and 40%, respectively.30 The effect of the aromatic 
amino acids on HpyCM alone was previously examined (Chapter 4.3) and no regulation was 
detected, although there was an increase in thermostability in the presence of Phe and Tyr. 
Kinetics assays were performed with various concentrations of potential regulatory ligands to 
investigate if the presence of HpyDAH7PS would alter the regulatory behaviour of HpyCM. 
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The three aromatic amino acids were tested as potential feedback-regulators of HpyCM 
individually and in combination with addition of ten-times molar excess of HpyDAH7PS.  
Table 4.9. Activity of HpyCM in the presence of excess HpyDAH7PS. Each condition contained 0.1 
µM HpyCM, 1 µM HpyDAH7PS and 500 µM of ligand(s). The mean activity of apo-HpyCM in the 
presence of HpyDAH7PS was set to be 100%. Error represents SD of triplicate measurements. 
Condition Activity (%) 
Apo 100 ± 0.8 
Phe 94 ± 5 
Tyr 107 ± 3 
Trp 100 ± 0 
Phe + Tyr 88 ± 1 
Phe + Trp 99 ± 0.5 
Tyr + Trp 87 ± 2 
Phe + Tyr + Trp 83 ± 2 
 
The kinetic assay showed no inhibitory effect of HpyCM activity in the presence of 
HpyDAH7PS by individual aromatic amino acid (Table 4.9). When two or more aromatic 
amino acids were present, weak inhibition of the CM activity within approximately 15% of its 
normal activity was detected. This insignificant inhibitory effect of aromatic amino acids on 
the HpyCM activity in the absence (Chapter 4.3) or presence of HpyDAH7PS indicates that 
physiologically HpyCM is unlikely to be regulated, although it is possible that regulatory 






4.5. Summary and discussion 
The work described in this chapter is successful in the establishment of cloning, expression, 
and purification strategies for two important biosynthetic enzymes from pathogenic bacteria H. 
pylori. Both HpyDAH7PS and HpyCM were characterised functionally and structurally for the 
first time. The proposed non-covalent interactions between the two proteins were examined, 
however little or no complex formation was detected. While the two proteins may interact with 
each other, this interaction is believed to be nonspecific under the conditions tested. The 
physiological role (if any) of this interaction under cellular conditions is not yet known.  
 
4.5.1. Regulation and structure of HpyDAH7PS 
Regulation – While HpyDAH7PS and MtuDAH7PS belong to the same subfamily, many 
differences have been identified in this study. In addition, CLAN analysis also suggests that 
the two enzymes belong to distinct clusters (Appendix D, Figure S11). The regulation strategy 
utilised by HpyDAH7PS is not straight forward as described previously. A moderate level of 
inhibition was observed in the presence of aromatic amino acid(s), particularly Tyr, and to a 
reduced level for Tyr and Phe. This inhibition is only detectable at low E4P concentration due 
to the impact of inhibitor on KM for E4P. In contrast, synergistic inhibition occurs in 
MtuDAH7PS, in which Trp, Phe and Tyr are able to occupy three distinct sites formed by barrel 
extensions and insertions, and completely eliminate DAH7PS activity.87 The binding mode of 
the inhibitors to HpyDAH7PS are analysed based on the modelled coordinates in comparison 
with that of MtuDAH7PS. Although HpyDAH7PS appears to be equipped with structural barrel 
decorations likely associated with ligand binding (Appendix D, Figure S9), there are 
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fundamental differences between HpyDAH7PS and MtuDAH7PS, particularly at Phe/Tyr-
binding sites (Figure 4.31).  
Site 1 is located near the tetramer interface and residues from the inserted α2a and α2b-helices 
of MtuDAH7PS contribute to the Trp binding site (Figure 4.31 B). This site is generally 
conserved in HpyDAH7PS, with well-maintained pocket of hydrophobic residues for Trp 
binding and a few charged residues to stabilise the carboxylate functionality of Trp. As this 
binding site is largely contributed by the α2b-β3 loop, it is likely that Trp can be accommodated 
at the same site in HpyDAH7PS. Indeed, a docking experiment conducted by Dr Wanting Jiao 
suggests that it is possible for Trp to bind in the HpyDAH7PS binding pocket with additional 
residues such as Lys106, Arg53, and Glu229 (HpyDAH7PS numbering) located nearby to 
potentially accommodate the carboxylate group of Trp, and the amino group of Trp can form 
hydrogen bonds with residues from the nearby loops in several poses. Although this binding 
pocket appears to be large enough to accommodate the side-chain of Trp and have the 
appropriate residues present, it is important to note that this site is located on the edge of the 
tetramer interface. In contrast to the tetrameric MtuDAH7PS, HpyDAH7PS is in dimer-
tetramer equilibrium with the twist in the tetramer plane as described in Chapter 4.2. This 
difference possibly affects the Trp binding affinity at this site of HpyDAH7PS, which may be 
associated with the relative weak inhibition of HpyDAH7PS by Trp.  
Phe or Tyr binding at site 2 in MtuDAH7PS is capped by two β0-sheets each contributed by 
the tight dimer. However, sequence comparison reveals that this N-terminal β0-strand is 
missing in HpyDAH7PS (Appendix D, Figure S9). The equivalents of some residues involved 
in Phe binding of MtuDAH7PS can be identified in HpyDAH7PS, including Pro56, Phe 91, 
Tyr173 and Ala178 (MtuDAH7PS numbering, Figure 4.31 C). However, perhaps more 
importantly, Ala174 is replaced by a His residue in HpyDAH7PS, Val51 is replaced by Glu, 
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and Val55 is replaced by Tyr. The increase in charged/polar features of this site may destabilise 
the binding of Phe, but promote interaction with the hydroxyl group of Tyr. Therefore, binding 
of Tyr at site 2 in HpyDAH7PS is highly likely, and Phe may or may not interact with this site. 
This is supported by the relatively strong inhibition of HpyDAH7PS activity by Tyr, and weak 
inhibition by Phe.  
 
Figure 4.31. Ligand binding sites of MtuDAH7PS in comparison with HpyDAH7PS. A. the 
homotetramer of MtuDAH7PS in complex with Phe, Tyr and Trp (PDB 5CKV). Vertical tetramer 
interface and horizontal dimer interface are indicated by red lines. The N-terminal barrel extensions (β0 
and α0a-α0c helices) are shown in red, and the additional α2a, α2b helices are shown in yellow. Ligands 
are shown as green spheres. B. Trp binding sites close to tetramer interface with key residues shown as 
sticks. C. Primary Phe binding sites in the tight dimer interface. D. Tyr/Phe binding site at N-terminus. 
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MtuDAH7PS residues that are on the N-terminal extension are shown as red sticks, the residues of the 
α2a-α2b helices are shown as yellow sticks, the rest are shown as blue sticks. All equivalent residues of 
HpyDAH7PS are shown as orange sticks in B, C and D. 
Site 3 is Phe or Tyr binding site nestled between the α0a and α0b-helices of the N-terminal 
extension and the α3-helix of the core barrel of MtuDAH7PS. Residues in these regions are not 
conserved in the HpyDAH7PS sequence (Figure 4.31 D). Only a couple of hydrophobic 
features can be identified at this site, and the hydroxyl, carboxylate and amino groups of Tyr 
(or the functional groups of Phe) cannot be sufficiently stabilised by nearby residues. Therefore, 
ligand binding in this site of HpyDAH7PS is not favourable compared to site 1 and 2. Based 
on the analysis above combined with results from kinetics, inhibition assays and DSF, it is 
logical to conclude that feedback regulation of HpyDAH7PS is substantially different from that 
of MtuDAH7PS. A more moderate inhibition level is observed in HpyDAH7PS, for instance, 
no complete elimination of activity is detected even when all three aromatic amino acids are 
present. Tyr and Phe may bind to the equivalent location of site 2, while Trp binding at site 1 
is ambiguous. Crystallographic data, ITC or NMR experiments may be required to assess the 
ligand binding mode in detail.   
Structure - Another important feature of HpyDAH7PS is the quaternary structure equilibrium 
of dimer-tetramer as evident from AUC and SAXS results. Although minor dimeric species of 
MtuDAH7PS occur at very low concentrations,207 the equilibrium shifts almost entirely 
towards the tetramer at protein concentrations greater than 0.2 mg·mL-1, whereas dimer species 
of HpyDAH7PS can still be distinguished at low protein concentration. The internal extensions 
(α2a and α2b-helices) form major contacts at the tetramer interface of MtuDAH7PS. The 
HpyDAH7PS sequence in this region appears similar to that of MtuDAH7PS; however, there 
are still subtle changes that may increase the flexibility of this region and result in a less stable 
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tetramer interface. Particularly, the twist of tight dimers across the tetramer plane identified 
from SAXS experiments changes the relative position of each tight dimer compared to the 
homology model. This twist is likely associated with the lack of (β0) and/or poorly conserved 
(α0a and α0b) N-terminal extensions in HpyDAH7PS compared to MtuDAH7PS, as these 
regions are important in the relative positioning of each unit in the tight dimer and are likely to 
be crucial in determining the interaction of the tetramer interface and the overall tetramer 
conformation. If substantial enough, this change could be responsible for the presence of the 
dimer-tetramer equilibrium and even contribute to the regulatory behaviour of the enzyme. The 
detailed role of the N-terminal modifications of HpyDAH7PS can be studied by engineering 
the missing β0 segment and investigating if the engineered changes at the N-terminus would 
alter the equilibrium and quaternary structure of the protein.  
Although there are substantial differences at the dimer and tetramer interfaces of HpyDAH7PS 
and MtuDAH7PS, the lack of crystallographic data for HpyDAH7PS makes it difficult to 
determine whether the ‘twist’ observed in the solution structure exists in crystalline form. 
Several studies have suggested that crystal-packing effects generally do not change protein 
folding, however, they rather affect the arrangement of flexible regions such as linkers and 
termini.122 Particularly for allosteric proteins, the various sampled conformations associated 
with allostery are possibly affected by lattice forces. Future work on optimising the atomic 
model of HpyDAH7PS with combination of crystallography, computational searches and 






4.5.2. Structure of HpyCM and complex formation 
HpyCM – The crystal structure of HpyCM (PDB 6AL9) reveals important features of this 
enzyme. While it adopts a typical AroQ-type CM fold with two tight dimers intertwined, each 
composed of three α-helices, it appears to moonlight as a lyase at least under crystallisation 
constraints. The active site promiscuity discovered in HpyCM catalysis is not unique in 
chorismate utilising enzymes.208-210 Although HpyCM shares substantial similarity with 
PaeIPL in both overall structures and detailed active site architectures, and the PredictProtein 
server also reports possible lyase activity of HpyCM based on gene ontology,211 it is still 
difficult to conclude that HpyCM moonlights as a chorismate lyase (CL) and catalyses the 
conversion of chorismate to PHB and PYR, as this reaction can also occur nonenzymatically.212 
It is possible that somehow in the crystallographic conditions, the CM active site is not 
sufficiently arranged for the conversion of chorismate from pseudoequatorial to pseudodiaxial 
conformation (the rate-limiting step, Appendix A), and the retention of chorismate at the active 
site facilitates the breakdown of chorismate into PHB and PYR. Upon completeness of the 
lyase reaction, PYR release is generally rapid and efficient as reported for the EcoCL (an 
enzyme catalysing the conversion of chorismate to PYR and PHB).212 Although it is unknown 
whether this rapid release of PYR is maintained in HpyCM, the fact that both PYR and PHB 
densities are present in the crystallography data is likely contributed by the covered active site 
in Chain B. Therefore, it is reasonable to speculate that under combined effects of 
crystallisation constraints and the unique electrostatic field of the active site identified in 
HpyCM, the disordering of the active-site loop results in a more capped active site, which 
facilitates the retention of chorismate and allow its breakdown into PHB and PYR 
enzymatically or nonenzymatically. Future investigations into this lyase activity may be 




Figure 4.32. Structure comparison between HpyCM and MtuCM. A. Superposition of HpyCM (blue, 
PDB 6AL9) with MtuCM (red, PDB 2VKL). B. Comparison of the C-terminal helices from the two 
proteins. 
Despite similar folding architectures, substantial differences can be identified between HpyCM 
and MtuCM. Firstly, the M. tuberculosis genome encodes two proteins with homology to CMs 
(intracellular and secreted), whereas there is only one CM in the H. pylori genome. This 
supports with the normal-range activity observed for the HpyCM in contrast to the unusually 
weak activity of MtuCM, in which a highly conserved Lys is replaced with an Arg.30 Secondly, 
MtuCM is strongly activated and becomes regulated when it forms a complex with 
MtuDAH7PS; although very weak activation of HpyCM activity by HpyDAH7PS is detected, 
it does not appear to be biologically relevant or significant. Additionally, HpyCM activity 
appears largely unregulated under all experimented conditions. Finally, unusual structural 
features are present in the MtuCM compared to the HpyCM. For instance, the C-terminal helix 
(α3) in HpyCM is significantly longer (around two-fold) than that of MtuCM (Appendix D, 
Figure S10, Figure 4.32). The missing segment carries a catalytically important and conserved 
Gln residue in other CMs, such as HpyCM and EcoCM. The special arrangement of the short 
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α3 helix of MtuCM plays an important role in complex formation and the mechanism of its 
activation by MtuDAH7PS.30 
 
Figure 4.33. Interactions between CM and DAH7PS in M. tuberculosis and H. pylori. A. Crystal 
structure of MtuCM (red)-MtuDAH7PS (blue) complex, with key interface residues shown as sticks 
(PBD 2W1A). B. Modelled HpyCM (orange) and HpyDAH7PS (teal) with potential interface residues 
shown as sticks.  
Complex - In the protein complex structure from M. tuberculosis (Figure 4.33 A), the major 
contribution from MtuDAH7PS to form the MtuCM-MtuDAH7PS interface is from the 
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inserted α2b helix and its preceding loop, as well as the α7 and α8 helices of the core barrel. 
MtuCM contributes residues from α1-α2 loop and the α2 and α3 helices. The most notable 
interactions are contributed by the C-terminus of MtuCM (Gly89 and adjacent residues), which 
are packed into a shallow groove on the surface of MtuDAH7PS forming interactions with Gln 
392 and Arg 399. As for HpyCM and HpyDAH7PS (Figure 4.33 B), although slight interactions 
between the α1-α2 loop of HpyCM with C-terminus of HpyDAH7PS barrel are possible, severe 
clashes between the elongated C-terminus (α3) of HpyCM and the α6, α7, α8 helices of 
HpyDAH7PS are contributed by many charged/polar side chain functionalities causing 
repulsive interactions at the interface. The differences in the α3 helices of HpyCM and MtuCM, 
as well as the altered relative position of the HpyDAH7PS barrel due to the twist on the tetramer 
plane make the complex formation less favourable compared to the MtuCM-MtuDAH7PS 
system.   
In addition, the oligomeric equilibrium in HpyDAH7PS may make complex formation 
entropically unfavourable as the tetrameric conformation of DAH7PS seems to be a 
prerequisite. Functionally, HpyCM alone is sufficiently active and displays little or no 
modifications of its biochemical properties by the presence of HpyDAH7PS and vice versa, 
reinforcing that its interaction with HpyDAH7PS is perhaps not biologically relevant. 
Nevertheless, the possibility that additional cellular conditions, such as co-factors and ligands, 
may improve complex formation cannot be ruled out.  Future experiments may include 
screening of optimal conditions and detailed AUC studies for precise detection of the protein 
complex. Furthermore, HpyCM can be artificially linked to the HpyDAH7PS to minimise the 





Chapter 5. High-resolution methods for studying 
intramolecular allosteric communication 
 
Preface 
Previous chapters explored the details of ligand binding and conformational changes associated 
with allosteric regulation from several protein systems using combinations of biochemical and 
physical techniques. While crystallographic data provides important information on a 
molecular level with atomic resolution, combinations with solution SAXS and other 
biochemical studies are powerful in illustrating the protein behaviours in biologically relevant 
states. However, a fundamental problem with those techniques is that important information 
such as the timescales and dynamics of allosteric motions are often lost due to many 
experimental limitations. This chapter identifies high-resolution motions from multiple protein 
conformations derived experimentally, by exploring the feasibilities of applying alternative 
biophysical techniques including FRET and EPR on available protein systems. This knowledge 








Mechanism of energy transfer 
The timescale of protein motions is strongly dependent on the nature of the conformational 
changes (Figure 5.1). Fast motions primarily consist of bond vibrations on femtosecond-
picosecond timescales. Side-chain rotations occur within picoseconds. Back-bone rotations of 
secondary structures are generally in the sub-nanosecond range.122 Movements or changes of 
domains are on a slower timescale of microseconds to seconds and are more difficult to 
examine.213 Protein motions including local fluctuations involved in side-chain and loop 
movements and highly corrected large domain conformational changes are of particular 
relevance to allostery, ranging from picosecond to second timescales.213  
 
Figure 5.1. Timescale of protein motions and experimental methods often used to study allostery. 
Among the techniques often used for studying protein motions associated with allostery, 
Förster resonance energy transfer (FRET) allows access to motions in the nanosecond to second 
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timescale. It is an electrodynamic phenomenon when a fluorescence donor molecule in its 
excited state interacts with an acceptor molecule in its ground state via long-range dipole-dipole 
forces (Figure 5.2).214 Factors that are important for FRET efficiency are underlined in the 
Förster equation (1).  






When the emission spectrum of the donor overlaps with the excitation spectrum of the acceptor, 
the efficiency of the energy transfer (E) is defined in this equation, where r is the distance 
between the two fluorophores and R0 (Förster distance) is the distance at which the energy 
transfer efficiency is 50%. Förster distance is highly dependent on the quantum yield and 
relative distance and orientation of the fluorophores as well as the level of spectral overlap. It 
typically ranges from 20 to 90 Å.214 
 
Figure 5.2. Scheme of FRET process. A. Mechanism of FRET. The excited energy of the donor is 
transferred to the acceptor via FRET. B. Schematic diagram of spectral overlap between donor and 




Protein modification strategies 
The typical distance range and sensitivity allows FRET to be widely used to study protein 
interactions,216 dynamic motions and conformational changes.214-215, 217 Despite the powerful 
applications of FRET in the field of chemistry, biology, and medicine in facile, real-time 
visualisation of a labelled protein, the development of site-specific labelling techniques 
remains a challenging problem, especially for assessing intramolecular changes.218  
A few protein modification strategies have been established. For small proteins, short peptide 
segments can be labelled individually with desired donor or acceptor fluorophores, and 
combined via chemical ligation.219 For large proteins, there are four dominant modification 
strategies.215 Firstly, a commonly used method is to fuse genetically the protein of interest to a 
fluorescent protein such as GFP.220 Although this method is intrinsically specific, the large size 
and steric bulk of the fluorescent protein pose many problems, including aggregate formation 
and the disruption of the natural function of the protein of interest.214, 220 Secondly, pendant 
enzymes can be fused to label protein using a fluorescent ligand specific to the pendant enzyme, 
exploiting the enzyme-substrate specificity. Examples of these pendant enzymes include the 
SNAP-tag,221 HaloTag,221 and TMP-tag.222 They are often smaller than the fluorescent proteins, 
however, they are still considerably large and often cause steric hindrance problems.218 Thirdly, 
modification can be achieved by exploiting a natural or introduced reactive functional group 
or enzyme recognition site on the protein. This reactive group can then be attached to a 
fluorescent label via ligation or enzymatic reaction.215 Enzymes such as microbial 
transglutaminase223 and farnesyl transferase224 are often used to introduce an azide or alkyne 
group on the protein, which can react with a complementary alkyne- or azide-containing 
fluorophore via a ‘click’ reaction. This method allows the attachment of small fluorophores 
with minimal modifications of the protein of interest, although the efficiency of the enzyme-
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catalysed reaction and removal of excess free labels can sometimes be problematic.218 Finally, 
small fluorogenic probes can react with and attach to minimal peptide tags attached on protein 
of interest and minimise disruption to the protein. Examples include organoarsenic labels 
FLAsH and ReAsH.225-226 This approach achieves specific and undisruptive labelling, but the 
reagent toxicity and strong background label persistence could be an issue.227 Besides these 
dominant strategies, another recent method is the incorporation of unnatural amino acids (UAA) 
that reacts with the label.228-229 Although it appears to be an elegant and reliable method for 
specific labelling, it is currently not generally available due to the difficulties in synthesis and 
incorporation of UAA, and requirement of specially designed rRNA synthetases. 
On the other hand, some non-specific labelling methods are also used. A common method is 
randomly mixing the protein of interest with both donor and acceptor fluorophores, followed 
by purification of each labelled product based on natural or engineered properties of the 
protein.230-231 Another popular method is step-wise addition of individual labels by controlling 
the stoichiometry between each dye and the target protein. However, variations in labelling 
efficiency may severe heterogeneity in the labelled product, which is difficult to address if the 
mixture cannot be chromatographically separated. These approaches are not selective or site-
specific, thus it is difficult to determine the location and types of the fluorophore. 
 
5.1.2. Experiment design 
Labelling targets and strategies 
Two protein systems were chosen to test the feasibility of applying intramolecular FRET 
techniques to study conformational changes associated with allostery. These included two Type 
Iβ DAH7PS enzymes TmaDAH7PS and GspDAH7PS, as both systems have been well studied 
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and the crystal structures were available for accurate design of labelling sites. After extensive 
literature research and thorough considerations, enzymatic modification using microbial 
transglutaminase (mTG) was chosen as the labelling strategy for specific labelling of 
GspDAH7PS due to its minimal disruption to the protein and high specificity towards certain 
substrates (Appendix E, Table S2).  
 
Figure 5.3. Transglutaminase-catalysed reaction (A) and site-specific labelling scheme using TGs (B).  
Transglutaminases (TGs) are a family of enzymes that catalyse the acyl transfer between 
carboxamide groups of Gln and various primary amines, such as the amino group of Lys 
residue.232 When a Lys residue serves as an acyl-acceptor, a γ-glutamyl-ε-lysine isopepetide 
bond is formed between two molecules (Figure 5.3 A). This intrinsic cross-linking property 
mediated by TGs is important for many biological processes and diseases, such as blood 
coagulation, type 2 diabetes, and several cancers.233-235 Microbial TGs are bacterial variants of 
the TG family. In contrast to other TGs, the mTG-catalysed isopeptide formation is calcium-
independent.236 Generally mTG is expressed as a proenzyme and activated by cleavage of the 
N-terminus, producing the active enzyme at around 38 kDa, significantly smaller than the 
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mammalian counterparts (greater than 70 kDa).236 Due to the broad substrate tolerance of 
mTGs towards primary amine and high specificity for Gln-containing peptide substrate, these 
enzymes are attractive catalysts for protein conjugation (Figure 5.3 B).  
Collaborations were established with Professor Keillor’s research group at the University of 
Ottawa to explore the application of newly developed high-affinity peptides (Q-tag) as 
substrates of mTG in labelling of the DAH7PS systems. The Q-tags are short peptides with Gln 
(Q) recognition site often situated in the centre of the sequence. Hitomi and co-workers 
reported peptide sequences that could serve as efficient Gln-substrates for mTG by screening 
of phage-displayed peptide libraries.237 Subsequently, Keillor’s group demonstrated that some 
selected sequences could be fused to target proteins and discovered three most efficient Q-tags 
as substrates of mTG, including WALQRPH (Q1), WELQRPY (Q2), and YPMQGWF (Q3).223, 
236 Among these peptides, Q1 was proven to exhibit the highest efficiency to attach to a 
fluorophore via the mTG-catalysed reaction.223 Fluorophores with Lys side-chain mimics 
substitute well for Lys as amine donor. Examples such as cadaverine fluorophores are shown 
to be successful amine substrates.238  
Distance estimation and protein modifications 
GspDAH7PS - Labelling sites were carefully chosen upon analysis of both open- and closed-
form coordinates of GspDAH7PS. Q-tag WALQRPH was engineered to the N-terminal CM 
domain of GspDAH7PS for specific labelling of one fluorophore (Chapter 7). Subsequently, 
traditional thiol labelling via Cys residue was used to attach the other fluorophore on the 
DAH7PS catalytic barrel. Thiol reactive probes are frequently used for protein labelling to 
identify conformational changes, complex formations, and ligand-binding.239 The primary 
targets of these probes are Cys residues, which have a low abundance of around 3.3% in 
proteins.240 Therefore, in proteins that contain multiple Cys residues, the number of Cys is 
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usually sufficiently small and easy to be removed by site-directed mutagenesis without 
significant disruption to the native protein. The low occurrence of Cys also allows saturated 
labelling with low risk of protein precipitation and fluorophore self-quenching.240 
The tetrameric nature of GspDAH7PS posed complications in selection of labelling sites as all 
possible FRET distances needed to be considered. Residue Asp302 on the DAH7PS barrel 
appeared to be an ideal site for attaching the second thiol label. In the open form, the distance 
between the fluorophore pair remained approximately 50 Å, greater than a typical R0. In the 
closed form, one pair of fluorophores was located sufficiently close to emit a FRET signal (~28 
Å) as shown in Figure 5.4. The difference between the fluorophore distances of the open- and 
closed-forms was expected to reflect the difference in energy transfer. Therefore, mutation 
D302C was designed to introduce Cys at position 302. This mutation was unlikely to disrupt 
catalytic function of the enzyme based on analysis of the crystal structure.  
 
Figure 5.4. FRET design for labelling of GspDAH7PS. A combination of N-terminus labelling via 
mTG and Cys-reactive labelling at residue 302 (red spheres) of the barrel was used.  
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Naturally occurring Cys residues in GspDAH7PS were also considered for substitution to avoid 
any unspecific labelling. There are three sequence-encoded Cys residues in GspDAH7PS, all 
of which are located on the DAH7PS catalytic barrel (Figure 5.5 A). Both Cys126 and Cys259 
appear buried within the barrel, while Cys307 is partially exposed and was replaced by Ser to 
avoid undesired labelling at this position. 
Together, GspDAH7PS was modified to include the double mutation D302C/C307S and N-
terminal modification with Q-tag (GspDAH7PSD302C-C307S-Q). Single mutants including 
GspDAH7PSD302C, and GspDAH7PSC307S, as well as the double mutant GspDAH7PDD302C-
C307S were also created to serve as controls and examine the effect of each modification on 
protein labelling and function. 
 
Figure 5.5. Naturally occurring Cys residues in GspDAH7PS (A) and TmaDAH7PS (B). Cys residues 
from a single chain are highlighted with lime spheres.  
TmaDAH7PS - The application of mTG labelling on TmaDAH7PS was carefully examined. 
However, dual labelling with one fluorophore on each domain was not an appropriate approach 
for this system due to the nature of the ACT domains (Chapter 2). Suitable FRET distances, 
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which produce sufficient signal differences between the open- and closed-forms, could not be 
identified. Specifically, the Q-tag could not be attached to the N-terminus of the ACT domain 
as its movement upon ligand binding is not sufficiently significant for FRET (~13 Å, Figure 
5.6 A). C-terminal labelling was not suitable either, as the largest distance displacement was 
still not sufficient for distinguishing signals between the open- and closed-forms (Figure 5.6 
B).   
 
Figure 5.6. Terminal labelling for TmaDAH7PS is not suitable for FRET. A. N-terminal labelling with 
the N-terminus highlighted as lime spheres only produces a distance displacement of around 13 Å 
between open- and closed-forms. With the engineered Q-tag at this position, this distance displacement 
would be even smaller, therefore it is not ideal for labelling. B. C-terminal labelling with C-termini 
from two diagonally opposing chains highlighted as spheres. E35 on the two ACT domains are also 
highlighted. The open-form highlighted locations are in lime spheres and the closed-from locations are 
in orange spheres. The highlighted positions in open- and closed-forms would produce similar distances, 
therefore are not suitable for FRET. 
Labelling on solely the ACT domains was used, as the displacement of each ACT domain 
relative to each other upon ligand binding was sufficient for FRET detection. Because the two 
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labelling sites were the equivalent sites from each monomeric chain, specific modification of 
individual site was challenging as it was difficult to introduce different reactive groups on the 
same residue of different chains. Therefore, a random labelling technique was applied 
exploiting Cys functionality on the ACT domains with controlled stoichiometry between the 
number of labelling sites and labels.   
There are four naturally occurring Cys residues in each chain of TmaDAH7PS (Figure 5.5 B). 
Two are located in the ACT domain, and another two are located in the DAH7PS barrel. Both 
Cys28 and Cys58 on the ACT domain are solvent accessible, while residues Cys102 and 
Cys235 in the catalytic barrel appear buried. Although Cys102 at the active site can be partially 
exposed transiently, the binding of metal ion and substrate PEP is expected to reduce the 
flexibility of the catalytic loop and decrease the possibility of label attachments at this position.    
Upon inspection of the crystal structures, residue Cys28 on the β2 sheet of the ACT domain 
provided ideal FRET distances (Figure 5.7). If a pair of thiol-reactive probes were attached to 
Cys28 residues, the distances between the two probes from diagonally opposing chains would 
produce the largest displacement of around 60 Å (ligand-free) to 17 Å (with Tyr). On the other 
hand, residue Cys58 located on the loop region between α3 and β4 of the ACT domain was 
partially buried based on MD simulations (kindly provided by Dr Eric Lang). Labelling on this 
residue would produce less ideal FRET distances than Cys28. Therefore, Cys58 of 
TmaDAH7PS was replaced with a Ser residue (TmaDAH7PSC58S) to minimise undesirable 





Figure 5.7. FRET design for labelling of TmaDAH7PS. Random labelling with controlled 
stoichiometry at Cys28 (blue spheres) of the ACT domain was used.  
It is important to note that the distances estimated based on the open-form crystal structures 
and models of both GspDAH7PS and TmaDAH7PS are representative of some extreme 
conformations the proteins can explore. In solution, these distances are expected to vary as the 
dynamics of the regulatory domains change relative to the positions of each other and of the 
catalytic domains. Therefore, the FRET distances between the designed labelled sites are 
expected to sample a range of distances emitting signals with various strength in the absence 
of ligand, whereas this distance distribution is expected to narrow down as the protein becomes 
more rigid in the presence of ligand. 
Selection of fluorophores 
A pair of thiol-reactive fluorophores were required to label Cys28 of TmaDAH7PS. A thiol-
reactive fluorophore was required to label Cys302 of GspDAH7PS, and an amine-containing 
fluorophore was required to serve as substrate of mTG for labelling of the N-terminus of 
GspDAH7PS. Based on considerations over the ease of synthesis and the brightness of the 
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fluorophores, maleimide fluorescein and coumarin were selected for labelling of TmaDAH7PS 
(Figure 5.8).  
 
Figure 5.8. Selection of fluorophores. A. Reaction of maleimide probes with Cys side-chain on 
protein of interest (P.O.I.). B. N-(5-Fluoresceinyl) maleimide used as acceptor for TmaDAH7PS 
labelling. C. Cadaverine form of FITC used as acceptor for GspDAH7PS labelling. The cadaverine 
functionality (–NH(CH2)5NH–) serves as substrate for mTG. D. Diethylamino (methylmaleimide) 
coumarin used as donor for both TmaDAH7PS and GspDAH7PS labelling.  
Maleimides are excellent thiol-reactive reagents for protein labelling and quantitation and do 
not appear to react with His or Met residues. A thioether bond is formed across the double bond 
of maleimides in the presence of thiol groups (Figure 5.8 A).240 The selected N-(5-fluoresceinyl) 
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maleimide (FITC), purchased from Sigma-Aldrich, is a green fluorescein with excitation and 
emission maximums of 490 and 510 nm respectively (Figure 5.8 B). The diethylamino 
(methylmaleimide) coumarin (CPM), kindly provided by Keillor group, is a small blue 
fluorophore with excitation wavelength of 440 nm and emission wavelength of 485 nm (Figure 
5.8 D). The emission spectrum of the donor (CPM) overlaps well with the excitation spectrum 
of the acceptor (FITC), fulfilling one of the primary conditions for FRET.215  
A cadaverine form of FITC (FITC-Cd) was synthesised by Keillor group and used as substrate 
for the mTG-catalysed reaction for labelling of GspDAH7PS (Figure 5.8 C). It has excitation 
wavelength of 496 nm and emission wavelength of 519 nm. The KM value of mTG towards 
FITC-Cd is around 54 µM in 200 mM MOPS (pH 7.2) and 1 mM EDTA, as per information 
provided by Keillor group. The donor molecule used was the same CPM molecule for labelling 
at Cys302. This pair of fluorophores also provides satisfactory spectral overlap.  
 
5.1.3. Mutagenesis and Q-tag engineering 
Single-point mutants of GspDAH7PSD302C and GspDAH7PSC307S were created using 
QuikChange® site-directed mutagenesis technique with wild-type GspDAH7PS plasmid as 
template (Chapter 7). Double mutation GspDAH7PSD302C-C307S was produced using the single 
mutant GspDAH7PSD302C as template. The Q-tag (WALQRPH) was subsequently fused to the 
N-terminus of GspDAH7PSD302C-C307S to produce GspDAH7PSD302C-C307S-Q using established 
PCR techniques. For TmaDAH7PS, single mutation TmaDAH7PSC58S was created via site-
directed mutagenesis. All primers used are listed in Chapter 7. All PCR products were treated 
with DpnI to eliminate contamination from wild-type plasmids. Once DNA sequences were 
verified to incorporate the correct mutation and Q-tag, the plasmids were transformed, 
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expressed and purified following the methods for wild-type GspDAH7PS and TmaDAH7PS 
as described in Chapter 7. Purified products were confirmed to have the correct molecular 
weights by mass spectrometry (Appendix E, Table S3). 
 
5.1.4. Function of protein variants 
Prior to labelling process for FRET, the functions of the protein variants were examined and 
compared with the parent proteins. Both activity and inhibition assays were performed under 
the same experimental conditions as the wild-type proteins. All GspDAH7PS and 
TmaDAH7PS variants were catalytically active with kinetics parameters comparable to that of 
the wild-type enzymes (Table 5.1, Table 3.1), and more active at elevated temperatures, 
although the Q-tagged GspDAH7PS variant appeared slightly less thermostable than other 
variants. In the presence of prephenate, all GspDAH7PS variants displayed similar inhibition 
profiles compared to the wild-type protein (Figure 3.4) with similar values of IC50. In the 
presence of Tyr, the activity of TmaDAH7PSC58S was inhibited by approximately 80%, 
consistent with the wild-type TmaDAH7PS. Therefore, the modifications of the proteins did 
not significantly disrupt their native functions. 
Table 5.1. Kinetic parameters for GspDAH7PS and TmaDAH7PS protein variants.  
Protein 






















GspDAH7PSD302C 44 ± 2 49 ± 4 30 ± 1 0.68 0.61 101 ± 9 4 ± 0.1 0.04 
GspDAH7PSC307S 55 ± 3.6 60 ± 6 32 ± 0.8 0.58 0.53 100 ± 8.6 3.2 ± 0.2 0.03 
GspDAH7PSD302C-C307S 48 ± 4 58 ± 3 29 ± 1.5 0.60 0.5 95 ± 7 3.5 ± 0.1 0.04 
GspDAH7PSD302C-C307S-Q 50 ± 3 61 ± 7 33 ± 2.5 0.66 0.54 98 ± 5 3.0 ± 0.3 0.03 
TmaDAH7PSC58S 11 ± 1 18 ± 2 17 ± 2 1.55 0.94 NA NA NA 
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5.1.5. Preparation of mTG 
Gene expression  
Plasmid containing the gene encoding for the Streptomyces mobaraensis mTG was kindly 
donated by Professor Markus Pietzsch from Martin Luther University of Halle-Wittenberg. 
The plasmid pDJ1-3 encodes for mTG with the N-terminal proenzyme sequence and a C-
terminal His6 tag. It was transformed into E. coli BL21*(DE3) cells by using standard 
procedures described in Chapter 7. An autoinducing medium was used for expression of mTG. 
A small preculture (~5-10 mL) was incubated overnight at 37 °C with shaking at 220 rmp in 
ZYP-0.8G medium (Chapter 7).241 The preculture was then used to inoculate a large culture of 
around 500 mL in ZYP-505 medium,241 which was subsequently incubated at 37 °C for two 
hours followed by overnight incubation at 22 °C with shaking at 220 rpm. The cells were 
harvested following standard procedures. Cell lysis was performed using standard on-ice 
sonication methods in 0.2 M Tris-Cl buffer at pH 6.0. Crude lysate was centrifuged at 14,000 
g for 30 min at 4 °C. 
Purification 
Activation of mTG by cleavage of the N-terminal pro-sequence was then performed by adding 
trypsin to the crude soluble fraction with ratio of 1:9 (v/v). The mixture was incubated at 30 °C 
for 45 minutes. The activated mTG was purified by using standard IMAC procedures 
exploiting the C-terminal His6 tag (Figure 5.9). The IMAC column was equilibrated in 50 mM 
phosphate buffer (pH 8.0) containing 300 mM NaCl. The desired protein was eluted with 0 to 
140 mM imidazole gradient. A final step using SEC (0.2 M Tris-Cl, pH 6.0) was optional 
depending on the level of purity. Typical yield of activated mTG was approximately 80 mg per 




Figure 5.9. Purification of pro-mTG. A. First step purification using IMAC column. M, marker. 1, 
flow-through fraction. 2-3, washed fractions. 4-8, eluted fractions containing mTG. B. Second step 
using SEC column. 1-10, eluted fractions containing purified mTG. 
Activity test 
The catalytic activity of mTG was tested by applying the hydroxamate assay described by Folk 
and Cole.242 Purified mTG was incubated with substrates 100 mM hydroxamate and 30 mM Z-
Gln-Gly (purchased from Sigma-Aldrich) in SEC buffer at 37 °C for 10 minutes. The reaction 
was then quenched by mixing with a solution containing 2 M FeCl3, 300 mM trichloroacetic 
acid, and 800 mM HCl. The iron complex produced was easily detected by eye and its 
absorbance could be measured at 535 nm after precipitate was removed by centrifugation 
(Appendix E, Figure S12). Typical activity of mTG was 1 µmol product formation (glutamic 






5.1.6. Labelling of GspDAH7PS 
FITC-cadaverine labelling 
The activated mTG was used to attach FITC-Cd on the N-terminus of GspDAH7PSD302C-C307S-
Q. Initially experimental procedures followed methods established by Oteng-Pabi et al.223 The 
purified protein (final concentration 0.5 mg·mL-1) was added to a solution containing 500 µM 
FITC-Cd (approximately ten-times of the KM value), 200 mM MOPS (pH 7.2), and 1 mM 
EDTA. One unit (U) of mTG was added to the mixture to initiate the transamidation reaction 
at a total volume of 500 µL. The reaction was then incubated at 37 °C for two hours with gentle 
stirring. Small aliquots were taken periodically at time 0, 15, 30, 60 and 120 minutes to record 
the progress of labelling.  
Visible protein precipitates were observed during the labelling reaction. The labelled product 
was centrifuged and the soluble fraction was applied on a PD-10 column and subsequently 
washed repeatedly over a membrane with 10 kDa cut-off to remove free labelling reagents. The 
effect of labelling was assessed by mass spectrometry and the resulting molecular weight of 
the product was consistent with the unlabelled protein. Labelling conditions were then varied 
in attempt to improve the result. A range of alternative reaction buffers were tested including 
BTP, phosphate, and Tris-Cl to reduce precipitation. However, severe level of precipitation 
was still observed with different buffers. Various reaction time, temperatures, substrate (FITC-
Cd) and protein concentrations, as well as higher FITC-Cd to protein ratios were also tested to 
determine whether the protein that remained in the soluble fraction could be labelled efficiently. 
However, these attempts did not successfully produce soluble labelled protein. Additionally, 
the DAH7PS activity could not be detected after the labelling reaction.  
A negative control with the same labelling conditions was performed except that mTG was not 
included (i.e. target protein and free label only), therefore no conjugation of the FITC-Cd probe 
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was expected. After incubation at 37 °C for two hours, the protein was tested to be catalytically 
active and remained unlabelled as verified by MS, suggesting that the presence of mTG or the 
mTG-catalysed reaction posed disruption to the native function of the protein. Another control 
was performed using the GspDAH7PSD302C-C307S mutant incubated with FITC-Cd and mTG 
protein under the same conditions. After incubation, this protein also remained catalytically 
active and unlabelled. This control verified that it was likely the interaction of mTG with the 
Q-tag attached on the GspDAH7PSD302C-C307S-Q variant that destabilised the target protein, 
rather than the presence of mTG causing random interactions with the target protein. This 
control verified that the naturally occurring Gln (Q) residues in GspDAH7PS were unlikely to 
react as substrates for mTG, and the only point of interaction appeared to be the engineered Q-
tag, demonstrating the sufficient specificity of this system. 
Dansylcadaverine labelling 
The initial mTG labelling experiments showed that attachment of FITC-Cd on GspDAH7PS 
perturbed the protein function. This was perhaps due to the size and hydrophobicity of the 
probe. Therefore, an alternative probe dansylcadavarine (DNS-Cd) was selected and tested to 
determine if it was less obtrusive than FITC-Cd (Figure 5.10). Dansylcadaverine is a smaller 
labelling reagent (Mw 335.46 g·mol-1) with the same cadaverine functionality (–
NH(CH2)5NH–) that serves as substrate for mTG. It has excitation wavelength of 335 nm and 
emission wavelength of 512 nm. 
Similar labelling procedures were applied for the mTG-catalysed reaction between DNS-Cd 
and GspDAH7PSD302C-C307S-Q as previously described for FITC-Cd labelling. After around 20 
minutes of incubation at room temperature, some white aggregates were observed, however 
less severe compared to the FITC-Cd labelling. A diluted reaction (2 mL instead of 0.5 mL) 
was used to reduce precipitation. After two-hours incubation at room temperature, the 
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remaining soluble fraction was isolated and washed (Appendix E, Figure S13). Although this 
fraction showed weak DAH7PS activity, MS results showed that the soluble protein remained 
unlabelled even with varied labelling conditions such as altering reaction temperatures and 
label concentrations.  
 
Figure 5.10. An alternative probe for mTG-mediated GspDAH7PS labelling. Dansylcadaverine is a 
broadly applied small amine probe that serves as substrate for mTG. 
Overall, the mTG-mediated labelling at the N-terminus of GspDAH7PS was troublesome and 
disruptive to the native protein folding and function. Both FITC-Cd and DNS-Cd labelling 
were unsuccessful in producing soluble, functional, and labelled protein. This suggests the 
modifications at the extended N-terminal loop region disturbs the protein significantly, 
although this region is located remotely from the DAH7PS active site. Fluorophore labelling 
in combination with the extended Q-tag possibly affects the flexibility of the loop, which may 
play an important role in the stability and activity of the GspDAH7PS. Furthermore, the 





5.1.7. Labelling of TmaDAH7PS 
Reaction setup 
Previously described random labelling strategy (Chapter 5.1.2) for TmaDAH7PSC58S using 
controlled stoichiometry of FITC and CPM was performed following standard methods for 
thiol-reactive probe labelling with some modifications.240 There are four Cys targets per 
molecule of TmaDAH7PSC58S (one Cys per chain), therefore two CPM (donor) molecules and 
two FITC (acceptor) were mixed with one molecule of TmaDAH7PSC58S, which was the 
equivalent of molar ratio 2:1:1 of the target protein, CPM and FITC. Protein stock was treated 
with ten-fold molar excess of dithiothreitol (DTT) for reduction of disulphide bonds. Thiol 
modification was then performed under inert atmosphere (N2) to minimise thiol oxidation. 
Approximately 57 µM target protein was prepared in 50 mM BTP buffer (pH 7.5) at room 
temperature. A 1:1 FITC and CPM (final 28.5 µM each) solution was freshly prepared prior to 
addition into the protein solution dropwise over a half-hour period. All thiol modification steps 
were carried out in the dark and the reaction was incubated at room temperature for two hours 
with gentle stirring. Upon completion of the reaction, the mixture was passed through a PD-10 
column to remove the remaining free labels from the protein. A fast-moving fluorescent band 
containing labelled protein was observed under natural light and the corresponding fractions 
were verified by NanoDropTM and collected. Free labels were eluted with subsequent buffer 
washes. An additional washing step of the labelled protein over a 10-kDa membrane was 




Figure 5.11. FITC and CPM labelled TmaDAH7PSC58S under white light (left) and fluorescence (right). 
M, marker. 1 (1’), crude labelled product. 2 (2’), unlabelled control. 3 (3’), purified and washed labelled 
product. 4 (4’), removed impurities and free labels.    
The size of the labelled product was analysed by MS. The results showed that majority of the 
protein was successfully labelled with FITC, however, very small amount had CPM attached, 
suggesting different labelling efficiencies of the two labels towards the same Cys28 residue. 
Therefore, the relative concentration of CPM to FITC was increased to enhance the attachment 
of CPM on Cys28. As some precipitation was observed during the thiol modification reaction 
with the previous experimental setup, the protein concentration was also reduced from 57 to 
28.5 µM. The new setup included 28.5 µM target protein, 14.25 µM FITC and 42.75 µM CPM 
(2:1:6 ratio of protein:FITC:CPM) with elongated incubation time of an additional eight hours 
at 4 °C. Although more CPM-labelled protein was easily detected by MS, the FITC-labelled 
protein was still significantly more dominant (~70% of labelled protein). The CPM 
concentration was then further increased to up to 15 M excess of the protein, however its 
labelling efficiency remained poor compared to FITC. 
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To avoid the competitive labelling of CPM and FITC and improve the CPM labelling, CPM 
was added prior to addition of FITC, instead of being added simultaneously. Final 
concentrations of 28.5 µM protein and 14.25 µM of each label were applied (2:1:1). CPM was 
added slowly into the protein solution first. The reaction was incubated at 4 °C overnight before 
the FITC aliquot was added and allowed to react for two hours at room temperature. This 
method significantly improved the production of CPM-labelled protein and further tests 
determined the optimal molar ratio of CPM and FITC was 3:1 with the stepwise reaction 
scheme to produce around equal amount of CPM- and FITC-labelled proteins. While this 
procedure achieved the ideal labelling result, some unlabelled protein was detected by MS. 
Therefore, the concentrations of both labels relative to the protein were assessed and increased 
accordingly. The final recipe contained molar ratio of 1:1:3 of protein:FITC:CPM with the 
stepwise procedure. 
Signal detection 
Fluorescence intensities were measured by using a Varian Cary Eclipse Fluorescence 
Spectrophotometer. Initial scanning of the BTP buffer showed interference at 384 nm 
excitation, therefore alternative buffers including HEPES, MES, MOPS and phosphate were 
examined. The labelled TmaDAH7PCC58S remained catalytically active in HEPES, MES and 
MOPS buffers and became inactive in phosphate buffer. HEPES buffer displayed high 
background absorbance at 232 nm. Therefore, MOPS buffer was chosen for subsequent 
measurements.  
The fluorescence intensities of the labelled TmaDAH7PSC58S were measured in the absence or 
presence of Tyr (Figure 5.12). Upon addition of Tyr, the protein was expected to undergo 
conformational change from the open to closed form as previously described, emitting FRET 
signal in which the acceptor intensity should increase. However, the addition of Tyr did not 
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result in obvious increase in the relative intensity of the acceptor (emission λ = 517 nm) 
compared to the apo protein.  
 
Figure 5.12. Fluorescence spectra of the dual labelled TmaDAH7PSC58S at different concentrations of 
Tyr. Intensities were recorded at room temperature with approximately 2 x 10-7 µM protein in 10 mM 
MOPS buffer (pH 7.5). 
Due to the tetrameric nature of the protein, the non-specific labelling strategy used for 
TmaDAH7PSC58S would have resultd in a heterogenous population of species, including 
molecules labelled with four donors (D), four acceptors (A), three Ds and one A, three As and 
one D, and two Ds and two As. Due to the small differences in the size of these species, they 
could not be separated effectively. This heterogeneity posed high background intensity as only 
proteins with dual labels would produce desired intermolecular energy transfer. The slight 
decrease in donor and/or increase in acceptor emission from intramolecular FRET may not be 





The function of proteins is determined by their structure, therefore precise structural 
information on all conformations accessible to the proteins is crucial in understanding their 
function. Biophysical techniques such as X-ray crystallography and NMR are powerful in 
providing high-resolution atomic structures of proteins. However, X-ray crystallography relies 
on successful production of protein crystals and provides only snapshots of the protein structure 
that represents one of the low-energy states under crystal constraints. While NMR can be used 
to obtain protein structures in solution, it becomes problematic for large proteins exceeding 
around 50 kDa.243 As an alternative, electron paramagnetic resonance (EPR) spectroscopy has 
been widely employed to provide structural information with atomic resolution on a local scale 
for proteins in solution or solid state without size restrictions. Distance information determined 
by EPR relies on magnetic dipole-dipole interaction between magnetic moments of two spin 
probes often attached on desired sites of the target protein.244 
Pulsed electron–electron double resonance (PELDOR), sometimes referred to as double 
electron–electron resonance (DEER), is a powerful pulsed EPR technique capable of detecting 
long range spins of up to 80 Å, making it complementary to FRET.243 While FRET can provide 
real-time dynamic information on single-molecule level in solution, PELDOR typically 
requires frozen samples at micromolar concentration range. PELDOR delivers accurate 
distance measurements within 1 Å precision and distribution ensembles reflecting accessible 
conformational dynamics of the protein.243 This feature is particularly powerful in studying 
dynamic systems, such as TmaDAH7PS. Instead of a static snapshot of one crystallographic 
conformation, a range of dynamic conformations can be sampled so that the real 
conformational dynamics associated with the ACT domain can be accessed. With the long-
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range distance information, more accurate biomolecule structures can be derived in conjunction 
with complementary techniques such as X-ray crystallography and molecular dynamics 
simulations.245-246  
 
Figure 5.13. Attachment of MTSSL spin label on Cys residue on protein of interest via disulphide 
bond formation. The PELDOR signal arises from the unpaired electron on the nitroxide group.  
As with other EPR methods, distance measurements from PELDOR experiments rely on the 
dipolar interaction between two paramagnetic probes. Types of these paramagnetic centres 
often include metal ions, clusters, amino acid radicals, organic radical cofactors, or artificially 
engineered spin labels.247 Most PELDOR experiments are based on site-directed spin labelling 
(SDSL). The most commonly used SDSL technique for proteins involves labelling of the target 
sites with (1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)-methanethiosulfonate (MTSSL) 
spin label.248 MTSSL reacts specifically with the thiol functionality of Cys residues and forms 
disulphide bonds (Figure 5.13).248 Cys residues can be introduced to the desired sites on 
proteins by mutagenesis and subsequently be attached to MTSSL labels. Advantages of 
applying SDSL with MTSSL label include its high selectivity towards thiol groups and it 





5.2.2. Experiment design 
As described in previous chapters, the unique ACT domain-mediated allostery in TmaDAH7PS 
and TyeDAH7PS has been examined using combinations of techniques such as X-ray 
crystallography and SAXS. While the crystal structures of two extreme conformations 
representing the open and closed forms of TmaDAH7PS are obtained in the absence or 
presence of ligand Tyr respectively, and SAXS experiments reveal the solution conformational 
change associated with allostery, the real dynamics of the ACT domain and its accessible 
conformation distribution remain unknown.  
The previously designed TmaDAH7PSC58S mutant (Chapter 5.1) was selected with Cys28 of 
the ACT domain as labelling target for MTSSL. MTSSL attachment on Cys28 provides ideal 
distance for PELDOR measurements (Figure 5.7) and previous FRET experiments showed that 
successful thiol-reactive labelling was achieved via Cys28 and resulting labelled protein 
remained functional.  
 
5.2.3. Spin labelling  
The MTSSL spin labelling procedures were similar to that of the FRET labelling described in 
Chapter 5.1.7. Purified TmaDAH7PSC58S was treated with 10 mM DTT at 4 °C overnight to 
ensure complete reduction of Cys residues and effective subsequent disulphide bond formation 
with the spin label.  Upon removal of DTT, MTSSL stock (1 mg·mL-1 in DMF, purchased from 
Toronto Research Chemicals) was added in the protein solution dropwise over a half-hour 
period with gentle stirring at room temperature under inert atmosphere. The final concentration 
of protein was 100 µM, and concentration of MTSSL was 1 mM in 50 mM BTP (pH 7.5). The 
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reaction was incubated at room temperature for four hours and at 4 °C overnight before the free 
label was washed and removed the next day.  
MS results indicated that significant portion of the product had a molecular weight consistent 
with the target protein attached to two MTSSL labels per chain. This was unexpected as only 
a single label was attached on the same protein during FRET labelling. Molar ratio of MTSSL 
label to protein was then reduced from 10:1 to 1:1 to limit MTSSL labelling on two sites of the 
protein. However, the labelled product still contained a substantial amount of dual labelled 
protein. Reaction time was then reduced to two hours at room temperature followed by six-
hours incubation at 4 °C. However, most protein remained unlabelled with the reduced reaction 
time.  
There are three Cys residues in TmaDAH7PSC58S, including the target labelling site at Cys28, 
active site Cys102 and Cys235 in the catalytic barrel (Figure 5.5 B). In contrast to the buried 
residue Cys235 (accessible area 0 Å2) in the DAH7PS barrels, Cys102 appears partially 
exposed transiently with accessible area of 32.29 Å2 therefore is more likely to be labelled due 
to the small size of MTSSL compared to FRET labels.132 Residue Cys102 is located in the 
active site of the DAH7PS catalytic barrel and responsible for interaction with metal ion 
essential for catalysis. Upon binding of substrates and metal ion, the accessible area of Cys102 
is reduced to 5.25 Å2 (Appendix E, Figure S14). Further test on the activity of the MTSSL 
labelled TmaDAH7PSC58S revealed that while the labelled product remained catalytically 
active and showed inhibition in the presence of Tyr, the specific activity was reduced to 
approximately 60% compared to that of the unlabelled protein.  
Docking experiments conducted by Dr Wanting Jiao suggest that the MTSSL probe adopts two 
possible conformations in or out of the active site pocket (Figure 5.14). In Conformation 1 
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(Figure 5.14 A), MTSSL occupies the active site, substrates PEP and E4P can no longer bind 
to this pocket. As the active sites are generally optimised for substrate binding, it is possible 
that binding of PEP and E4P may displace MTSSL and force it outward into the alternative 
conformation with rotated Cys side-chain (Conformation 2, Figure 5.14 B). In Conformation 
2, MTSSL can be stabilised by similar degree of interactions with the nearby loop compared 
to the interactions of Conformation 1 with the active site. Coordination of divalent metal ion 
with Conformation 2 is possible through alternative interactions allowing catalysis to occur. 
The predicted MTSSL binding conformations and the heterogeneity of the labelled product 
(mixture between single and dual labelled proteins) support the reduced activity of the protein 
upon labelling.  
 
Figure 5.14. MTSSL binding conformations on Cys102 of TmaDAH7PSC58S. Docking experiments 
reveal 2 possible conformations of MTSSL (green sticks) in or out of the active site pocket when 




Figure 5.15. MS results for MTSSL labelling of TmaDAH7PS. A. Unlabelled control had Mw of 
37347.49 Da, consistent with theoretical Mw of 37346.04 Da. B. In the absence of Mn2+ and PEP, the 
protein was labelled with 2 MTSSL molecules with Mw of 37714.73 Da, consistent with the calculated 
value of 37716.6 Da. C. With the presence of 1 mM Mn2+ and 1 mM PEP in the labelling reaction, the 
target protein was labelled with only one MTSSL and had Mw of 37531.26 Da, consistent with the 
theoretical value of 37531.3 Da.    
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Conditions for the labelling reaction was therefore modified based on the analysis above to 
produce target protein with a single MTSSL label per chain. A solution containing 1 mM Mn2+ 
and 1 mM PEP was added into the reaction to protect the Cys102 from reacting with MTSSL 
with other experimental conditions remained unchanged. This approach was proven successful 
in producing single labelled product as verified by MS (Figure 5.15). The activity of the 
labelled protein was tested and it retained normal activity and showed inhibition in the presence 
of Tyr. As a control, a C235S mutant was also produced using TmaDAH7PSC58S as template 
to generate the TmaDAH7PSC58S-C235S double mutant. When the same labelling conditions were 
applied using this double mutant, two MTSSL label were attached in the absence of Mn2+ and 
PEP. Only a single label was identified when Mn2+ and PEP were present in the labelling 
reaction, as was observed for the TmaDAH7PSC58S mutant. This control supported the 
prediction that the Cys102 residue was labelled with MTSSL in the absence of the additives, 
rather than the buried Cys235; and that Cys102 could be protected by adding Mn2+ and PEP in 
the labelling reaction.  
 
5.2.4. MMM analysis 
PELDOR distance measurements can be interpreted appropriately only if the possible 
conformations of the spin label are considered.249 Due to the level of freedom around the five 
rotatable bonds between the electron spin and the Cys protein backbone (Figure 5.16), the 
distance distributions measured by PELDOR may vary.247, 249 Therefore, all possible rotamers 
of MTSSL attached on the TmaDAH7PS must be analysed for accurate interpretation of the 
experimental data. Multiscale modelling of macromolecules (MMM) software is for modelling, 
visualisation and analysis of models of spin labels on target protein using the rotamer library 




Figure 5.16. Rotatable bonds of MTSSL-Cys conjugation. This freedom causes variations in the 
distance distributions of the electron spin with respect to the Cα atom of the Cys residue in the protein. 
Dihedral angles χ1-χ5 are indicated.  
MMM analysis for TmaDAH7PS system was performed with kind assistance from our 
collaborator Dr Alistair Fielding (University of Manchester). Coordinates from crystal 
structures PDB 1RZM and 3PG9 of TmaDAH7PS were used as input for the analysis. Figure 
5.17 shows the distance distributions between the MTSSL spin labels attached to Cys28 
derived from the top 26 highest populated rotamers. In the open form, Cys28 residues on the 
β2 sheets of the opposite ACT domains were well separated with an average distance of around 
8 nm. The spin location at the Cys28 residues were also relatively close to the equivalent sites 
from adjacent subunits (A-G and B-F, Figure 5.17 A), producing peaks at around 6 nm. Other 
possible pairwise contributions produced interspin distances at approximately 7 nm and 8 nm. 
In the closed form, labelled sites became close together (A-F and B-G, Figure 5.17 B) 
producing peak in distance distribution at around 2 nm. Other contributions from possible 




Figure 5.17. MMM analysis of MTSSL labelled TmaDAH7PS. Spin-label distance distribution 
predicted by using the possible rotamer library approach with the modelling software MMM. Rotamers 
of MTSSL attached on Cys28 are shown as sticks. Each protein subunit is coloured and labelled 
separately. A. Open-form prediction was based on coordinates from PDB 1RZM. B. Closed-form 
prediction was based on PDB 3PG9.   
 
5.2.5. PELDOR measurements 
The MTSSL-labelled TmaDAH7PSC58S sample was buffer exchanged into D2O buffer 
containing 50 mM BTP (pD 7.5), 100 mM KCl, and 200 µM PEP and sent to University of 
Manchester for PELDOR measurements. Sample was prepared by centrifugation of 70 µL of 
181 
 
protein mixed with 30 µl d6-glcerol. Then the sample was placed inside a 4 mm o.d. quartz 
EPR tube and heated at 60 °C for 5 minutes, followed by shock freezing in liquid nitrogen. The 
heat treatment step was due to consideration of the thermophilic nature of the protein. PELDOR 
measurements were performed at 50 K using a Bruker Elexsys 580 spectrometer for 24 hours. 
Software DEERAnalysis2013.2 was used for data processing and subtraction of background 
factor caused by intermolecular interactions.252 
 
Figure 5.18. PELDOR data and distance distributions obtained from MTSSL-labelled TmaDAH7PS. 
A. Background corrected PELDOR traces shown as black (apo) or red (Tyr) line. Form factor fits are 
shown as blue (apo) or pink (Tyr) line. B. Distance distribution derived using Tikhonov regularisation 
shown as black (apo) or red (Tyr) line. 
Data collected were of sufficient quality to derive reliable mean and width from the distribution 
based on the acquisition window. Distances beyond 5 nm were not accessible due to the 
limitation of the PELDOR spectrometer used in measuring long-range distances. Both 
PELDOR traces in the absence and presence of Tyr showed shallow oscillations, indicative of 
generally wide distributions of conformational states (Figure 5.18). In the absence of Tyr, the 
extracted distance distribution displayed a dominant mean distance at 4.03 nm. Two other 
smaller populations were also identified with mean distance of 3.26 and 2.73 nm. The least 
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dominant distance population peaked at 1.92 nm. These distance distributions were not present 
in the MMM prediction (Figure 5.17), suggesting that the protein naturally adopted various 
conformational states that were in between of the crystal extremes with the spin-labelled sites 
in the ~3-4 nm range of each other. Additionally, the presence of a small population at 1.92 
nm, consistent with the MMM prediction for the opposite chains in the closed form, indicated 
that ‘closed-like’ conformations existed even in the absence of Tyr. 
In the presence of 1 mM Tyr, although similar population maximums were observed at 4.06, 
3.30 and 2.69 nm compared to the apo experiments (Figure 5.18), a significant shift in 
population towards the small distance at 2.06 nm was detected. This was consistent with the 
prediction from MMM analysis, in which the distance between spin-labelled sites from 
opposite chains ranged from approximately 1.5-2.5 nm (A-F and B-G, Figure 5.18). This 
observation verified that the presence of Tyr promoted formation of the inhibited closed form 
of the protein, resembling the crystal structure. However, the occurrence of distance 
populations at ~3-4 nm suggested that some proteins adopted ‘closed-like’ or ‘open-like’ 
conformations regardless the presence of absence of Tyr.   
 
5.3. Summary and discussion 
Studies conducted in this chapter explored the feasibility of employing FRET and EPR 
techniques in the multi-oligomeric TmaDAH7PS and GspDAH7PS model systems. Protein 
variants and tailored labelling strategies for both techniques were successfully established and 
executed. Although the mTG-mediated labelling for FRET posed multiple problems in 
labelling efficiency and protein stability of GspDAH7PS, the approach was proven to be a 
highly specific and sufficient labelling method, which could be further investigated in different 
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protein systems or altered labelling sites of GspDAH7PS. Future directions for specific 
labelling of GspDAH7PS may include identification of alternative labelling sites on the 
regulatory CM domains that leave the N-terminal flexible loop undisturbed and simultaneously 
satisfy appropriate FRET distances. For example, the α1 helix on the CM domain could be 
mutated to include a reactive Gln residue for mTG recognition, or a spacer sequence might be 
inserted at the N-terminus between the Q-tag and the beginning of first α helix. Extensive 
screening for reactive and undisruptive Gln-containing insertions might be involved.  
On the other hand, albeit unspecific labelling of TmaDAH7PS caused high background FRET, 
a successful labelling scheme was established after various tests and alterations. The protein 
was effectively labelled with a pair of fluorophores with undisrupted functions. Single 
molecular FRET could be the next step towards measuring specific intramolecular FRET of 
the labelled TmaDAH7PS system in response to Tyr and differentiating that from non-specific 
intermolecular FRET. A more specific and orthogonal labelling approach without using 
enzymatic labelling could include the application of the fluorogenic addition reaction (FIARe) 
labelling strategy using a dimaleimide fluorophore.253-254 This approach relies on use of 
fluorophores that bear two maleimide functional groups, which react with target protein 
containing appropriately spaced Cys residues through thiol addition reactions. The probes only 
fluoresce upon occurrence of the FIARe (Figure 5.19). Although it is a relatively new technique, 
the principles behind it have been demonstrated by successful testing on labelling of the 
epidermal growth factor receptors.253 This approach can also be combined with mTG-mediated 




Figure 5.19. FlARe protein labelling strategy using a dimaleimide fluorophore.  
The differences between PELDOR distributions of apo and Tyr-bound TmaDAH7PS show a 
clear trend in which the closed-form conformation becomes dominant upon addition of Tyr, 
and multiple conformational states that are different from the crystal structures constantly exist 
in the presence or absence of Tyr. This result is complementary to the molecular dynamic (MD) 
simulations performed by Dr Eric Lang.255 The broadly open conformation obtained from the 
crystal structure did not maintain for longer than a few nanoseconds during the simulation 
(Figure 5.20). The ACT domains immediately deviated from the starting conformation and 
began exploring the nearby space. This information combined with the PELDOR results 
suggest that the wide-open conformation observed from the crystal structure is unstable in 
solution and may only exist under crystallisation constraints possibly due to the intermolecular 
interactions described in Chapter 2.3.3.  
In contrast, the closed form remained stable over the course of MD simulations even in the 
absence of Tyr, with small displacements within 2 to 3 Å away from the original conformation, 
consistent with PELDOR distance distributions. The small displacements away from the 
closed-form crystal structure as observed from both MD simulations and PELDOR 
measurements support the incomplete inhibition of TmaDAH7PS activity by Tyr (Chapter 2), 
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in which a portion of the protein population is not fully closed allowing substrate access to the 
active site. MD simulations support that the ‘closed-like’ populations detected by PELDOR in 
the absence or presence of Tyr represent low-energy states that are likely to exist in solution. 
Future PELDOR measurements may consider conducting MMM calculations using 
coordinates from MD simulations for more accurate and realistic distance predictions.   
 
Figure 5.20. RMSD traces of Cα atoms in TmaDAH7PS from MD trajectories. Open form simulations 
were calculated based on crystal structure PDB 1RZM. Closed form simulations were calculated based 





Chapter 6. Summary and remarks 
6.1. Conformational equilibrium in Type Iβ DAH7PS 
This thesis presents detailed functional and structural studies associated with allosteric 
regulation of several DAH7PS and CM enzymes and expands our current understanding of the 
remarkably diverse allosteric mechanisms employed by the DAH7PS family.80 This diversity 
in allostery is largely related to the structural variations within the protein family.  
The discrete ACT domain attached to the uninterrupted catalytic barrel of the Type Iβ 
DAH7PSs is responsible for the binding of allosteric effectors, which are the end-products of 
the shikimate pathway including Tyr and Phe (Chapter 2). In the absence of allosteric effectors, 
the protein adopts a relatively open and flexible active form with the ACT domains randomly 
exploring surrounding areas. In the presence of Tyr or Phe, the conformational population of 
the protein shifts towards more compact and rigid forms. ACT domains from diagonally 
opposite chains form interactions mediated by the allosteric ligand and physically hinder 
substrate access to the active site. Results from SAXS, PELDOR experiments and MD 
simulations (Chapter 5) on TmaDAH7PS and/or TyeDAH7PS variants, suggest that the apo 
protein can sample conformations that are ‘closed-like’ forms. Furthermore, in the presence of 
ligand, part of the population still adopts ‘open-like’ conformations rather than the fully closed 
inactive form observed in the crystal structure. The occurrence of ‘open-like’ conformations in 
the presence of ligand is also supported by the observed incomplete inhibition of catalysis. 
These results indicate that the allosteric mechanism of the ACT-DAH7PS enzymes is likely 
based on conformational selection in which the allosteric ligand alters the conformational 
equilibrium and stabilises the inactive conformations.  
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A similar conformational equilibrium likely exists in the CM-DAH7PS enzymes, such as 
GspDAH7PS, in which binding of chorismate or prephenate stabilises conformations 
resembling the closed-form crystal structure (Chapter 3). However, due to the dimeric nature 
of the CM domain, the relationship between the CM and the DAH7PS domains appears more 
intimate compared to the ACT-DAH7PS system, therefore the conformational freedom that the 
protein can explore may be less than those with the ACT domain. Overall, multiple lines of 
evidence have suggested that Type Iβ DAH7PSs with the discrete ACT or CM domains explore 
more diverse conformations in solution than those observed in the crystal structures. The 
presence of ligand is not required to initiate conformational changes in these DAH7PS enzymes, 
and sampling of intermediate states is reduced by the presence of allosteric ligand, which 
stabilises closed conformations.  
 
6.2. Ser/Ile31 determines allosteric ligand selectivity in ACT-
DAH7PS 
Characterisation of TyeDAH7PS demonstrates that the ACT domain mediated allosteric 
regulation of DAH7PS, first discovered in TmaDAH7PS,63 is not unique, and the 
conformational change upon ligand binding is likely a common allosteric mechanism 
employed by the ACT-DAH7PS enzymes. Investigations into the important interactions 
between the allosteric ligand and the ACT domain show that the presence of a key residue Ile 
at position 31, located at the ACT domain antiparallel β-sheets interface of TyeDAH7PS, 
results in a Phe-inhibited protein. In contrast, residue Ser31 in TmaDAH7PS stabilises the 
hydrogen bonding interactions with inhibitor Tyr. Studies on complementary mutations of I31S 
in TyeDAH7PS and S31I in TmaDAH7PS reinforce that the hydroxyl side-chains of Ser31 is 
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a key determinant for selective binding and potency of Tyr, whereas the hydrophobicity 
introduced by Ile is essential for binding of Phe at the equivalent site. These results combined 
with multiple sequence analysis of the ACT-DAH7PS family indicate that proteins with the 
‘His-X-Ser’ motif at the ligand binding site of the ACT domain are responsible for reporting 
cellular level of Tyr, whereas proteins with the ‘His-X-Ile’ motif are often feedback regulated 
by Phe. Variations observed in SAXS profiles of TmaDAH7PS, TyeDAH7PS and their variants 
also support the multiple conformational states adopted by the ACT domain in solution due to 
its high degree of freedom. The conformation variations also indicate that features of the ACT 
domain, especially at the interfaces where ligand binding usually occurs, may affect the 
sampling of various energy states and likely plays a role in determining the conformational 
equilibrium between open and closed forms in the absence or presence of ligand, therefore 
determining the average population distribution.  
 
6.3. Allosteric regulation can be interchanged  
Exchanging the regulatory domains between TmaDAH7PS and GspDAH7PS results in two 
new functional proteins with interchanged allosteric behaviour, one of which is additionally a 
new bifunctional enzyme, and the other displays remarkably enhanced thermostability adopted 
from the more thermophilic element of the chimera (Chapter 3). Statistical coupling analyses 
on multiple protein systems provided the foundation and proposed the feasibility of engineering 
artificial allosteric systems. These analyses identified networks of coevolving amino acids that 
were involved in communication of allosteric signal in modular proteins and these networks 
showed strong connectivity.144, 155 The full amino acid networks involved in the TmaDAH7PS 
and GspDAH7PS systems are yet to be defined, however, the interchangeable allostery and the 
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significant overlap between catalytically important residues and residues involved in allostery, 
identified in Chapter 3, shed light on the evolution of the residues associated with allostery.  
 
Figure 6.1. Superposition of PfuCM (orange, PDB 1YBZ), and PfuDAH7PS (red, PDB 1ZCO) with 
GspDAH7PS (blue). 
Another protein chimera could be developed by fusion of PfuCM as a putative regulatory 
domain on to the unregulated PfuDAH7PS. Sequence and structural analyses of PfuDAH7PS 
in relation to the requirements of allostery identified in Chapter 3, show that PfuDAH7PS is 
equipped with allosterically important residues. Additionally, the tetrameric structure of 
PfuDAH7PS provides a platform ready for adoption of allosteric regulation.117 On the other 
hand, although PfuCM shares high structural similarity with the CM domain of GspDAH7PS 
(Figure 6.1), the α2-α3 loop and the third helix (α3) of PfuCM appear slightly shorter compared 
to those of GspCM. These regions are important in interactions with the DAH7PS barrels. 
Careful design of the loop, and the linker region connecting the PfuCM and PfuDAH7PS is 
likely to be crucial for successful construction of the chimera.  The PfuCM-PfuDAH7PS fusion 
may provide insights into the evolutionary process in which gene fusion events between the 
regulatory and the catalytic components led to acquisition of allostery in contemporary Type 
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Iβ DAH7PS enzymes, and the modifications required for addition of regulatory properties on 
the discrete CM enzyme.   
A trade-off between catalytic activity and allostery is evident in the Type Iβ family, and the 
degree of attenuated activity depends on the nature of the regulatory domains. Removal of the 
regulatory domains from both TmaDAH7PS and GspDAH7PS resulted in catalytically 
enhanced proteins.63, 78 The GspCM-TmaDAH7PS chimera with the more restricted dimeric CM 
domain displayed impaired catalytic activity compared to the wild-type TmaDAH7PS with the 
mobile ACT domains. In contrast, the TmaACT-GspDAH7PS chimera displayed a two-fold boost 
in catalysis compared to the wild-type GspDAH7PS. This trade-off may be linked to allosteric 
regulation utilising conserved catalytic residues as detailed in Chapter 3. 
 
6.4. Type II DAH7PS and AroQ CM 
Although it was proposed that the formation of protein complex between AroQ CM and Type 
II DAH7PS as observed in M. tuberculosis might be a common allosteric strategy utilised by 
all AroQ CM and Type II DAH7PS enzymes,30 this hypothesis could not be validated with the 
HpyDAH7PS system (Chapter 4). HpyDAH7PS displays different allosteric regulation 
compared to MtuDAH7PS. It exhibits only a moderate level of inhibition by aromatic amino 
acids at low substrate concentrations, and adopts different oligomeric structures and quaternary 
arrangement compared to MtuDAH7PS. Overall, the allosteric regulation employed by Type 
II DAH7PS appears to vary in different organisms, however, the structural extensions at the 
dimer and tetramer interfaces of these proteins likely play an important role in allosteric ligand 
binding. The allosteric mechanisms of Type II DAH7PSs do not display dramatic 
conformational changes compared the Type Iβ, but are conferred via subtle changes in dynamic 
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communications. The AroQ CM from H. pylori also displays substantial functional and 
structural differences compared to the MtuCM. It is the only CM in the H. pylori genome and 
has normal-range catalytic activities, therefore does not require activation by HpyDAH7PS. 
Successful crystallisation of HpyCM reveals the elongated C-terminal helix that does not fit 
into the groove on top of the HpyDAH7PS barrels and severe clashes could occur at the 
interfaces between the two proteins. In contrast, the equivalent helix in MtuCM plays an 
important role in formation of the protein complex between MtuCM and MtuDAH7PS.30  
 
6.5. The role of oligomerisation in allostery and protein 
stabilisation  
Variations in quaternary structure of the DAH7PS family are evident. Whilst many members 
of the Type Iβ DAH7PS are tetrameric (Chapter 2 and 3), TyeDAH7PS displays an oligomeric 
equilibrium between dimer and tetramer. Besides altering the equilibrium between active and 
inactive conformations of TyeDAH7PS, the presence of allosteric inhibitor Phe also appears to 
affect the oligomeric equilibrium by shifting the position of the equilibrium towards tetramer 
formation. The HpyDAH7PS from Type II family also displays dimer-tetramer equilibrium 
(Chapter 4), and has a weaker tetramer interface compared to the Type II DAH7PS from M. 
tuberculosis, which is predominantly tetrameric with minor dimeric species only observed at 
very low concentrations.207 It is not yet known whether these dimeric species observed in both 
Type Iβ and Type II families exist in the cell, or if they have any physiological relevance. 
However, the relatively weak tetramer interfaces and the interface modifications identified in 
both TyeDAH7PS and HpyDAH7PS may provide insights into the evolution of their quaternary 
structure. Oligomerisation appears to be a prerequisite for allostery of DAH7PS that involves 
dimerisation of the regulatory module. For instance, removal of regulatory ACT domain from 
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TmaDAH7PS and CM domain from GspDAH7PS both produced functional dimers with no 
allosteric behaviour.63, 78 Additionally, single amino acid substitutions at tetramer interface of 
MtuDAH7PS were able to render the protein dimeric, and the dimers were functional with 
significantly impaired allosteric regulation.140 Therefore, it appears that the formation of 
tetrameric species is to provide allostery in regulated Type Iβ and Type II DAH7PSs. If the 
observed dimeric species exist in the cell, it may be possible that the protein is en route to 
modify the level of existing allosteric regulation by evolving weaker tetramer interfaces to 
produce dimers that are not subject to immediate allosteric regulation. This hypothesis may be 
linked to the moderate level of inhibition displayed by HpyDAH7PS (Chapter 4) and the 
increase in tetramer formation of TyeDAH7PS in the presence of Phe (Chapter 2).  
In addition to the delivery of allosteric regulation, oligomerisation in some members of the 
DAH7PS family also serves a role in stabilisation of the protein. It has been reported that an 
unregulated member of Type Iβ DAH7PS from P. furiosus was tetrameric, and rendered 
dimeric by a single amino acid substitution at the tetramer interface. The dimers were 
catalytically more active, however their thermostability was significantly compromised 
compared to wild-type protein.134 In another example, the tetrameric interface of Type Iα 
DAH7PS from N. meningitidis was disrupted and resulted in dimers that were catalytically 
active and allosterically inhibited to the same extend as the wild-type protein, however, showed 
reduced thermal stability.139 It seems that whether oligomerisation primarily facilitates 
allostery and/or provides protein stability, depends on the nature of the allosteric system. If the 
delivery of allostery requires the discrete regulatory domains (in the case of regulated Type Iβ 
DAH7PS), or binding of allosteric ligands occurs at the tetramer interfaces (in the case of Type 
II DAH7PS), the tetramer formation is unequivocally crucial for allostery. However, it is not 
ruled out that oligomerisation may also have a role in protein stabilisation in such cases. For 
DAH7PS enzymes that display no regulation (in the case of unregulated Type Iβ DAH7PS) or 
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regulation that is not directly dependent on dimerisation of the regulatory elements (in the case 
of Type Iα DAH7PS), tetramer formation appears to have the primary role of protein 
stabilisation.  
 
6.6. Evolution of DAH7PS 
Based on previously reported studies and the results presented in this thesis,62-63, 72, 78, 117, 134 a 
fuller model for the evolution of allostery in DAH7PS can be proposed (Figure 6.2). It has been 
suggested that the ancestral DAH7PS may be a dimer incapable of allosteric regulation.72 
Association of the dimers into tetramers, such as PfuDAH7PS, was likely followed by the 
acquisition of allosteric regulation via gene fusion events with the ACT or CM domains, 
leading to the formation of the Type Iβ DAH7PS family (Figure 6.2). The Type Iα and Type II 
DAH7PS families share similar catalytic barrel structures, but low sequence identity with the 
Type Iβ. They are also equipped with N-terminal structural extensions that may lead to tetramer 
formation. Interestingly, the Trp binding site at the tetramer interface of Type II DAH7PS (such 
as MtuDAH7PS) displays vague topological similarity to a CM domain, which has strong 
predilection for dimerisation. Additionally, the N-terminal extension and insertion of the Type 
Iα DAH7PS (such as NmeDAH7PS and EcoDAH7PS) display features resembling the ACT 
domain and result in weaker tetramer interfaces compared to the Type II. It is yet to be 
determined whether the excision of the N-terminal extension from its host would still fold into 
a compact structure, maybe given its length, into an ACT-like or CM-like structure. However, 
it is possible that the Type Iα and Type II were evolved from Type Iβ, with truncated, 
differently folded or smeared out extensions that evolved from the ACT or CM domains 
respectively. More sophisticated allosteric communication networks were subsequently 
evolved in Type Iα and Type II families than the gating mechanism of the Type Iβ family. 
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Further phylogenetic studies are necessary to fully understand the evolutionary relationships 
among the DAH7PS families.  
 
Figure 6.2. Schematic representation of proposed evolutionary relationships among DAH7PS 
subfamilies. Conformational equilibrium in the regulated Type Iβ family is also shown. The DAH7PS 
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barrel is shown in blue. The CM and the ACT domain in Type Iβ DAH7PS are shown in orange and 
red, respectively. The insertions in the DAH7PS barrel of Type II are shown in orange, the insertions 
and extensions in the DAH7PS barrel of Type Iα are shown in red.   
 
6.7. Conclusion 
The DAH7PS enzyme family, situated at a pivotal gateway, links primary metabolism of 
carbohydrates with the aromatic amino acids pathways en route to biosynthesis of numerous 
metabolites. Presented with such an important role, it is truly fascinating that the DAH7PS 
family has adapted remarkably disparate allosteric networks in response to cellular demand in 
different organisms under various selection pressure. Believed to have evolved from an 
unregulated enzyme, the Type Iβ DAH7PSs fused with ACT or CM terminal domains employ 
simple gating mechanisms associated with large conformational changes to control catalysis. 
Many conserved catalytic residues appear to have been repurposed with additional allosteric 
roles. Studies on several protein systems included in this thesis reveal the truly dynamic 
conformational equilibrium that lies behind the conformational changes, which extends far 
beyond the crystallographic snapshots. This study also demonstrates that members of DAH7PS 
from the same subgroup can adopt variations in conformations and allostery, albeit sharing 
similarities in many aspects such as their ligand binding motif in the ACT domain. Regulation 
by the intermediate product of the shikimate pathway, is interchangeable with, feedback 
regulation by pathway end-products, demonstrating the ease and portability of which different 
allosteric strategies can be acquired by the organism. This finding also contributes to the 
understanding of the amino acid networks associated with allostery. The discrete regulatory 
domains were possibly modified and repurposed in different organisms during evolution, 
leading to the establishment of Type Iα and Type II DAH7PS families, in which subtle and 
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sophisticated allosteric networks without dramatic conformational changes have been 
developed. The methodologies and techniques developed in this study for the examination of 
the dynamic allostery in DAH7PS model systems can provide valuable resources for future 





Chapter 7. Experimental procedures 
 
7.1. General methods 
7.1.1. Sequence analysis 
Sequence alignments figures were generated with Clustal Ω 256 and formatted with ESPript 
3.257 For Chapter 3, total of 2523 sequences from the DAH7PS family of interest (Type Iβ) 
were obtained from Pfam (PF00793)258, aligned using SeaView 4259 and conserved residues 
were identified and graphed with WebLogo3.120 
7.1.2. Protein structure images 
Structural representation of proteins were generated using the PyMOL Molecular Graphics 
System (version 1.8.2.1, Schrödinger, LLC).260  
7.1.3. Water 
Water used in all experiments was purified by a Millipore Milli-Q® system. For molecular 
biology and cell culture related experiments, water was sterilised by autoclaving prior to use. 
For EPR measurements, heavy water (D2O) was used.  
7.1.4. Buffer solutions 
All standard buffers and solutions used were made with Milli-Q water, and the pH values were 
determined using a Mettler Toledo™ S220 SevenCompact™ pH/Ion meter and adjusted by 
using HCl or NaOH solutions. The pD values for buffers made with heavy water were adjusted 
with the equation pD = pH + 0.4, where pH was the observed value. 
198 
 
When metal ions were required to be removed from buffer solutions, such as for metal 
selectivity measurements, Chelex® 100 resin (Bio-Rad) was incubated with the target solution 
overnight with gentle stirring. The mixture was filtered using a 0.22 µm membrane prior to use. 
7.1.5. Media 
All standard E. coli cell cultures were grown in lysogeny broth (LB) at 20 g·L−1 (unless 
otherwise stated) made up with Milli-Q water and sterilised by autoclaving. Appropriate 
antibiotics were added before use. For agar plates, LB-agar media (Miller’s) was dissolved in 
water at 37 g·L-1 before sterilisation by autoclaving. The appropriate antibiotics were added 
after the media was cooled to desired temperatures, and the mixture was subsequently plated 
in petri dishes. SOC media used during transformation consisted of 2% (w/v) tryptone, 0.5% 




All genes encoding wild-type proteins of interest were synthetic genes purchased from GeneArt 
and codon optimised for expression in E. coli cells. Protein variants were created from the wild-
type genes by PCR techniques.  
Plasmids containing genes of interest were isolated from overnight cell cultures by using the 
High Pure Plasmid Isolation Kit (Roche). Concentrations of DNA products were determined 




Table 7.1. Primers used for cloning. 
Protein Primer 5’-3’ 
Chapter 2  
Cloning of TyeDAH7PS constructs 
TyeDAH7PS-His6 (C-
terminus, uncleavable)  
FWD AGGAGATATACCATGGTGATTGTGATG 
REV GTGGTGGTGCTCGAGAATTTTTTCGGCAATGC 







TmaDAH7PSS31I FWD CTTGAAGTGTCACATTATTAAAGGTCAGGAAAG 
REV CTTTCCTGACCTTTAATAATGTGACACTTCAAG 
TyeDAH7PSI31S FWD CTATAAACCGCATGTTTCTTATGGCACCACCCGT 
REV CGGGTGGTGCCATAAGAAACATGCGGTTTATAG 
Chapter3  
Cloning of TmaACT-GspDAH7PS 
PCR 1-TmaACT domain 
and linker with overlap 
FWD GCTTCGAAGGAGATAGAACCATGATTGTCGTTTTGAAACCC  
REV GACGAAATATTGATTGCCGTTTCCTATCTTCACATCT 
PCR 2-GspDAH7PS 











Cloning of GspCM-TmaDAH7PS 
PCR 1-GspCM domain and 














Chapter 4  
Cloning of HpyDAH7PS  
His6-HpyDAH7PS FWD GGCAGCGGCGCGATGTCAAACACAAC 
REV GAAAGCTGGGTGTCAAGTGCGTTGTT 
Chapter5  
Cloning of Q-tagged GspDAH7PS 
PCR 1-Q-tag FWD ATGTGGGCGCTGCAGCGTCCGCATGGTAATGAACGTCTGGAT 
REV TTATTACTCGAGTGCACGAACAAACTGACG 




GspDAH7PDD302C FWD GCACCGGTCGTCGTTGCCTGCTGATTCCGTGTG 
REV CACACGGAATCAGCAGGCAACGACGACCGGTGC 

















7.2.2. Polymerase chain reaction  
Primers used for polymerase chain reaction (PCR) were purchased from Invitrogen and diluted 
to desired concentrations using sterile water or TE buffer (10 mM Tris-Cl, 0.1 mM EDTA, pH 
8.0). PCR experiments were performed using a Veriti® 96-well Thermal Cycler (Applied 
Biosystems). Phusion® High-Fidelity DNA Polymerase was generally used unless otherwise 
stated.  
Colony PCR experiments were usually performed to verify the size of the gene product. Small 
portions of cell colonies were collected from agar plates and used as templates for PCR. A pair 
of primers including a gene specific primer and a plasmid specific primer, and Taq DNA 
polymerase were used. An optional elongated denaturation step was sometimes added at the 
start of the reaction to allow sufficient cell lysis.  
7.2.3. Gateway® cloning 
Gateway recombination technology is a universal clothing method that allows fast and efficient 
transfer of DNA segments into various vectors in fewer steps compared to traditional restriction 
enzyme cloning.261 Protein constructs including TmaACT-GspDAH7PS, GspCM-TmaDAH7PS, 
and HpyDAH7PS were cloned using this technique (Table 7.1). Specific recombination sites 
were added to the amplified target gene using PCR. Optional TEV cleavage site was included 
when required. Linear DNA product was transformed into pDONRTM221 vector via BP clonase 
reaction and into TOP10 competent cells following the product manual. The pDONRTM221 
vector permits recombination cloning into multiple destination vectors allowing optimal 
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expression of the gene of interest. The resulting clone was plated on LB-agar plates with 
Kanamycin, from which cell colonies were selected and used for plasmid extraction. The 
purified plasmid was used for the LR clonase reaction and transformed into pDESTTM14, 
pDESTTM15, or pDESTTM17 depending on requirement for a tagless, GST tag, or His6 tag, 
respectively (Table 7.2). Subsequent transformation procedures into expression vectors 
followed standard method described below.   
Table 7.2. Proteins used in this study.  
Protein Vector  Expression cell line 
(E. coli) 
TyeDAH7PS-His6  pET28-b(+)  BL21*(DE3) 
TyeDAH7PS (untagged)  pET28-b(+)  BL21*(DE3) 
His6-TyeDAH7PS  pET28-a(+)  BL21*(DE3) 
TyeDAH7PSI31S pET28-b(+)  BL21*(DE3) 
TmaDAH7PS pT7-7  BL21*(DE3) 
TmaDAH7PSS31I pT7-7  BL21*(DE3) 
TmaDAH7PSS31V pT7-7  BL21*(DE3) 
TmaACT-GspDAH7PS pDEST14  BL21*(DE3) 
GspCM-TmaDAH7PS pDEST15  BL21(DE3)pLysS 
GspDAH7PS pET28-b(+)  BL21*(DE3) 
HpyDAH7PS pDEST17  BL21*(DE3) 
HpyCM pDEST15  BL21*(DE3) 
PfuCM pDEST15  BL21*(DE3) 
GspDAH7PSD302C pET28-b(+)  BL21*(DE3) 
GspDAH7PSC307S pET28-b(+)  BL21*(DE3) 
GspDAH7PSD302C-C307S pET28-b(+)  BL21*(DE3) 
GspDAH7PSD302C-C307S-Q pET28-b(+)  BL21*(DE3) 
TmaDAH7PSC58S pT7-7  BL21*(DE3) 
TmaDAH7PSC58S-C235S pT7-7  BL21*(DE3) 
mTG pDJ1-3  BL21*(DE3) 
 
7.2.4. In-Fusion® cloning  
In-Fusion® HD cloning (Clontech) is a rapid cloning method allowing directional cloning of 
DNA fragments into various vectors by enzymatic recognition of a 15-basepair overlap 
engineered at the ends of the target DNA. Constructs for TyeDAH7PS were cloned using this 
technique (Table 7.1, 7.2). Target vector was linearised using restriction enzyme digest and 
purified by NucleoSpin® gel purification kit. Restriction sites NcoI and XhoI were used for 
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the construct TyeDAH7PS-His6 (C-terminus), and restriction sites NdeI and XhoI were used 
for His6-TyeDAH7PS (N-terminus). Gene-specific primers were designed for PCR to 
incorporate the recognition sites at both ends of the gene based on selected restriction sites 
(Table 7.1). The PCR product, linearised vector, and In-Fusion® enzyme mixture were 
incubated and transformed as per manufacturer’s instructions.  
7.2.5. Site-directed mutagenesis  
QuikChange® site-directed mutagenesis technique was used to generate protein variants 
including TmaDAH7PSS31I, TmaDAH7PSS31V, TmaDAH7PSC58S, TmaDAH7PSC58S-C235S 
TyeDAH7PSI31S, GspDAH7PSD302C, GspDAH7PSC307S, GspDAH7PSD302C-C307S. Primers for 
mutagenesis were designed with the point of mutation in the centre and sufficient overlaps (~15 
base pairs) on both ends (Table 7.1). Mutagenesis was performed using a QuikChange II Site-
Directed Mutagenesis Kit (Agilent), using cycling protocols and reaction components (50 µL) 
recommended by the manufacturer. PCR products were treated with Dpn1 (New England 
BioLabs) for removal of methylated templates. 
7.2.6. Agarose gel electrophoresis 
Agarose gels were prepared by mixing 1% (w/v) LE agarose (Seakem) with Tris-acetate EDAT 
(TAE) buffer (50 mM Tris, 20 mM acetic acid, and 1 mM EDTA) and heating until all agarose 
was dissolved. SYBR® Safe DNA gel stain (Invitrogen) was then added to the mixture before 
the gel was casted. DNA samples were mixed with 6x loading buffer [60 mM Tris-HCl, 60 
mM EDTA, 0.2% (w/v) Orange G, 0.05% (w/v) xylene cyanol FF, 60% (v/v) glycerol] and 
loaded in each well. The electrophoresis was conducted at 85 V in TAE buffer for 45 minutes 





Chemically competent cells TOP10 (Invitrogen) and StellarTM (Clontech) were used for 
plasmid propagation, and E. coli BL21* (DE3) or BL21* (DE3) pLysS cells were used for 
protein expression. An aliquot of the competent cell (50 µL) was thawed on ice and gently 
mixed with the target plasmid (~100-200 ng) before incubation on ice for 30 minutes. A heat 
shock of 42 °C for 45-60 seconds was used, followed by further incubation on ice for 2 minutes. 
SOC media (250 µL) was added into the cell mixture and this was incubated at 37 °C with 
shaking at 200 rpm for one hour. The resulting cell was plated on LB-ager plates with 
appropriate antibiotics and incubated overnight at 37 °C to produce colonies used for colony 
PCR, subsequent cell culture or plasmid extraction.  
7.2.8. DNA sequencing 
DNA sequencing service was provided by the Canterbury Sequencing Facility at the University 
of Canterbury, or Macrogen DNA Sequencing Service. Approximately 100 ng·µl-1 DNA 
product was supplied for each sample. Sequencing primers used for this study can be found in 
Table 7.3.  
Table 7.3. Sequencing primers. 
Sequencing primers 5’-3’ 
M13 
FWD  GTAAAACGACGGCCAG  
REV AACAGCTATGACCATG 
T7 







7.3. Cell cultures 
7.3.1. Protein expression 
Precultures (50-200 mL culture in 200-500 mL flasks) were prepared by inoculation of LB 
media containing appropriate antibiotics with the expression cell strains, followed by overnight 
growth at 37 °C with shaking at 200 rpm. The precultures were then used to inoculate 1 L LB 
media in 3-L baffled flasks. Cell cultures were grown at 37 °C with shaking (200 rpm) until 
mid-logarithmic phase (OD600 0.4-0.8 AU). 
Most genes (except for mTG) used in this study were inserted in pDEST, pET or pT7-7 series 
expression vectors (Table 7.2). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to 
induce protein expression with final concentration of 0.5 mM. The concentration of IPTG 
might be varied from 0.1 to 1 mM during test expressions. Following induction by IPTG, cell 
culture was incubated at 23 °C overnight or 37 °C for four hours with shaking at 200 rpm.  
7.3.2. Autoinduction 
Autoinduction of protein expression was used for mTG. The mTG proenzyme with C-terminal 
His6 tag in the pDJ1-3 plasmid was transformed into E. coli BL21*(DE3). The preculture was 
grown in the ZYP-0.8G media under standard conditions as described in Chapter 5.1. ZYP-
0.8G is a rich growth medium for production of high cell densities with little to no induction 
of expression.241 A preculture (5 mL) was used to inoculate a large culture (500 mL) in ZYP-
505 media. ZYP-505 is another rich growth medium with little to no induction of expression 
during log phase and allows autoinduction as the culture approaches saturation.241 The 
inoculated culture was harvested after two hours incubation at 37 °C and overnight incubation 
at 22 °C with shaking at 220 rpm. The components of the autoinduction media are listed below. 
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ZY: 10 g N-Z-amine AS (or tryptone), 5 g yeast extract, 925 ml water 
NPS: 50 mM KH2PO4, 25 mM (NH4)2SO4, 50 mM Na2HPO4 (20 x NPS stocks were usually 
prepared)  
505: 0.5% glycerol, 0.05% glucose, 0.2% α-lactose (100 x 505 stocks were usually prepared) 
Metals mixture: 50 µM FeCl3, 20 µM CaCl2, 10 µM MnCl2, 10 µM ZnSO4, 2 µM CoCl2, 2 µM 
CuCl2, 2 µM NiCl2, 2 µM Na2MoO4, 2 µM Na2SeO3, 2 µM H3BO3 (1000 x metals mixture 
stocks were usually prepared) 
All metal stocks were prepared individually and autoclaved. FeCl3 was dissolved in 50 mM 
HCl and filtered using a 0.22 µm membrane.  
ZYP-0.8G recipe contained final concentrations of 1mM MgSO4, 0.8% glucose, 1x NPS, 100 
µg·mL-1 kanamycin, 25 µg·mL-1 chloramphenicol, and 50 µg·mL-1 ampicillin dissolved in ZY 
stock. MgSO4 was added before NPS to avoid precipitation.  
ZYP-505 recipe contained 1mM MgSO4, 1 x metals mixture, 1x 505, 1x NPS, 100 µg·mL
-1 
kanamycin, 25 µg·mL-1 chloramphenicol, and 50 µg·mL-1 ampicillin all dissolved in ZY stock. 
MgSO4 and metal mixture was added before NPS to avoid precipitation. 
7.3.3. Cell harvesting 
Large cell cultures (> 500 mL) were harvested by centrifugation in a FiberliteTM F9-6x1000 
LEX fixed-angle rotor (Thermo Fisher Scientific) using 1 L bottles at 14000 g for 30 minutes 
at 4 °C. Cultures less than 50 mL were harvested in sterile 50 mL tubes using a FiberliteTM 
F14-14x50cy fixed-angle rotor (Thermo Fisher Scientific). Small cultures (< 5 mL) were 
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harvested in 1.5 mL micro-centrifuge tubes at 17000 g for 1 minutes. Harvested cell pellets 
were either immediately lysed or snap frozen and stored at -80 °C. 
 
7.4. Protein purification 
7.4.1. Cell lysis 
Most cell lysis was performed using sonication, although chemical lysis and cell disruptor were 
also occasionally used. Cell pellets were resuspended in 30-40 mL chilled lysis buffer per litre 
of cell growth and sonicated on ice using an Omni-Ruptor 4000 Ultrasonic Homogeniser with 
4–6 repeats of 5 minutes at 80% power with 40% pulsation. The lysis buffer contained 0.2 M 
Tris-Cl (pH 6.0) for mTG, or 50 mM BTP (pH 7.5), 1 mM EDTA, 100 mM KCl, 200 µM PEP, 
and 200 µM TCEP for other proteins. 
Cell cultures with small volumes, such as test expression cultures, were chemically lysed using 
BugBuster® Protein Extraction Reagent (Novagen). Cell pellets were resuspended in lysis 
buffer containing 5% (v/v) BugBuster® and incubated at room temperature with gentle shaking 
for at least 20 minutes. 
A cell disruptor (M-110P Microfluidiser®) was used to recover maximum level of soluble 
proteins from a large cell culture or when the yield obtained from sonication was not sufficient. 
Resuspended cell pellets were applied on the cell disruptor with chilled buffers at 18,000 psi 
for 3-5 times until the cell lysate reached ideal clarity and viscosity. All cell lysate was treated 
with Benzonase® for 10 minutes at room temperature before centrifugation at 40000 g for 30 
minutes at 4 °C to remove the insoluble cell debris.  
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7.4.2. Heat treatment 
Following cell lysis, heat treatment was performed as the first step of purification for proteins 
that tolerate high temperatures. These proteins include variants of TmaDAH7PS, GspDAH7PS 
and TyeDAH7PS. The heat treatment was conducted at 70 °C for 30 minutes for TmaDAH7PS 
variants and 60 °C for GspDAH7PS and TyeDAH7PS variants. The sample was then left to 
cool to room temperature and clarified by centrifugation. 
7.4.3. Hydrophobic interaction chromatography 
Proteins without purification tags, including TmaDAH7PS variants, TmaACT-GspDAH7PS, and 
the tagless TyeDAH7PS, were purified using hydrophobic interaction chromatography (HIC). 
1 M (NH4)2SO4 was slowly added into the crude supernatant following heat treatment, with 
gentle stirring at room temperature until dissolved. This solution was then filtered using a 0.22 
µm membrane and loaded on a SOURCE™15Phe column (GE Healthcare) preequilibrated 
with 20 mM BTP (pH 7.5), 1 M (NH4)2SO4. A linear gradient of 1 to 0 M (NH4)2SO4 was 
applied over 70 mL elution. The fractions containing protein of interest were immediately 
collected and exchanged into low salt buffers to avoid protein precipitation. 
7.4.4. Immobilised metal affinity chromatography 
Proteins with engineered His6 purification tag, including TyeDAH7PS variants, GspDAH7PS 
variants, HpyDAH7PS variants, and mTG, were purified using immobilised metal affinity 
chromatography (IMAC). The 5 mL HiTrapTM HP (Ni2+) columns (GE Healthcare) were used 
for IMAC purifications. The columns were equilibrated with binding buffer containing 20 mM 
BTP (pH 7.5), 20 mM imidazole, 150 mM NaCl (or 100 mM KCl), 200 µM PEP, and 200 µM 
TCEP (unless otherwise specified). Filtered protein samples were loaded on the column and 
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washed with at least 5 column volumes of binding buffer to remove unspecific binding of 
impurities. A gradient of 20 to 500 mM imidazole was applied over 50 mL for protein elution. 
For mTG, activation of the enzyme by trypsin (Chapter 5.1) was performed before IMAC. 
Buffer containing 50 mM phosphate (pH 8.0) and 300 mM NaCl was used to equilibrate the 
column. Protein was eluted with a gradient of 1 to 140 mM imidazole.  
7.4.5. Immobilised glutathione affinity chromatography 
Proteins with GST solubility tag, including HpyCM, PfuCM, and GspCM-TmaDAH7PS, were 
purified using immobilised glutathione affinity chromatography (IGAC). The 5 mL GSTrapTM 
HP columns (GE Healthcare) were used for IGAC purifications following same procedures as 
that of IMAC. Eluted fractions containing the protein of interest might be collected and 
reloaded on the GSTrap column multiple times to achieve desired purity. Binding buffer was 
standard phosphate-buffered saline (PBS, 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4, pH 7.3), and elution buffer contained 10 mM reduced glutathione and 50 mM 
Tris-Cl (pH 8.0).  
7.4.6. TEV protease treatment 
Tobacco etch virus protease (TEV) was used when cleavage the affinity tags off the target 
protein was required. TEV was expressed and purified from E. coli BL21*(DE3) cells 
containing pRIL and pRK793 plasmids using the IMAC procedure outlined above, and stored 
at ~1 mg·mL-1 in 1 mL aliquots in buffer containing 25 mM KH2PO4 (pH 8.0), 200 mM KCl, 
10 mM DTT, 2 mM EDTA and 10% (v/v) glycerol. Concentration ratio of 1:100 between TEV 
and target protein was generally used. The reaction was incubated at 4 °C overnight or until 
the tag was sufficiently cleaved. After tag removal, the protein was subjected to another IMAC 
or IGAC step to remove the cleaved tag and the TEV protease.  
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7.4.7. Size exclusion chromatography 
A size exclusion chromatography (SEC) step was used for all protein purifications as a final 
step to produce highly pure proteins. A HiLoadTM 26/60 SuperdexTM 200 prep grade column 
or a HiLoadTM 16/60 SuperdexTM 75 prep grade column (GE Healthcare) was used based on 
size of the target protein. SEC was performed at 4 °C using buffer containing 0.2 M Tris-Cl 
(pH 6.0) for mTG, or 10 mM BTP (pH 7.5), 150 mM NaCl (or 100 mM KCl), 200 µM PEP, 
and 200 µM TCEP for other proteins. 
7.4.8. Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SDS-PAGE was performed using Bolt® 10% Bis-Tris Plus protein gels (Invitrogen) in MES 
running buffer. Protein samples were prepared and denatured following the product manual by 
adding LDS sample buffer, DTT, and heating at 95 °C for 10 minutes. A premixed Novex® 
Sharp prestained protein standards (Invitrogen) was used as the molecular weight marker. 
Electrophoresis was performed at 165 V for 35 minutes and the resulting gels were stained 
using a heated solution containing 0.1% (w/v) Coomassie brilliant blue R-250, 10% (v/v) 
glacial acetic acid, and 40% (v/v) methanol for 30 minutes with gentle shaking. The staining 
step was repeated with fresh staining solution when necessary to generate sufficiently stained 
gels. Gels were then destained using a heated solution containing 10% (v/v) glacial acetic acid, 
40% (v/v) methanol until the protein bands were sufficiently visible.  
7.4.9. Determination of protein concentration  
Nanodrop® ND-1000 spectrophotometer was used to determine protein concentrations by 
measuring absorbance at 280 nm with protein-specific molar extinction coefficient values 
(calculated using ProtParam online tool).262  
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For protein with low extinction coefficient values, such as the CMs, Bradford’s assay was used 
to determine protein concentrations.263 Bovine serum albumin (BSA) stock was used to create 
six standards at 0, 0.2, 0.4, 0.6, 0.8 and 1 mg·mL-1. Protein solutions containing each BSA 
standard (20 µL) were mixed with Bradford reagent to a total volume of 1 mL. The absorbance 
values of the standards were measured in triplicates at 595 nm to create a calibration curve. 
Target protein was prepared to approximately 0.2, 0.4 and 0.8 mg·mL-1 based on Nanodrop 
reading and mixed with Bradford reagent. The absorbance values were measured following the 
same methods as for the standards. Concentrations of the target protein was then calculated 
based on the standard curve generated from the standards.  
Protein samples were concentrated to desired concentration using a VivaspinTM Turbo 15 mL 
centrifugal concentrator with 10 kDa or 3 kDa molecular weight cut off (Sartorius Stedim 
Biotech). 
7.4.10. Protein verification 
Mass spectrometry 
The molecular mass of purified proteins was verified using electrospray ionisation with a 
Micromass LCT Classic, Bruker maXis 3G at the University of Canterbury Chemistry 
Department. Protein samples (100 µL) were prepared at 1 mg·mL-1 in water. 
 
Circular dichroism  
Circular dichroism (CD) was used to verify whether the protein of interest was properly folded 
with the correct secondary structure. CD spectra were recorded using a JASCO J-815 
Spectropolarimeter for range of 250 nm to 190 nm at 25 °C using 1 nm data pitch and 
bandwidth at 1 s response. Protein solution (~0.03 mg·ml−1) prepared in water in a 3 mL quartz 
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cuvette with 1 cm path length were used for measurements. Background spectra of water were 
recorded and subtracted. Resulting data were smoothed by performing a five-point moving 
average. 
 
7.5. Protein characterisation 
7.5.1. Kinetic assays 
DAH7PS assay 
The standard DAH7PS assay used in this study measured the consumption of PEP at 232 nm 
(ε = 2.8 x 103 M-1·cm-1) following published procedures using a Varian Cary 100 UV-visible 
spectrophotometer.63, 78, 177 Initial velocity values were determined with respect to varying 
concentrations of each substrate, when the concentration of the other substrate was fixed at 
saturating concentrations (defined as at least 5-fold higher than the KM value). The reaction 
mixture contained ~0.05 µM protein, specified or saturating concentrations of PEP (for 
determination of KM
E4P), specified or saturating concentrations of E4P (for determination of 
KM
PEP), 100 µM of appropriate divalent metal ion in 50 mM BTP buffer (pH 7.5 or as specified). 
Reactions were initiated by addition of E4P. Assays at elevated temperatures were performed 
following the same methods. Enzyme activities are specified in U (1 U = consumption of 1 
μmol substrate·min-1). Specific enzyme activities are given as U·mg−1. Kinetic parameters 
were determined by fitting triplicate data to the Michaelis-Menten equation using GraphPad 
Prism 7. 
Specifically, concentration of PEP was fixed at 215 µM when KM for E4P of TmaDAH7PS 
variants was determined in Chapter 2. Concentration of E4P was fixed at 310 µM when KM for 
PEP was determined. For TyeDAH7PS, concentration of PEP was fixed at 300 µM when KM 
for E4P was determined. Concentration of E4P was fixed at 210 µM when KM for PEP was 
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determined. For DAH7PS assays described in Chapter 3, concentration of E4P was varied 
between 5 µM and 400 µM while PEP was held at 295 µM. Concentration of PEP was varied 
between 6 µM and 350 µM while E4P was held at 310 µM. Mn2+ was used for proteins 
containing the catalytic barrel from T. maritima, whereas Cd2+ was used for proteins containing 
the catalytic barrel from G. sp. For HpyDAH7PS described in Chapter 4, concentration of PEP 
was fixed at 98 µM when KM for E4P was determined. Concentration of E4P was fixed at 211 
µM when KM for PEP was determined. 
For assays assessing the effect of temperature on specific activities of TmaDAH7PS and 
TyeDAH7PS variants (Chapter 2), each reaction contained 283 µM PEP, 308 µM E4P, and 100 
µM Mn2+ in 50 mM BTP with pH fixed at 7.5 at all temperatures tested (30 °C-80 °C). Activity 
profiles of the chimeric proteins and parent proteins (Chapter 3) at elevated temperatures were 
assessed with each reaction containing 100 µM appropriate metal ion, 215 µM PEP and 227 
µM E4P in 50 mM BTP buffer at pH 7.5 at the temperatures tested (30 °C-80 °C). 
Metal dependency studies were performed using the DAH7PS assay with a range of alternative 
metal ions or EDTA at 100 µM. For inhibition studies, the rate of reaction was measured 
following incubation of the protein for 5-10 minutes with varying concentrations of Tyr or Phe 
(0 to 1 mM), or 3 to 5 minutes-incubation with varying concentrations of prephenate (0 to 500 
µM). For assays containing mixture of two proteins of interest, such as HpyCM and 
HpyDAH7PS, the reaction mixture was incubated for at least 5 minutes before the reaction was 
initiated. 
CM activity 
Standard assays for the CM-catalysed reactions were measured by monitoring consumption of 
chorismate at 274 nm (ε = 2.630 x 103 M-1·cm-1).30, 78 Buffers used were same as that for 
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DAH7PS assays and reactions were initiated by addition of chorismate (9 µM to 400 µM). 
HpyCM activity was measured at 30 °C. Activities of PfuCM, GspCM-TmaDAH7PS and 
GspDAH7PS variants were measured at 50 °C.  
Chorismic acid (CA) stock solutions used for kinetic assays were prepared in appropriate buffer 
at an approximate concentration of 10 mM. Accurate concentrations of CA were determined 
using a standard CM assay. The reaction mixture contained 0.05 µM enzyme, 50 mM BTP (pH 
7.5) and 5 µL of CA stock with total volume of 1 mL. Based on Beer’s law (A = ε·L·C), the 
change in absorbance from before enzyme was added until the reaction had reached completion 
was used to calculate the change in concentration of CA (ɛ = 2.630 x 103 M-1cm-1) upon 
addition of enzyme. The change in absorbance did not account for the increase in background 
absorbance due to addition of enzyme, so correction factor was determined by an identical 
assay without CA present and was subtracted to calculate the corrected concentrations. The 
concentration of PEP and E4P were determined using similar methods. 
7.5.2. Differential scanning fluorimetry 
Melting temperatures of the proteins were determined by using differential scanning 
fluorimetry with an iCycler iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad). 
Protein samples (0.1 mg·mL-1) were prepared in storage SEC buffer with SYPRO orange dye 
in the presence of appropriate metal ions (100 µM) and ligands (1 mM Tyr/Phe/Trp, or 500 
M prephenate). Controls were similarly prepared for each condition, with buffer in place of 
protein. The temperature was set to increase from 20-98 °C at a rate of 1°C per minute and 
fluorescence was measured in 0.2 °C increments. Melting temperatures were determined as the 
temperature of maximum inflection of the first melting event after subtracting background from 
the control. Errors were calculated based on standard deviation from triplicate measurements.  
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7.5.3. Determination of protein oligomeric state  
Analytical size exclusion chromatography and analytical ultracentrifugation (AUC) were 
typically used to determine the size of the target protein in solution. This information was also 
derived from SAXS experiments when required.  
Analytical SEC 
A SuperdexTM 200 10/300 GL column (GE Healthcare) was used for analytical SEC. It was 
equilibrated with SEC buffer and calibrated by protein standards with known molecular 
weights, including ovalbumin, conalbumin, aldolase, ferritin, thyroglobulin and blue dextran. 
Protein standards and samples were applied to the column at 1 mg·mL-1 in 500 µL volume 
unless otherwise stated. The elution volume of blue dextran was recorded as the void volume. 
Elution volumes for all samples were recorded and graphed against the log [protein standard 
mass (Da)] producing a linear graph, from which unknown protein masses were calculated. 
AUC 
Sedimentation velocity (SV) and sedimentation equilibrium (SE) experiments were performed 
using a Beckman Coulter Model XL-I analytical ultracentrifuge equipped with UV/Vis 
scanning optics. Reference buffer solution (20 mM Tris–HCl or BTP, 150 mM NaCl, pH 7.5) 
and sample solutions were loaded into 12 mm double-sector cells with quartz windows and the 
cells were then mounted in an An-60 Ti 4-hole rotor.   
Purified and dialysed protein samples at concentrations of 0.1 to 1.6 mg·mL-1 and the reference 
buffer were centrifuged at 50000 rpm (for SV) at 20 °C and absorbance data were collected in 
continuous mode at 278 nm without averaging. Data were fitted to a continuous size 
distribution model using the program SEDFIT.129 The SE data were collected over a 
concentration gradient at 7000, 10000, 12000, and 18000 rpm at 20 °C and 280 nm. The partial 
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specific volume of the sample, buffer density and viscosity were calculated using the program 
SEDNTERP.130 
For analysis of the SE data collected from TyeDAH7PS, the meniscus, cell bottom, and fitting 
limits were adjusted using SEDFIT. The data was then exported for further processing with 
SEDNTREP. The ‘monomer-dimer self-association’ model was selected as the protein was 
expected to display dimer-tetramer equilibrium, and the Global Parameters window was then 
completed by filling the molecular weight and sedimentation coefficient of each component. 
Global Fit was initiated until the fit converged. Fit qualities from various models were 
compared based on the reduced global χ2 values as well as fitting residuals to identify the best-
fitted model. Key information such as log Ka, χ2, and errors were obtained under the Statistics 
function.  
7.5.4. Small angle X-ray scattering 
Small angle X-ray scattering (SAXS) measurements were collected at the Australian 
Synchrotron SAXS/WAXS beamline equipped with a Pilatus detector (1 M, 170 × 170 mm, 
effective pixel size, 172 × 172 μm). The X-ray wavelength was 1.0332 Å. The sample-detector 
distance was 1.6 m, which delivered a s range of 0.01–0.40 Å-1 [where s is the magnitude of 
the scattering vector, which is related to the scattering angle (2θ) and the wavelength (λ) as 
follows: s = (4π/λ)·sinθ].  
For SEC samples, scattering data were collected at 25 °C (unless otherwise specified) following 
elution of the protein samples (< 10 mg·mL-1) from a size-exclusion chromatography column 
(Superdex 200_Increase 5/150), which was pre-equilibrated with buffer containing 10 mM 
BTP (pH 7.5), 100 mM KCl, 200 µM PEP, and 3% (v/v) glycerol in the absence or presence 
of inhibitors (1 mM Tyr or 500 µM prephenate). For static samples, proteins were prepared 
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with serial dilutions at concentration range of 0.5 to 4 mg·mL-1 and filtered before loading in 
96-well plates. Scattering data were collected directly from the degassed samples in the plates. 
Raw data were processed and background-subtracted using Scatterbrain.63 Scatterings from 
A280nm peaks were summed and averaged for SEC experiments. All scatterings excluding 
outliers were summed and averaged for static experiments. Guinier plots were linear for sRg < 
1.3. Scattering intensity (I) versus s of each protein was generated with Primus and plots were 
scaled for comparison.264 Theoretical scattering profiles were generated from model 
coordinates were compared and fitted with corresponding experimental scatterings with 
Crysol.187 Specifically, the model coordinates used in this study include crystal structures of 
TmaDAH7PS PDB 1RZM (apo), 3PG9 (Tyr), homology model of GspDAH7PS (apo) and 
crystal structure 5J6F (prephenate), crystal structure of MtuDAH7PS (3NV8), homology model 
of HpyDAH7PS, and crystal structure of HpyCM (6AL9). 
7.5.5. X-ray crystallography 
Crystallisation  
Automated screening for protein crystals was performed using Mosquito® Crystal robot (TTP 
Labtech) with sitting drop vapour diffusion technique. The screen conditions typically included 
PACT premierTM HT-96, JCSG-plusTM HT-96, Clear StrategyTM I HT-96, Clear StrategyTM II 
HT-96, ProPlex™ HT-96, MIDASplus™ HT-96, and Morpheus® II HT-96 crystallisation 
screens (Molecular Dimensions). The protein samples (400 nL) were diluted to half by addition 
of a screening condition (400 nL). Volume of 40 µL of each screening solutions were used as 
reservoir. When required, ligands with appropriate concentrations were added into the sample 
drops and co-crystallised. Manual screening using 10 mL reagent kits was also occasionally 
performed with 24-well hanging drop plates. Plates were incubated at 20 or 5 °C and examined 
regularly to record crystal growth.  
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If a suitable lead condition was identified, the condition was generally optimised to improve 
crystal growth. The optimisations were performed using hanging drop vapour diffusion 
technique. Conditions such as pH, salt and precipitant concentrations, and protein 
concentrations were varied to achieve optimal formation of crystals. Sample drop size was 2 
or 4 µL with 500 µL reservoir solution in a 24-well hanging drop plates (Hampton Research). 
As described in Chapter 2.3, leading conditions for producing TmaDAH7PSS31I crystals in the 
presence of Phe were optimised. These conditions are listed below. 
PACT C7 0.2 M Sodium chloride, 0.1 M HEPES (pH 7.0), 20% w/v PEG 6000 
PACT G5 0.2 M Sodium nitrate, 0.1 M Bis-Tris propane (pH 7.5), 20% w/v PEG 3350 
JCSG+ B8 0.2 M Magnesium chloride hexahydrate, 0.1 M Tris (pH7.0), 10% w/v PEG 8000 
Conditions that produced ideal crystals of HpyCM were optimised from MIDAS conditions D8 
and G7 as listed below. Chorismate at a final concentration of 500 µM was included in all 
conditions. Conditions optimised from MIDAS G7 produced crystals with optimal quality. A 
relatively long incubation at 20 °C for at least three days was required for crystal formation.  
 
MIDAS D8 0.1 M Tris (pH 8.0), 20% v/v glycerol ethoxylate  
MIDAS G7 0.2 M Ammonium acetate, 0.1 M MES (pH 6.5), 30% v/v glycerol ethoxylate 
 
Structure determination and refinement 
X-ray diffraction data of the protein crystals were collected at the Australian Synchrotron using 
Macromolecular Crystallography (MX1) or Micro Crystallography (MX2) beamline. Detailed 
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structure determination and refinement of HpyCM can be found in Chapter 4.3.3. Briefly, data 
were processed using X-ray Detector Software (XDS), AIMLESS and TRUNCATE (CCP4 
program suite).123-125 Initial phase was predicted by molecular replacement using MOLREP 
with coordinates from crystal structures or models as search models.126 CHAINSAW was used 
when smaller units of the search models were required.201 Density Modification (CCP4 
program suite) was used when improvement of density was required. If a satisfactory solution 
was identified, multiple refinement processes were performed using rigid body, NCS, TLS and 
restrained refinements using Refmac5 with iterative model building using Coot.203, 265 Water 
molecules and ligands were added at last by interpretation of the 2|Fo|-|Fc| and |Fo|-|Fc| maps. 
Resulting structure models were validated and adjusted using the Coot validation tools and 












Appendix A - Supporting information for Chapter 1 
Mechanism of the CM-catalysed reaction 
 
Figure S1. Claisen rearrangement of chorismate to prephenate. The two conformers of chorismate are 
shown. Reaction occurs via a chair-like transition state (atom numbers labeled, adapted from Walsh et 
al.27). B. Transition state analog, endo-oxabicyclic dicarboxylic acid. Bond formation and cleavage are 
shown as dashed lines. 
The CM-catalysed reaction is a pericyclic Claisen rearrangement involving an ether oxygen 
bond cleavage between C5 and O7, followed by the formation of a new bond between C1 and 
C9 (Figure S1). In solution, the chorismate molecule favours a lower energy pseudoequatorial 
conformation, which is in equilibrium with the pseudodiaxial conformation. However, CM 
selects the minor pseudodiaxial conformer, which is set up for the rearrangement. Both 
uncatalysed and catalysed rearrangements of chorismate to prephenate occur via a chair-like 
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transition state.27 The endo-oxabicyclic dicarboxylic acid (Figure S1 B), a geometric mimic of 
this transition state, is currently the best inhibitor of a broad range of CM, which is consistent 
with the idea that the enzyme catalysed reaction proceeds through a corresponding pericyclic 
transition structure.266 CM accelerates the rate of reaction by 2×106 fold compared to the 
uncatalysed reaction. The origins of this remarkable rate enhancement still remain a matter of 







Appendix B - Supporting information for Chapter 2 
 
 
Figure S2. Sequence alignment of TmaDAH7PS and TyeDAH7PS. Numbering corresponds to 
TmaDAH7PS. The region of interest is highlighted with black rectangle. Sequences were aligned using 





Table S1. Molecular mass confirmation of TmaDAH7PS and TyeDAH7PS variants. Calculated 






TmaDAH7PSWT 37378.2 37379.4 
TmaDAH7PSS31I 37404.2 37405.1 
TmaDAH7PSS31V 37390.2 37390.5 
TyeDAH7PSWT 37989.1 37992.4 








Figure S4. Sequence alignment of the two Type Iβ DAH7PS enzymes in T. yellowstonii. The aroF1 




Figure S5. Gel filtration of N-terminal His6-TyeDAH7PS.* This protein is solely tetrameric.   
*Three constructs of TyeDAH7PS (listed below) were created in this study as mentioned in Chapter 2. 
Primers used for these constructs can be found in Table 7.1. 
1. C-terminal His6-tagged construct was used in all experiments. 
2. Construct without purification tag was used as a control. 





Appendix C - Supporting information for Chapter 3 
 
 
Figure S6. Purification of TmaACT-GspDAH7PS (A) and GspCM-TmaDAH7PS (B). A. 1, soluble fraction 
after cell lysis and centrifugation. 2, insoluble fraction. 3, soluble fraction after heat treatment. 4-7, 
eluted fractions from HIC. 8-11, impurities eluted from SEC. 12-15, purified TmaACT-GspDAH7PS from 
SEC. B. 1, soluble fraction after cell lysis and centrifugation. 2-4, eluted fractions from GSTrap. 5-6, 
protein after TEV treatment with the higher band corresponding to the protein of interest, and lowered 






Figure S7. DAH7PS activity of the parent and chimeric proteins in the presence of 1 mM Phe. 
Wild-type TmaDAH7PS and TmaACT-GspDAH7PS showed inhibition with Phe. 
 
Figure S8. Thermostability of the parent and chimeric proteins in the presence or absence of 1 mM Phe. 
Error bars represent SD of triplicate measurements.  
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Appendix D - Supporting information for Chapter 4 
 
 
Figure S9. Sequence alignment of HpyDAH7PS and MtuDAH7PS generated by ClustalW and graphed 





Figure S10. Sequence alignment of HpyCM, EcoCM, and MtuCM generated by ClustalW and graphed 
by ESPript.257, 274  
 
Figure S11. CLANS clustering of Type II DAH7PS sequences. Each dot represents a sequence. 




Appendix E - Supporting information for Chapter 5 
 
Table S2. Kinetic parameters of various enzymes used for protein labelling. Table was adapted from 
Rashidian et al.218 







Site of the tag 
Formylglycine 
generating enzyme 
CXPXR or 13-mer 
LCTPSRGSLFTGR 
- - - N-/C-terminus 
Phosphopantetheinyl 
transferase 





60.8 14.7 0.242a N-/C-terminus 
or loops 
Sortase LPXTG 5,500 16.2 0.003 Any site 
Transglutaminase XXQXX 7  45  6 Any site 
Farnesyltransferase CaaX 1.71 31.2  18.2b C-terminus 
Biotin ligase GLNDIFEAQKIEWHE 4.2 9.6 2.3c N-/C-terminus 
Lipoic acid ligase GFEIDKVWYDLDA 2.88 - - N-/C-terminus 
or loops 
a500 μM ybbR 13 mer and biotin-CoA; 
 byPFTase and 2.4 μM CVIA for FPP; 





Table S3. Molecular mass confirmation of TmaDAH7PS and GspDAH7PS variants. Calculated 






TmaDAH7PSC58S 37362.1 37362.2 
TmaDAH7PSC58S-C235S 37346.0 37346.5 
GspDAH7PSWT 41374.4 41374.8 
GspDAH7PSD302C 41362.5 41362.2 
GspDAH7PSC307S 41358.3 41358.1 
GspDAH7PSC307S-D302C 41346.4 42346.4 
 
 
Figure S12. Activity test for mTG. Iron complex produced after quenching of the mTG-catalysed 




Figure S13. DNS-Cd labelling of GspDAH7PS. Labelled protein largely remained in insoluble fraction. 
1. Soluble fraction after centrifugation. 2. Insoluble fraction after centrifugation. 3. Crude mixture 
before centrifugation. Arrow indicates the size of the target protein.   
 
Figure S14. Active site of TmaDAH7PS with PEP, E4P and Cd2+. Substrates are shown as blue sticks. 
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